---
document_datetime: 2023-09-21 19:35:27
document_pages: 80
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/sprycel-h-c-709-ii-0059-epar-assessment-report-variation_en.pdf
document_name: sprycel-h-c-709-ii-0059-epar-assessment-report-variation_en.pdf
version: success
processing_time: 185.1707511
conversion_datetime: 2025-12-27 21:26:46.356758
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

13 December 2018 EMA/CHMP/3851/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Sprycel

International non-proprietary name: dasatinib

Procedure No. EMEA/H/C/000709/II/0059

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

+44 (0)20 3660 6000

Facsimile

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................5                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                      | ..................................................................................................5     |
| 1.2. Steps taken for the assessment of the product.........................................................6                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................7                       |
| 2.1. Introduction.........................................................................................................9 |                                                                                                         |
| 2.2. Non-clinical aspects                                                                                                   | ..............................................................................................9         |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | ...........................................................9                                            |
| 2.2.2. Discussion and Conclusion on non-clinical aspects                                                                    | .................................................9                                                      |
| 2.3. Clinical aspects                                                                                                       | ....................................................................................................9   |
| 2.3.1. Introduction......................................................................................................9  |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................11      |                                                                                                         |
| 2.3.3. Discussion on clinical pharmacology...................................................................22             |                                                                                                         |
| 2.3.4. Conclusions on clinical pharmacology.................................................................23              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................24    |
| 2.5. Dose response studies                                                                                                  | ........................................................................................24              |
| 2.5.1. Discussion on clinical efficacy............................................................................50        |                                                                                                         |
| 2.5.2. Conclusions on the clinical efficacy.....................................................................52          |                                                                                                         |
| 2.6. Clinical safety                                                                                                        | ....................................................................................................52  |
| 2.6.1. Discussion on clinical safety                                                                                        | ..............................................................................70                        |
| 2.6.2. Conclusions on clinical safety ............................................................................72        |                                                                                                         |
| 2.6.3. PSUR cycle                                                                                                           | .....................................................................................................73 |
| 2.7. Risk management plan........................................................................................73         |                                                                                                         |
| 2.7.1. User consultation.............................................................................................74     |                                                                                                         |
| 3. Benefit-Risk Balance..............................................................................75                     |                                                                                                         |
| 3.1. Therapeutic Context ...........................................................................................75      |                                                                                                         |
| 3.1.1. Disease or condition.........................................................................................75      |                                                                                                         |
| 3.1.2. Available therapies and unmet medical need.......................................................75                  |                                                                                                         |
| 3.1.3. Main clinical studies                                                                                                | .........................................................................................75             |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................75        |
| 3.3. Uncertainties and limitations about favourable effects.............................................76                  |                                                                                                         |
| 3.4. Unfavourable effects...........................................................................................76      |                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................76                                                             |
| 3.6. Effects Table......................................................................................................76  |                                                                                                         |
| 3.7. Benefit-risk assessment and discussion.................................................................77              |                                                                                                         |
| 3.7.1. Importance of favourable and unfavourable effects..............................................77                    |                                                                                                         |
| 3.7.2. Balance of benefits and risks.............................................................................77         |                                                                                                         |
| 3.7.3. Additional considerations on the benefit-risk                                                                        | balance ...........................................77                                                   |

3.8. Conclusions .......................................................................................................  78

<div style=\"page-break-after: always\"></div>

## 4. Recommendations .................................................................................  78 5. EPAR changes  ........................................................................................  79

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ALL         Acute lymphoblastic leukemia BCR-ABL The abnormal fusion tyrosine kinase which causes CML BMS        Bristol-Myers Squibb BP-CML   Blast-phase chronic myeloid leukemia CI           Confidence interval CML        Chronic Myeloid Leukemia CMR        Complete molecular response COG        Children's Oncology Group CP           Chronic Phase CSR         Clinical study report EU           European Union HSCT       Hematopoietic stem-cell transplantation K-M          Kaplan-Meier MO          Major objection MR4         Rate of molecular response at a 4-log reduction from a standardized baseline MRD         Minimal Residual Disease N or n       Number (of subjects or observations) NA            Not applicable OC            Other concern OS            Overall survival PFOS         Powder for oral suspension Ph             Philadelphia chromosome positive QD             Once per day SAP           Statistical analysis plan SCE           Summary of Clinical Efficacy SD             Standard deviation SRC           Family of non-receptor tyrosine kinases including Hck, Lyn, Lck, and c-Src TKI            Tyrosine-kinase inhibitor US             United States y               years

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 28 November 2017 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include a paediatric indication for Philadelphia chromosome positive acute lymphoblastic leukaemia for Sprycel; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, and 5.2 of the SmPC are updated.

The Package Leaflet is updated in accordance. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial changes to the product information.

The RMP version 16.0 has also been submitted.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0042/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0042/2018 was completed.

The PDCO issued an opinion on compliance for the PIP P/0042/2018.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Scientific advice

The applicant sought Scientific Advice at the CHMP:

<div style=\"page-break-after: always\"></div>

| References of the paediatric scientific advices                                                                                                                    | Date       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| EMA/CHMP/SAWP/97503/2011 - protocol assistance for the treatment of paediatric patients with newly diagnosed Ph+ ALL, in combination with multiagent chemotherapy. | 2011-02-17 |
| EMA/CHMP/SAWP/629716/2012 - quality and clinical development in paediatric Ph+ CML and ALL                                                                         | 2012-10-18 |
| EMA/CHMP/SAWP/629717/2012 - protocol assistance for paediatric Ph+ CML and ALL, for clinical development.                                                          | 2012-10-18 |

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

Fátima Ventura

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 28 November 2017  |
| Start of procedure:                                  | 3 March 2018      |
| CHMP Rapporteur Assessment Report                    | 2 May 2018        |
| CHMP Co-Rapporteur Assessment Report                 | 15 May 2018       |
| PRAC Rapporteur Assessment Report                    | 4 May 2018        |
| PRAC members comments                                | 7 May 2018        |
| Updated PRAC Rapporteur Assessment Report            | 14 May 2018       |
| PRAC Outcome                                         | 17 May 2018       |
| CHMP members comments                                | 22 May 2018       |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 26 May 2018       |
| 1st Request for supplementary information (RSI)      | 31 May 2018       |
| CHMP Rapporteur Assessment Report                    | 24 August 2018    |
| PRAC Rapporteur Assessment Report                    | 24 August 2018    |
| PRAC members comments                                | 29 August 2018    |
| Updated PRAC Rapporteur Assessment Report            | 30 August 2018    |
| PRAC Outcome                                         | 6 September 2018  |
| CHMP members comments                                | 10 Sep 2018       |
| Updated CHMP Rapporteur Assessment Report            | 13 Sep 2018       |
| 2nd Request for supplementary information (RSI)      | 20 September 2018 |
| MAH responses                                        | 12 Oct 2018       |
| Restart of procedure:                                | 15 Oct 2018       |
| CHMP Rapporteur Assessment Report                    | 13 Nov 2018       |

<div style=\"page-break-after: always\"></div>

| Timetable                                                                                                              | Actual dates   |
|------------------------------------------------------------------------------------------------------------------------|----------------|
| PRAC Rapporteur Assessment Report                                                                                      | 13 Nov 2018    |
| PRAC members comments                                                                                                  | 21 Nov 2018    |
| Updated PRAC Rapporteur Assessment Report                                                                              | n/a            |
| PRAC endorsed relevant sections of the assessment report ³                                                             | 29 Nov 2018    |
| CHMP members comments                                                                                                  | 03 Dec 2018    |
| Updated CHMP Rapporteur Assessment Report                                                                              | 06 Dec 2018    |
| Opinion                                                                                                                | 13 Dec 2018    |
| The CHMP adopted a report on similarity of SPRYCEL with Xaluprine, Blincyto, Iglusig and Besponsa on date (Appendix 1) | 13 Dec 2018    |

## 2. Scientific discussion

## Problem statement

The European Commission granted a Marketing Authorization for Sprycel in November 2006 for the following indications:

For the treatment of adult patients with:

newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.

chronic,  accelerated  or  blast  phase  CML  with  resistance  or  intolerance  to  prior  therapy  including imatinib.

Ph+ acute lymphoblastic  leukaemia  (ALL)  and  lymphoid  blast  CML  with  resistance  or  intolerance  to prior therapy.

For the treatment of paediatric patients with:

newly  diagnosed  Ph+ CML  in  chronic  phase  (Ph+ CML-CP)  or  Ph+ CML-CP  resistant  or  intolerant  to prior therapy including imatinib.

The scope of this variation is the extension of indication of dasatinib in combination with chemotherapyfor the treatment of paediatric patients with newly diagnosed Ph+ ALL.

## Disease or condition

The proposed indication is for the treatment of paediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy.

## Epidemiology and risk factors

The annual incidence of ALL in childhood is approximately 9 to 10 cases per 100,000, with 3% to 5% of  cases  being  Ph+  ALL.  ALL  is  the  most  common  form  of  cancer  during  childhood,  affecting  about 2500 children annually in Europe [1].

## Biologic features, aetiology and pathogenesis

Paediatric ALL is a biologically heterogeneous cancer with multiple genetically defined subtypes. The disease is characterized by the accumulation of malignant lymphoblasts in the marrow or in various

<div style=\"page-break-after: always\"></div>

extramedullary sites, frequently accompanied by suppression of normal hematopoiesis. The presence of the Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 that creates the BCR-ABL fusion protein, defines a well-known subtype of ALL which is associated with a poorer prognosis.

## Clinical presentation, diagnosis and stage/prognosis

Patients with ALL may present with a variety of hematologic derangements ranging from pancytopenia to hyperleukocytosis. The symptoms of ALL develop rapidly and are indicative of a reduced production of  functional  blood  cells  and  bone  marrow  metaplasia,  thus  including  fever,  pain,  increased  risk  of infections, increased tendency to bleed and signs indicative of anaemia, including pallor, tachycardia, fatigue, and headache.

## Management

The  standard  of  care  for  newly-diagnosed  children  and  adolescents  with  Ph+  ALL  varies  somewhat among the paediatric  cooperative  groups.  Before  the  development  of  ABL  tyrosine  kinase  inhibitors (TKIs), there was no consensus on the optimal treatment of Ph+ ALL.

In  EU,  imatinib  is  indicated  for  the  treatment  of  adult  and  paediatric  patients  with  newly  diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.

The survival rate among subjects with Ph+ ALL still lags behind most other cytogenetic subgroups in paediatric ALL. Until recently, HSCT in first complete remission offered the best opportunity for longterm EFS for children with Ph+ ALL, with an improvement in disease free survival of up to 65% and OS 72%.  This  strategy  is  limited  by  the  availability  of  a  suitably  matched  donor,  by  the  risk  of  posttransplant-related morbidity and mortality and by relapses after HSCT, particularly in those who are MRD positive prior to transplantation. Paediatric patients with no suitable donor for HSCT have an even more critical unmet need for disease management.

## About the product

Dasatinib inhibits the activity of the BCR ABL kinase and SRC family kinases along with a number of other selected oncogenic kinases including c KIT, ephrin (EPH) receptor kinases, and PDGFβ receptor. Dasatinib is a potent, subnanomolar inhibitor of the BCR ABL kinase with potency at concentration of 0.6 0.8 nM. It binds to both the inactive and active conformations of the BCR ABL enzyme (SmPC, section 5.1).

In  vitro,  dasatinib  is  active  in  leukaemic  cell  lines  representing  variants  of  imatinib  sensitive  and resistant  disease.  These  non-clinical  studies  show  that  dasatinib  can  overcome  imatinib  resistance resulting  from  BCR  ABL  overexpression,  BCR  ABL  kinase  domain  mutations,  activation  of  alternate signalling  pathways  involving  the  SRC  family  kinases  (LYN,  HCK),  and  multidrug  resistance  gene overexpression.  Additionally,  dasatinib  inhibits  SRC  family  kinases  at  subnanomolar  concentrations (SmPC, section 5.1).

In vivo, in separate experiments using murine models of CML, dasatinib prevented the progression of chronic CML to blast phase and prolonged the survival of mice bearing patient derived CML cell lines grown at various sites, including the central nervous system (SmPC, section 5.1).

The recommended starting daily dosage of SPRYCEL tablets in paediatric patients is shown in Table 1.

<div style=\"page-break-after: always\"></div>

| Table 1 Dosage of Sprycel tablets for paediatric patients with Ph+ ALL   | Table 1 Dosage of Sprycel tablets for paediatric patients with Ph+ ALL   |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Body Weight (kg) a                                                       | Daily Dose (mg)                                                          |
| 10 to less than 20 kg                                                    | 40 mg                                                                    |
| 20 to less than 30 kg                                                    | 60 mg                                                                    |
| 30 to less than 45 kg                                                    | 70 mg                                                                    |
| at least 45 kg                                                           | 100 mg                                                                   |

SPRYCEL can be taken with or without a meal, either in the morning or in the evening (SmPC, section 4.2).

## Type of Application and aspects on development

The applicant requested the approval for the following indication:

SPRYCEL  is  indicated  for  the  treatment  of  paediatric  patients  with  newly  diagnosed  Ph+  ALL  in combination with chemotherapy.

The CHMP adopted this indication without changes.

## 2.1. Introduction

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

No ERA studies were submitted (see discussion on non-clinical aspects).

## 2.2.2. Discussion and Conclusion on non-clinical aspects

The justification provided by the MAH for not performing environmental risk assessment studies was considered acceptable. The addition of the paediatric population to the currently approved indications is not expected to significantly increase the use of dasatinib on the EU market. Therefore, it is unlikely that dasatinib will pose a significant risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

<div style=\"page-break-after: always\"></div>

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

## Table 2 Overview of dasatinib paediatric development program of clinical studies

| Study                                                        | Study Description                                                                                                                        | Patient Population                                                                                                                                                 | Dose Regimen                                                                                                                                                                                                                                                                                                                                                                                                                      | Subjects Treated                                                                            | Status                                                                                        |
|--------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| CA180204 (Children's Oncology Group study Protocol AALL0622) | Phase 2, open- label, multi- center, single- arm study in children and young adults with newly diagnosed Ph+ ALL                         | Children , adolescents, and young adults from >1 to ≤30 years (at time of diagnosis) with newly diagnosed Ph+ ALL Region: : Australia, Canada, New Zealand, and US | All subjects: 2 weeks of Induction therapy, followed by 2 weeks of Induction + dasatinib 60 mg/m 2 QD. Cohort 1 (discontinuous dasatinib): Dasatinib 60 mg/m 2 QD during first 2 weeks of each 3-4 week post-Induction treatment block. Cohort 2 (continuous dasatinib):Dasatinib 60 mg/m 2 QD during each 3-4 week post-Induction treatment block. Dasatinib was offered at 48 mg/m 2 QD if 60 mg/m 2 QD dose was not tolerated. | Total (All): 62 Cohort 1: 40 Cohort 2: 22 Total (Paediatric ): 55 Cohort 1: 35 Cohort 2: 20 | Complete Final CSR: 26-Aug- 2015                                                              |
| CA180372                                                     | Phase 2, open- label, multi- center single- arm, historically- controlled study in children and adolescents with newly diagnosed Ph+ ALL | Paediatric/adolescent subjects with newly diagnosed Ph+ ALL Age range: >1 to <18 years (at time of diagnosis) Region: Canada, Australia, UK, Italy, and US         | Dasatinib PO 60 mg/m 2 and/or dasatinib PFOS 60 mg/m 2 in combination with the AIEOP-BFM ALL 2000 chemotherapeutic protocol                                                                                                                                                                                                                                                                                                       | Total: 106                                                                                  | Ongoing Last patient last visit for the 3-year analysis: 28-May- 2017 Final CSR: 03-Nov- 2017 |
| Bioequivalence Study for PFOS                                | Bioequivalence Study for PFOS                                                                                                            | Bioequivalence Study for PFOS                                                                                                                                      | Bioequivalence Study for PFOS                                                                                                                                                                                                                                                                                                                                                                                                     | Bioequivalence Study for PFOS                                                               | Bioequivalence Study for PFOS                                                                 |
| CA180352                                                     | Open-label, randomized, 3- period, 3- treatment crossover                                                                                | Healthy subjects (not of childbearing potential) Age range: 18 to 55                                                                                               | Dasatinib PO single dose 100 mg as reference tablet (2 x 50 mg tablets; Treatment A) Dasatinib PO single dose                                                                                                                                                                                                                                                                                                                     | Total: 78                                                                                   | Complete Final CSR: 06-Jun- 2012                                                              |

<div style=\"page-break-after: always\"></div>

| Study   | Study Description                        | Patient Population   | Dose Regimen                                                                                                                                                              | Subjects Treated   | Status   |
|---------|------------------------------------------|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------|
|         | bioequivalence study in healthy subjects | years Region: US     | 100 mg administered as 10 mL of the PFOS (10 mg dasatinib/mL; Treatment B) Dasatinib PO single dose 100 mg as dispersed tablet (2 x 50 mg reference tablets; Treatment C) |                    |          |

## 2.3.2. Pharmacokinetics

The  clinical  pharmacology  profile  of  dasatinib  in  paediatric  cancer  patients  has  been  characterized based on the PK data from 3 clinical studies (CA180018 in leukemia patients, CA180226 in CP-CML patients, and CA180038 in solid tumor and leukemia patients) (Table 3).

No PK data have been collected in the two clinical Phase 2 Ph+ ALL studies included in this variation application, CA180204 and CA180372.

Table  3  Summary  of  studies  contributing  to  dasatinib  clinical  pharmacology  profile  in paediatric Ph+ CML Patients, as assessed in a previous application

| Study number   | Type of study Objective                                                                                                                                                     | Patient population                                                                                                                                                                                                                                                     | Dose regimen Number of evaluable subjects                                                                                        | Analysis conducted   |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------|
| CA180018       | Phase I, open label, dose-finding design (3+3, intra-subject dose escalation) Establish RP2D of dasatinib in children and adolescents with relapsed or refractory leukemia. | Paediatric subjects (≥1 to ≤ 21 years of age) with: • Ph+ CML in chronic, AP, or BP CML resistant or intolerant to imatinib, • in first or subsequent relapse of Ph+ ALL • Ph+ acute myeloid leukemia (AML) after prior imatinib, • in second or subsequent relapse of | Dasatinib PO (tablets or tablet for dispersion) 60, 80, 100 and 120 mg/m 2 QD N = 53 (Plasma PK data available) N = 9 (CSF data) | PK (NCA) and PPK     |
| CA18038        | Phase I, open-label, dose-escalation (3+3 design) To define toxicities, estimate MTD, and recommend a Phase 2 dose of dasatinib                                             | Children (≥1 to ≤ 21 years of age) with: recurrent/refractory solid tumors or imatinib-resistant Ph+                                                                                                                                                                   | Dasatinib PO (tablets or tablet for dispersion) 50, 65, 85, and 110 mg/m2 BID N = 19 (Plasma PK data available)                  | PK (NCA) and PPK     |

<div style=\"page-break-after: always\"></div>

|          | administered as an oral agent given BID in children with solid tumors and imatinib resistant Philadelphia chromosome (Ph+) leukemia.                                                                                                                                                                        | leukemia                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                             |                                    |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| CA180226 | A Phase II study to estimate the MCyR rate to dasatinib therapy in children and adolescents with CP-CML who proved resistant or intolerant to imatinib. To estimate the CCyR rate to dasatinib therapy in children and adolescents with newly diagnosed CP-CML who are treatment-naïve (except hydroxyurea) | Children and adolescents Children (≥1 to ≤ 21 years of age) with: • newly diagnosed CP CML • with Ph+ leukemias resistant/intolerant to imatinib | For subjects with CP- CML: 60 mg/m 2 dose (for subjects receiving tablets or tablet for dispersion) or 72 mg/m 2 dose Cohort 1: CP-CML Cohort 2: Advanced CML and Ph+ ALL 8 subjects with BP-CML 9 subjects with Ph+ ALL Cohort 3: Treatment Naiive CP-CML 51 subjects in Cohort 3a (tablet) 33 (32 evaluable) subjects in Cohort 3b (PFOS) | PPK, D-R/E-R and PFOS Palatability |
| CA180352 | Phase 1, open-label, randomized, 3-period, 3-treatment crossover. BE study to assess the BE of 100 mg dasatinib PFOS and dispersed tablet relative to the intact tablet                                                                                                                                     | Healthy adult subjects                                                                                                                           | Dasatinib PO • Single dose cross- over: 2 x 50 mg intact tablet, • 100 mg PFOS and • 2 x 50 mg dispersed tablets N = 77                                                                                                                                                                                                                     | PK (NCA) and PFOS Palatability     |

The number and age distribution of paediatric patients providing PK data are presented in Table 4.

## Table 4 Age distribution of paediatric subjects providing PK data in the clinical studies

|                                 |   CA180018 |   CA180038 |   CA180226 |
|---------------------------------|------------|------------|------------|
| Infant/toddler < 2 years        |          2 |          0 |          2 |
| Children ≥2 to <12 years        |         43 |          9 |         16 |
| Adolescents and older ≥12 years |         28 |          9 |         15 |

<div style=\"page-break-after: always\"></div>

There  are  two  dasatinib  formulations  for  use  in  paediatric  patients:  (1)  film-coated  tablets  and  (2) powder for oral suspension (PFOS) for use in paediatric patients who cannot swallow or choose not to take the tablets. Dasatinib film-coated tablets are available in strengths of 20, 50, 70, 80, 100, and 140 mg and dasatinib PFOS is a powdered drug product, which, when constituted with water, provides a suspension at a dasatinib concentration of 10 mg/mL.

A physiologically-based pharmacokinetic (PBPK) model was developed and used to describe the clinical behaviours (BE, food effect, and particle size effect) of dasatinib PFOS and tablet in paediatric patients.

Body surface area (BSA)-normalized dosing was evaluated in paediatric clinical trials. Additionally, WTtiered dosing was evaluated using PPK model-based simulations.

Dose-response  (D-R)  and  exposure-response  (E-R)  relationships  were  characterized  in  paediatric patients with newly diagnosed Ph+ CP-CML from the Phase 2 study CA180226.

## Pharmacokinetics of dasatinib tablet in paediatric patients

Non-compartmental analysis (NCA) PK analysis of dasatinib tablet  formulation  was  performed  using data collected in 72 paediatric subjects age ≥ 1 year old with relapsed or refractory leukemia or solid tumors  (CA180018  and  CA180038).  The  investigated  once-daily  (QD)  and  twice-daily  (BID)  doses ranged from 60 to 120 mg/m 2  and 50 to 110 mg/m 2 , respectively. The dasatinib tablet was rapidly absorbed with a mean time of maximum observed concentration (Tmax) between 0.5 and 6 hours. Mean half-life (T-HALF) ranged from 2 to 5 hours across all dose levels and age groups. Similar to that observed  in  adults,  high  inter-subject  variability  was  observed  in  the  PK  parameters  of  paediatric subjects,  with  coefficient  of  variation  (CV)  of  maximum  concentration  (Cmax)  and  area  under  the concentration-time curve from time zero to infinity (AUC[INF]) greater than 50% for the 60-mg/m 2 tablet. Dasatinib PK showed dose proportionality with a dose-related increase in exposure observed in this  paediatric  population.  There  was  no  significant  difference  in  dasatinib  PK  between  children  and adolescents.  The  geometric  means  of  dose-normalized  (DN)  dasatinib  Cmax,  area  under  the concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-T]), and AUC(INF) were similar between children and adolescents across dose levels.

## Pharmacokinetics of dasatinib powder for oral suspension in adult and paediatric patients

Dasatinib PFOS was developed as an age-appropriate formulation for paediatric patients who cannot swallow  the  tablet  formulation.  Study  CA180352  compared  the  PK  of  dasatinib  PFOS  to  the  intact tablet formulation in 77 healthy adult subjects. Results showed that the exposure (by AUC[INF]) with PFOS was approximately 19% less than that obtained with intact tablets in healthy adults treated with a dose of 60 mg/m 2 . On the basis of these results, a PFOS dose of 72 mg/m 2  was selected to evaluate the efficacy, safety, and PK of dasatinib in paediatric patients age ≥ 1 year old with newly diagnosed CP-CML (Cohort 3b of CA180226). This dose was selected to match exposure for the selected Phase 2 dose of intact tablet at 60 mg/m 2 .

The  concentration  data  from  the  PFOS  cohort  of  Study  CA180226  (Cohort  3)  was  pooled  with  data from the Phase 1 studies for a population pharmacokinetic (PPK) analysis (694 observed concentrations  from  104  paediatric  subjects).  The  analysis  characterized  the  PK  of  dasatinib  in paediatric subjects by a linear 2-compartment model with first-order absorption, similar to that of the PK model in adult CML subjects. Both the apparent clearance (CL/F) and central volume of distribution (VC/F) increased with increasing body weight (WT) in paediatric subjects. The analysis showed that the bioavailability of PFOS was approximately 40% lower than that of tablet in paediatric patients, and as a result of the low bioavailability, the exposure of PFOS (as measured by time-averaged concentration at steady state [Cavgss]) at 72 mg/m 2  was approximately 30% lower than that of the tablet at 60 mg/m 2 in paediatric subjects newly diagnosed with CP-CML.

<div style=\"page-break-after: always\"></div>

## Drug-Drug Interactions

Dasatinib is extensively metabolized in humans, and CYP3A4 plays a major role in its metabolism.

When a single morning dose of dasatinib was administered in adults following 8 days of continuous evening administration of 600 mg of rifampin, a potent CYP3A4 inducer, the mean Cmax and AUC of dasatinib were decreased by 81% and 82%, respectively. Substances that inhibit CYP3A4 activity may decrease metabolism and increase concentrations of dasatinib. A 20-mg dasatinib QD co-administered with 200 mg of ketoconazole twice daily in adults increased the dasatinib Cmax and AUC by four- and five-fold, respectively.

Dasatinib is a weak CYP3A4 inhibitor and has little potential to induce CYP3A4. Single-dose data from a study  in  adults  indicate  that  the  mean  Cmax  and  AUC  of  simvastatin,  a  CYP3A4  substrate,  were increased by 37% and 20%, respectively, when simvastatin was administered in combination with a single 100-mg dose of dasatinib.

The list of co-administered chemotherapy agents is provided in Table 5 together with their categories as CYP3A4 substrate, inducer or inhibitor.

Table 5 List of chemotherapy agents in combination with dasatinib for treating paediatric Ph+ ALL

| Chemotherapy Regimen   | CYP3A4Substrate   | CYP3A4Inducer   | CYP3A4Inhibitor   |
|------------------------|-------------------|-----------------|-------------------|
| Cyclophosphamide       |                   |                 |                   |
| Mercaptopurine         |                   |                 |                   |
| Cytarabine             |                   |                 |                   |
| Methotrexate           |                   |                 |                   |
| Dexamethasone          | yes               |                 |                   |
| Vincristine            | yes               |                 |                   |
| Leucovoin              |                   |                 |                   |
| Hydrocortisone         | yes               |                 |                   |
| L-Asparaginase         |                   |                 |                   |
| Ifosfamide             |                   |                 |                   |
| Daunorubicin           |                   |                 |                   |
| Etoposide              |                   |                 |                   |
| Thioguanine            |                   |                 |                   |
| Doxorubicin            |                   |                 |                   |

## Dasatinib exposure comparison in paediatric patients by disease status (AP/BP-CML/ALL/AML and CPCML)

Dasatinib  plasma  concentration  data  were  collected  in  paediatric  leukaemia  patients  in  the  Phase  1 Study  CA180018.  CA180018  was  an  open-label,  dose-escalation  (3+3  design,  intra-subject  dose escalation) study in children and adolescents/adults, ≥ 1 to &lt; 21 years of age, who were treated with dasatinib  orally  60,  80,  100  and  120  mg/m 2 QD  until  refractory  disease  progression,  intolerable toxicity, or patient/physician preference.

Plasma PK data were available for 53 subjects, including 15 with CP-CML, 3 with advanced phases CML (2 in accelerated phase and 1 in lymphoid blast phase), 12 with Ph+ ALL, and 23 with Ph- ALL or AML.

<div style=\"page-break-after: always\"></div>

To support bridging of the dose recommendation from paediatric CP-CML to Ph+ ALL, an assessment was done by comparing the exposure by disease status (ie, CP-CML vs Ph+ ALL).

The exposure metrics (Cavg, Cmin and Cmax) were normalized by the mg/m 2  dose for comparison. Body  weight  was  shown  to  have  effect  on  dasatinib  PK  in  paediatric  patients.  Normalization  was performed  using  the  nominal  mg/m 2 dose  in  order  to  account  for  potential  difference  of  body  size between the 2 disease groups (CP-CML and advanced phases CML/Ph+ ALL).

The results are presented in Figure 1.

Figure 1 Dose-normalized exposure to dasatinib in paediatric patients, by disease status

## Dose-normalized Cavg:

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Dose-normalizedCmax:

<!-- image -->

Note:AdvancedPhaseN=15:CP-CMLN=21;AcceleratedPhaseCMLN=4:BlastPhaseCMLN=1:Ph+ALL N=16;Ph-ALLN=8;Ph-AMLN=19

Dasatinib exposure measures [Cavgss, Cminss and Cmaxss]) stratified by disease type and separately for adult and paediatric subjects are presented in Figure 2.

Figure 2 Population PK Model-Estimated Individual Exposure By Disease Status for Dasatinib Tablet Formulation

<!-- image -->

DiseaseType

<div style=\"page-break-after: always\"></div>

<!-- image -->

DiseaseType

1. Abbreviations: Cavgss = time-averaged concentration at steady state; Cminss = minimum concentration at steady state; Cmaxss = maximum concentration at steady state; CP-CML= chronic phase chronic myeloid leukemia; PH+ ALL = Philadelphia chromosome positive acute lymphoblastic leukemia; QD = once daily.
2. Note: The bar inside the box represents the median, edges of the box represent the 25th and 75th percentiles, and whiskers represent the 5th and 95th percentiles.

## Dose Selection and Justification in Paediatric Subjects with Ph+ ALL

The recommended dose for paediatric patients with Ph+ ALL is identical to the dose recommended for CP-CML, ie, a WT-tiered dosing recommended as presented in Table 6.

<div style=\"page-break-after: always\"></div>

Table 6 Comparability of Predicted Dasatinib Exposure at Recommended WT-Tiered Doses to Tablet 60 mg/m 2

| Body Weight [kg]   | OnceDaily Dose[mg]   | Formulation   | Gh Difference in Geo. Mean   | Gh Difference in Geo. Mean   | Gh Difference in Geo. Mean   |
|--------------------|----------------------|---------------|------------------------------|------------------------------|------------------------------|
| Body Weight [kg]   | OnceDaily Dose[mg]   | Formulation   | Cavgss                       | Cminss                       | Cmarss                       |
| 5 - ≤ 10²          | 40                   | PFOS          | -2.67                        | -11.2                        | 28.54                        |
| 10 -≤20            | 40                   | tablet        | 2.86                         | 2.70                         | 3.29                         |
|                    | 60                   | PFOS          | 1.90                         | -6.31                        | 25.39                        |
| 20 -≤30            | 60                   | tablet        | 8.33                         | 8.04                         | 8.37                         |
|                    | 90                   | PFOS          | 9.17                         | 0.00                         | 40.11                        |
| 30-≤45             | 70                   | tablet        | -3.62                        | -3.23                        | -3.63                        |
|                    | 105                  | PFOS          | -6.52                        | -20.89                       | 23.36                        |
| 245                | 100                  | tablet        | 8.00                         | 7.94                         | 8.08                         |
|                    | 150                  | PFOS          | 9.33                         | -3.97                        | 38.22                        |

Tablet is not recommended for 5 to &lt; 10 kg group. Patients in this body weight group are not likely to swallow the tablet.

Program Souwce: Analysis-Directory/R/scripts/smr-simresults-uspi-ipred.r

Source: Analysis-Directory/R/export/cmp-t60-tabtier.csv

Analysis-Directory/R/export/cmp-t60-pfostier.csv

## · Dose selection and justification for tablet

Dasatinib 60-mg/m 2  tablet was tested in the Phase 2 study CA180372 in paediatric Ph+ ALL subjects. The study was designed when the optimal schedule was being explored in adults, which showed that the QD schedule had similar overall efficacy and improved safety as compared with the BID schedule in adults. Once-daily dosing in the paediatric population was, therefore, selected over the BID dosing schedule.

In a Phase 1 dose-escalation study (CA180018) of dasatinib in children and adolescents with relapsed or refractory leukemia, treatment responses were seen in Ph+ patients who received single-agent dasatinib 60 or 80 mg/m 2 . No maximum tolerated dose was identified up to doses of 120 mg/m 2  daily. Rates of both major cytogenic response (MCyR) and complete cytogenetic response (CCyR) among 17 paediatric patients with advanced phase CML/Ph+ ALL (stratum 2/3) were 50% and 77.7% with 60 mg/m 2  and 80 mg/ m 2  QD, respectively. The proportion of subjects in this stratum with drug-related SAEs was 25% and 33% in the 60 and 80 mg/m 2  cohorts, respectively. Based on these data and preliminary COG AALL0622 data which showed that 60 mg/m 2  QD can be safely combined with chemotherapy, the 60 mg/m 2  QD dose was selected for further testing in the Phase 2 study CA180372.

The benefit-risk profile at the tablet dose of 60 mg/m 2 in paediatric Ph+ ALL was further characterized in the Phase 2 study CA180372. The 3-year binomial EFS rate with dasatinib plus chemotherapy was 66.0% (90% CI: 57.7, 73.7), which was superior compared to chemotherapy alone in AIEOP-BFM 2000 (49.2% [90% CI: 38.0, 60.4]), and non-inferior (90% CI: -3.3, 17.2) compared to continuous imatinib plus chemotherapy in the Amended EsPhALL Trial (59.1% [90% CI: 51.8, 66.2]). The safety profile of dasatinib treatment in paediatric subjects with treatment-naive Ph+ ALL indicated that daily dasatinib dosing was well-tolerated and safe. No new safety signals were observed. The most common dasatinib-related AEs were anemia (28.3%), neutropenia (24.5%), and febrile neutropenia (23.6%), which were consistent with the known safety profile of dasatinib.

The tablet is available in the strength of 20, 50, 70, 80 and 100 mg. A WT-tiered dosing in paediatric patients was selected to produce similar summary steady-state exposures to target exposures of the

<div style=\"page-break-after: always\"></div>

60-mg/m 2  tablet QD. The dosing was evaluated by simulating dasatinib exposures for each WT tier using the developed paediatric PPK model (5-120 kg with every 5-kg increment) under various dosing scenarios, taking into account the available tablet dosing strengths. The difference of exposure measures produced by the selected WT-tiered dosing was less than 20% from the reference exposure for all WT tiers.

The WT-tiered dosing is also recommended for paediatric Ph+ ALL based on the same set of simulations, which is supported by the following:

1) There were no marked disease-related differences in the PK parameters of dasatinib, both in adults and in paediatrics. Figure 3 shows the distribution of PPK model estimated dasatinib clearance by paediatric disease status.

Figure 3 PPK model-estimated individual clearance, by disease status

<!-- image -->

- 2) The same reference dose of tablet 60 mg/m 2  has been showed in Study CA180226 to be safe and efficacious in paediatric CP-CML patients, as well as in Study CA180372 with a favorable benefit-risk profile when co-administered with chemotherapy in paediatric Ph+ ALL patients.

3) Dasatinib PK is unlikely to be changed when it is co-administered with chemotherapy in treating paediatric Ph+ ALL.

The previously conducted PPK model based simulation can, therefore, be applied to recommending WT-tiered dosing in paediatric Ph+ ALL, by matching the same reference exposure of the 60 mg/m 2 tablet.

- Dose selection and justification for PFOS in paediatric patients newly diagnosed with Ph+ ALL

The use of the PFOS formulation was introduced into Study CA180372 in order to provide dosing flexibility for the very young children (as young as 1 year old) enrolled who experienced difficulty with the tablet formulation (whole or dispersed).

In procedure EMEA/H/C/000709/X/0056/G, a bioequivalence study was submitted (CA180352) to compare the ratio and extent of absorption of dasatinib between 100 mg dasatinib PFOS and 2 x 50 mg dasatinib tablet as reference (Table 7).

<div style=\"page-break-after: always\"></div>

Table 7 Bioequivalence of Powder for Oral Suspension (PFOS) and Reference Tablet (Pharmacokinetic Evaluable Population)

| Treatment and Comparison   | AUC(INF) (ng • h/mL) GM [n]    | Cmax (ng/mL) GM [n]            | AUC(0-T) (ng • h/mL) GM [n]    |
|----------------------------|--------------------------------|--------------------------------|--------------------------------|
| A                          | 419 [75] a                     | 114 [78]                       | 374 [78]                       |
| B                          | 339 [77]                       | 106 [77]                       | 328 [77]                       |
|                            | Ratio of Adjusted GMs (90% CI) | Ratio of Adjusted GMs (90% CI) | Ratio of Adjusted GMs (90% CI) |
| B vs A                     | 0.808 (0.750, 0.869)           | 0.937 (0.822, 1.067)           | 0.878 (0.796, 0.967)           |

Treatment A: A single oral dose of dasatinib, 100 mg as reference tablet (2 x 50 mg tablets).

Treatment B: A single oral dose of dasatinib, 100 mg administered as PFOS.

a AUC(INF) could not be determined in 3 subjects (10052, 10057, and 10060) after receiving Treatment A.

Results showed that the PFOS and the dispersed tablet were not bioequivalent to the reference tablet formulation. The exposure (by AUC[INF]) for PFOS was found to be approximately 19% less than that with intact tablets in healthy adults. These results suggested a dose increase of 20% may be needed when using the PFOS formulation to potentially match the exposure of the tablet formulation in adults.

There were no safety data available at that time on the impact of such a dose increase on Ph+ ALL paediatric patients, who were being treated with chemotherapy. The PFOS dose was not increased to 72 mg/m 2  until further safety evidence was available.

PFOS dose of 72 mg/m 2  was further studied in paediatric subjects with treatment-naïve CP-CML in Study CA180226. The PK, efficacy, and safety of PFOS 72 mg/m 2  provided the basis for dose recommendation of paediatric CP-CML patients. The result of this trial suggested that a dose of dasatinib PFOS 72 mg/m 2  may not be sufficient to achieve a comparable exposure level to that from a 60 mg/m 2  tablet in CML paediatric patients, and that an increase to 90 mg/m 2  may be needed. A PBPK model indicated the mechanism that likely drives reduced bioavailability for suspension treatments relative to tablets is inherent to the in vivo gastric behaviour of the two different dosage forms (shorter gastric transit for suspensions) and not likely related to the formulation composition. Safety data from Study CA180226 showed that the PFOS dose could safely be increased from 60 mg/m 2  to 72 mg/m 2 . Since the PK of dasatinib was assessed to be independent of disease state (ie, CML or ALL) and given the safety data already accumulated in Ph+ ALL population with dasatinib 60 mg/m 2  tablet combined with chemotherapy, it was determined that a dose increase of PFOS to at least 72 mg/m 2  in Ph+ ALL paediatric patients would be safe. However, the PFOS dose was not increased to 72 mg/m 2  because study enrollment had closed and the treatment for the remaining subjects was near to completion. Therefore, PFOS continued to be offered at 60 mg/m 2  in Study CA180372.

The dasatinib PFOS dose recommendation for paediatric Ph+ ALL is identical to the dose recommendation for CP-CML. In Study CA180372, 24 subjects received at least 1 dose of the PFOS, and 8 out of the 24 were administered this formulation exclusively.

Specifically, the previous PPK model was developed using data from multiple studies including data from Ph+ ALL paediatric subjects. Given the PK similarity between disease statuses, the PPK model inference was expected to apply to Ph+ ALL as well. The model identified ~40% lower bioavailability of PFOS, which was reflected in the WT-tiered dosing table by a fixed ratio between PFOS and tablet doses in each WT tier.

<div style=\"page-break-after: always\"></div>

Dasatinib was tolerated at tablet doses up to 120 mg/m 2  and showed a safety profile that was manageable in paediatric subjects with leukemia. Exposure resulting from the WT-tiered dosing of PFOS was expected to be similar to tablet 60 mg/m 2  and, therefore, within the established safety margin.

## The effect of GI toxicity on the PK of dasatinib

In order to quantitatively assess the effect of GI toxicity on dasatinib absorption, sensitivity analyses were  performed  using  a  physiologically  based  pharmacokinetic  (PBPK)  model.  The  steps  of  the analyses are illustrated in Figure 4.

Figure 4 Flow Chart of PBPK Sensitivity Analyses

<!-- image -->

The results of the PBPK model predicted percent change of dasatinib exposure related to GI toxicity, by formulation and food is presented in Table 8.

Table 8 PBPK Model Predicted Percent Change of Dasatinib Exposure Related to GI Toxicity, by Formulation and Food

| Tablet (60mg/m 2 )            | Tablet (60mg/m 2 )   | Tablet (60mg/m 2 )   | Tablet (60mg/m 2 )    |
|-------------------------------|----------------------|----------------------|-----------------------|
|                               | Baseline Fasted      | GI Tox Fasted        | %Change from Baseline |
| GM Cmax (%CV) ng/mL           | 82.2 (60.3)          | 101 (47.2)           | 22.9                  |
| GM AUC(0-24hr) (%CV) ng-hr/mL | 338.1 (69.7)         | 482.7 (59)           | 42.8                  |
| Median Tmax (Range)           | 1.16 (0.68-1.84)     | 1.56 (0.8-3.2)       | NA                    |
| PFOS (90mg/m 2 )              | PFOS (90mg/m 2 )     | PFOS (90mg/m 2 )     | PFOS (90mg/m 2 )      |
|                               | Baseline Fasted      | GI Tox Fasted        | %Change from Baseline |
| GM Cmax (%CV) ng/mL           | 108.9 (59.4)         | 153.2 (47.3)         | 40.7                  |
| GM AUC(0-24hr) (%CV) ng-hr/mL | 386.4 (67)           | 598.7 (61.0)         | 54.9                  |
| Median Tmax (Range)           | 0.7 (0.4-1.64)       | 1.36 (0.68-2.7)      | NA                    |

<div style=\"page-break-after: always\"></div>

Abbreviations: CV = coefficient of variation; GI = gastrointestinal; GM = geometric mean; NA = not applicable; Tox = toxicity. Source: /global/pkms/data/CA/180/EMA-ALL-response/dev/pk/final

Study CA180204, included a safety phase (dose finding phase) dedicated to a stepwise incorporation of dasatinib into the backbone chemotherapy as used in COG study AALL0031 - which included imatinib. Study CA180204 was an open-label, multi-center, single-arm Phase 2 study in children and young adults with newly diagnosed ALL (see description of the study under section ''Supportive study'').

Figure 5 Diagram of Safety Phase

<!-- image -->

Note: Six subjects were evaluated beginning at DL0 (60 mg/m* daily), dose given discontinuously. If 2 or more of the 6 subjects had unacceptable delays, then the dosc of dasatinib was reduced to 48 mg/m* daily (DL-1). An additional 6 subjects Wcre then accrued at this lowcr dosc level (DL-1). If ≥ 5/6 subjects safely completed Intensification Block 1 at a given dose level, Cohort 2 opened at DL0, with the dose given continuously. When a safe dose level was cstablished, the efficacy phase of the trial opcned to accrual. Subjects treated at the cstablished dose level during the safety phase were included in the analyses for the efficacy phase.

Subjects included in this phase received dasatinib discontinuously in 2-week periods followed by 1 to 2 weeks off. A tolerable level of 60 mg/m 2  was established, enrolment into the safety phase was stopped and the efficacy phase of the trial opened with dasatinib administered continuously. Patients in this trial are later reviewed and referred to the discontinuous and (part of the) continuous tablet group.

## 2.3.3. Discussion on clinical pharmacology

Two clinical studies have been conducted in paediatric subjects with Ph+ ALL where dasatinib has been co-administered with chemotherapy. Most patients have been treated with tablets. Out of 106 subjects in  study  CA180372,  24  received  at  least  one  PFOS  dose  and  8  subjects  were  treated  with  PFOS exclusively.

Dasatinib  is  primarily  metabolised by  CYP3A4  however  most  chemotherapeutic  agents  used  for  Ph+ ALL are not inhibitors or inducers of CYP3A4 and no change in PK is expected when dasatinib is coadministered with chemotherapy.

<div style=\"page-break-after: always\"></div>

Concomitant use of dexamethasone, a weak CYP3A4 inducer, with dasatinib is allowed; dasatinib AUC is  predicted  to  decrease  approximately  25%  with  concomitant  use  of  dexamethasone,  which  is  not likely to be clinically meaningful (SmPC, section 4.5).

A BE study in healthy adults concluded that the bioavailability of PFOS was approximately 19 % lower compared to tablets and therefore a dose of 72 mg/m 2  PFOS was expected to be comparable to the tablet dose of 60 mg/m2 and used in the CP-CML studies. However, the PFOS dose of 60 mg/m 2  was not increased in the Ph+ ALL study CA 180372 as enrolment was completed. In study CA180372, out of  106  subjects,  24  received  at  least  one  PFOS  dose  and  only  8  subjects  were  treated  with  PFOS exclusively.

Dasatinib exposure measures appeared to be consistent across disease type (CP-CML and Ph+-ALL) for both adult and paediatric subjects, though PK data from paediatric Ph+ ALL subjects are limited. Pop PK  analysis  in  paediatric  subjects  has  showed  that  the  bioavailability  of  PFOS  is  even  lower  in paediatric subjects. The analysis showed that the bioavailability of PFOS was approximately 40% lower than that of tablet in paediatric patients. This is expected to be due to faster gastric transit time of the formulation. The importance of an oral solution is acknowledged. Paediatric subjects treated also with chemotherapy may have difficulties swallowing tablets and will have a high need for an alternative oral formulation. However, no clinical data are available to support the proposed dose and no PK data are available from paediatric Ph+ ALL patients treated only or partly with PFOS. With the use of a PBPK model the applicant has adequately justified the proposed PFOS dose.

The MAH has not planned to conduct a 'window' study with the PFOS dose 90 mg/m 2  in Ph-positive paediatric ALL. A PBPK model has been used to justify the proposed PFOS dose. The results showed that  dasatinib  exposure  is  likely  to  increase  modestly  for  both  tablet  and  PFOS  with  GI  toxicity (including change in gastric transit time and small intestinal transit time, inflammation related change in  permeability,  and  variations  of  gastric  pH  values).  The  modest  increase  in  exposure  is  not considered to be clinically relevant and especially no impact on clinical efficacy due to GI toxicity is expected.  Even  though  the  model  has  some  limitations,  it  is  acknowledged  that  PK  should  not  be further  explored  in  the  rare  and  vulnerable  target  population  of  this  application.  The  presented simulations  and  justifications  for  a  bridging  strategy  between  CP-CML  and  Ph+-ALL  are  considered adequate.

For CP-CML a PFOS dose of 90 mg/m 2  has been proposed and endorsed by CHMP, but bioequivalence will  be  investigated  in  a  PK  window  study  in  CP-CML  conducted  post-approval.  As  the  PK,  including bioavailability, of dasatinib appear to be comparable across disease status, the PFOS dose used in CPCML has also been endorsed for the Ph+ ALL indication. The MAH is committed to provide the results of this PK-window study post-approval. In relation to this it needs to stressed that although (based on the  mechanistic  understanding,  the  analysis  of  efficacy  versus  GI  toxicity,  formulation  and  patient populations, and the analysis of PK in the different patient populations) the PBPK model is considered to provide reassuring data on the extrapolation of PK across the patient populations, the PBPK model is not fully  validated.  The  CHMP recommended the MAH to confirm (post-approval) that post-approval analysis  will  be  conducted  to  demonstrate  that  the  PBPK  model  adequately  captures  the  effects  of chemotherapy on absorption in line with the existing guideline on Reporting and Qualification of PBPK models.  .

## 2.3.4. Conclusions on clinical pharmacology

The pharmacokinetics of dasatinib has been investigated to a reasonable extent in the paediatric population in ALL. The PK of dasatinib appears to be similar in paediatric patients with CP-CML and

<div style=\"page-break-after: always\"></div>

Ph+ ALL. The impact of chemotherapy -related gastrointestinal side effects on dasatinib absorption and bioavailability in the paediatric population has been explored with a PBPK model, and no concerns have been identified.

## 2.4. Clinical efficacy

N/A

## 2.5. Dose response studies

Please refer to section 2.3.2.  Pharmacokinetics.

## Main study - Study CA180372 ()

Study CA180372 was a Phase 2, open-label, multi-centre, single-arm, historically-controlled study of dasatinib  added  to  standard  chemotherapy  in  paediatric  patients  with  newly  diagnosed  Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

## Methods

## Study participants

## Inclusion Criteria

- Children and adolescents &gt; 1 year and &lt; 18 years of age with newly diagnosed Ph+ ALL, and have  documented  presence  of  t(9;22)  determined  by  cytogenetics  or  BCR-ABL  fusion  via RTPCR or FISH (local laboratory), who are candidates for standard multi-agent chemotherapy (AIEOP-BFM ALL 2000 regimen)
- Started  induction  chemotherapy  up  to  14  days  prior  to  enrolment  according  to  institutional standard of care
- Performance status &gt;=60% (Karnofsky for subjects &gt; 16 years of age and Lansky for subjects ≤16 years of age)
- Direct bilirubin ≤3 times the ULN for age
- ALT and AST &gt;10 times the ULN for age
- Serum creatinine ≤1.5 times the institutional ULN for age/gender or
- Creatinine clearance or GFR ≥80 ml/min/1.73 m2
- QTc &lt; 450 msec on baseline ECG (within 21 days prior to study enrollment)
- LVEF ≥50% by gated radionuclide study or shortening fraction &gt; 27% by echocardiogram

For  COG  sites  (excluding  DFCI  Consortium  sites),  subjects  must  had  been  enrolled  in  the  COG classification trial (AALL08B1 or successor).

## Exclusion Criteria

- Prior treatment with a BCR-ABL inhibitor (e.g. imatinib)

<div style=\"page-break-after: always\"></div>

- Biopsy-proven Ph+ ALL extramedullary involvement of the testicles
- Active  systemic  infection  in  conjunction  with  septic  shock  syndrome  that  requires  either vasopressor support or mechanical ventilation.
- Known clinically significant disorder of platelet function (eg, von Willebrand's disease)
- Clinically significant cardiovascular disease including ANY one of the following:
- o Congenital long QT syndrome
- o History of ventricular arrhythmias or heart block
- Down syndrome (constitutional trisomy 21)
- Prior stem cell transplant
- Ph+ ALL occurring as a second malignant neoplasm after treatment of a prior malignancy

## Treatments

Dasatinib was orally delivered as a tablet, as a dispersed tablet, or as a suspension from a powder (PFOS) at a dose of 60 mg/m 2  daily. For children and adolescents capable of swallowing tablets, the existing  tablets  in  strengths  of  5  mg,  20  mg,  and  50  mg  were  given  to  cover  the  anticipated  dose range. If necessary for administration in young children not able to swallow tablets, dasatinib tablets were allowed to be dispersed in 100% preservative-free juice (ie, orange or apple juice or lemonade). The PFOS bottle was constituted with 77 mL purified water or sterile water for injection to give a total volume of 99 mL with a 10 mg/mL suspension. Dasatinib PFOS (offered at the same dose as the tablet [60 mg/m 2 ]) was developed for paediatric patients who are unable to swallow the tablet.

This  study  utilized  the  standard  Associazione  Italiana  di  Ematologia  Paediatrica  -  Berlin-FrankfurtMuenster  (AIEOP  BFM)  ALL  2000  chemotherapeutic  protocol.  Chemotherapy  was  obtained  by  the investigating  site's  standard  prescribing  procedures  according  to  country  availability  and  specific regulatory requirements. The chemotherapy regimen used in study CA180372 was the same as the chemotherapy regimen used in European Intergroup Study on Post-induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukemia (EsPhALL) and AIEOP BFM ALL 2000 trials.

<div style=\"page-break-after: always\"></div>

Table 9 Non-investigational Products - Study CA180372

<!-- image -->

| Plhiase                   | Chemotherapy Regiinen                                                                                              | Phase                       | ChemotherapyReginen                                                                                       |
|---------------------------|--------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.Induction Block IB      | Cyclophosphamide Mercaptopurine Cytarabine Methotrexate                                                            | 5)1\" Reinduction Block (R1) | Dexamethasone Vincristine Doxorubicin L-Asparaginase Cyclophosphamide Cytarabine Thioguanine Methotrexate |
| 2.High Risk Block 1 (HR1) | Dexamethasone Vincristine Methotrexate Leucovorin Cytarabine Hydrocortisone Cyclophosphamide L-Asparaginase        | 6 Interim Maintenance (IM)  | Mercaptopurine Methotrexate                                                                               |
| 3.HighRiskBlock#2 (HR2)   | Dexamethasone Vincristine Methotrexate Lelcovorin Ifosfamide Cytarabine Hydrocortisone Daunorubicin L-Asparaginase | 7）2”Reinduction Block (R2)  | Dexamethasone Vincristine Doxorubicin L-Asparaginase Cyclophosphamide Cytarabine Thioguanine Methotrexate |
| 4.High RiskBlock#3 (HR3)  | Dexamethasone Cytarabine Etoposide L-Asparaginase Methotrexate Hydrocortisone                                      | 8)Continuation Therapy      | Mercaptopurine Methotrexate                                                                               |

The components of treatment were divided into successive blocks as follows:

## Phase I - For all subjects:

- Induction  IA  (4  -  5  weeks):  During  the  first  2  weeks,  the  subjects  received  frontline  ALL induction chemotherapy outside the protocol. They were enrolled in the study and started to receive dasatinib when Ph+ status was confirmed via cytogenetics, FISH, or PCR prior to Day 15.
- Induction IB (dasatinib continued) (28 days, 4 weeks)
- Recovery period (dasatinib continued, no chemotherapy given) (2 - 4 weeks)
- Three successive consolidation blocks (HR1, HR2, and HR3) of 21 days each, 3 weeks each
- Recovery period (dasatinib continued, no chemotherapy given) (14 days, 2 weeks)

## Phase IIa - For the subjects who do not meet the criteria for HSCT:

- Re-induction Block 1, including phase IIa and IIb (63 days, 9 weeks)
- Interim  maintenance (29 days, 4 weeks). Subjects with CNS3 disease at diagnosis received cranial irradiation during the Interim Maintenance period.
- Re-induction Block 2 (63 days, 9 weeks)

<div style=\"page-break-after: always\"></div>

- Continuation therapy (62 weeks)

## Phase IIb - For the subjects who met the criteria for HSCT:

- Subjects who met pre-defined criteria at specific time points in treatment received a HSCT and had the option to receive 12 additional months of post-HSCT dasatinib (not mandatory).

## Figure 6 Schematic Study Design - Study CA180372

<!-- image -->

3-yearsofFollow-upforPrimaryandSecondaryEndpoints

(additionalfollow-uppartofstudyextensionphase)

IA-InductionA (beginspre-study entry)

IB-InductionB (IB)

HR1-ConsolidationHighRiskblock1

HR2-Consolidation High Fiskblock 2

HR3-ConsolidationHighRiskblock3

## Key

## Objectives

The primary objective of the study was to compare the 3-year efficacy based on event free survival (EFS) of dasatinib plus chemotherapy with external historical controls.

Secondary objectives included the estimation of the below:

- The safety and feasibility of dasatinib added to standard chemotherapy
- The EFS of dasatinib plus chemotherapy (including 3 and 5-year rates)
- Complete remission rates (&lt; 5% blasts in bone marrow and no peripheral blasts) at end of induction compared with AIEOP BFM 2000 and the amended EsPhALL trials
- The difference in 3-year EFS rate with the 3-year EFS rate of available historical controls such as the COG AALL0031 study
- Minimal  residual  disease  (MRD)  quantification  (defined  by  PCR  detection  of  clone-specific immunoglobulin and T-cell receptor gene rearrangements) using three methods
- BCR-ABL mutation status at baseline and time of disease progression or relapse

R1 - Reinduction 1

IM-Interim Maintenance

R2-Reinduction 2

Continuation-Continuation therapy throughwk104

CxrT-CNS3-CranialRT

156

<div style=\"page-break-after: always\"></div>

Exploratory objectives included the assessment of the following:

- Disease-free survival (DFS)
- Overall survival (OS)
- Growth and development and bone mineral content
- Prognostic value of MRD on EFS
- Correlation  between  the  3  methods  of  assessing  MRD:  real-time  qPCR  for  clone  specific immunoglobulin  and  T-cell  receptor  gene  rearrangements,  real-time  qPCR  for  BCR-ABL transcripts, and multiparameter flow cytometry
- Rates of HSCT and safety of post-HSCT dasatinib

## Outcomes/Endpoints

- The primary efficacy endpoint of the study was the 3-year binomial EFS rate. EFS was defined as the time from the starting date of dasatinib (upon confirmation that ALL is Ph+ ALL) until an event. In the primary analysis, the 3-year EFS response rate was defined as the number of subjects  without  event  after  3  years  since  the  start  of  dasatinib  divided  by  the  number  of treated subjects. Events for EFS are defined as any first one of the following: lack of complete response in bone marrow; relapse at any site; development of second malignant neoplasm; death from any cause.

Secondary endpoints:

- EFS defined as the time from the starting date of dasatinib (upon confirmation that ALL is Ph+ ALL) until an event.

The EFS endpoint is also considered for secondary/sensitivity analyses, including:

1. HSCT considered as an event if the subject discontinues
2. Lost to follow-up considered as an event (at the date of last contact)
3. Induction failures considered as an event at time 0
4. Stratified subgroup analysis of 3-year EFS rates for HSCT status looking at 3 groups: subjects who had HSCT, subjects who were eligible to have HSCT but did not, and subjects who were ineligible for HSCT.
5. Using Kaplan-Meier estimates of EFS probabilities (for overall EFS estimation including the 3year and 5-year Kaplan-Meier estimates)
6. Stratified by high versus low/standard risk
7. Comparing 3-year EFS with results in COG AALL0031 (with alignment of EFS definition)

## Historical Control Studies

- Complete Remission Rate (CRR) defined as &lt; 5% lymphoblasts in the bone marrow (ie, M1 bone marrow) and CSF with no evidence of other extra medullary disease.
- Minimal  Residual  Disease  (MRD):  The  MRD  levels  are  the  proportion  of  leukemic  cells  in  a sample at a specific time point. The method of reference is the quantitative PCR detection of

<div style=\"page-break-after: always\"></div>

clone-specific immunoglobulin and T-cell receptor gene rearrangements (Ig/TCR). The limit of detection of this assay will be approximately  10 -4 - 10 -5  or 0.01% - 0.001%.

- PCR for BCR-ABL defined as a ratio of BCR-ABL transcripts compared to a control gene (eg ABL) with log reduction compared to baseline.
- BCR-ABL mutation defined as the presence of a detectable amino acid substitution in the ABL kinase domain.

Exploratory endpoints:

- EFS by MRD level and concordance between assessment methods.
- Disease-free survival  (DFS)  defined  as the  time of  first  day of  complete  response  (M1  bone marrow)  until  relapse  at  any  site,  development  of  a  second  malignant  neoplasm,  or  death without relapse. The definition of relapse used for DFS is the same as for EFS. Subjects who neither relapse nor die or who are lost to follow-up will be censored on the date of their last assessment. Subjects who undergo HSCT would not be considered as having an event, and would continue to be followed.
- Overall  survival  defined  as  time  from  the  first  day  of  dasatinib  treatment  until  the  time  of death. Subjects who have not died or who are lost to follow-up will be censored on the last date the subject is known to be alive.

## Sample size

The sample size and power calculations incorporated the following assumptions:

- 3-year  EFS  rate  of  chemotherapy  alone  in  AIEOP-BFM  was  52%  (41  event  free  out  of  79 subjects)
- 3-year  EFS  rate  of  continuous  imatinib  plus  chemotherapy  (amended  EsPhALL  trial)  will  be 78% (70  event  free  out  of  90)  (assumes  the  same  rate  as  3-year  EFS  rate  of  continuous imatinib plus chemotherapy in COG AALL0031)
- 3-year EFS rate of continuous dasatinib plus chemotherapy will be 88% (absolute improvement of 10% over imatinib plus chemotherapy)
- A non-inferiority margin of 5% (corresponding to approximately 1/4 of the effect size of 18% anticipated in the amended EsPhALL trial over the chemotherapy-only historical control)
- One-sided type I error rate of 0.05

Based on the above assumptions, this study required 75 subjects evaluable for the primary endpoint, including at least 20 subjects evaluable for the primary endpoint in each of the following age ranges: 1 to &lt; 12 years and 12 to &lt; 18 years. This sample size yielded 100% power to detect a true difference of  36% in 3-year EFS of dasatinib plus chemotherapy (AIEOP BFM 2000) over chemotherapy alone (AIEOP-BFM 2000).

For non-inferiority testing against imatinib plus chemotherapy 75 subjects would yield 83% power to reject the null hypothesis and declare non-inferiority of dasatinib/chemotherapy and imatinib/chemotherapy (EsPhALL).

Under the same assumptions, a sample size of 75 subjects would yield 54% power to detect a true difference  of  10%  in  3-year  EFS  between  dasatinib/chemotherapy  over  imatinib  /chemotherapy (EsPhALL).

<div style=\"page-break-after: always\"></div>

It was assumed that the rate of subjects discontinuing study participation prior to reaching 3 years of follow-up from the start of dasatinib without having an event, might potentially reach 20%. Additional 15  subjects  were  to  be  treated  in  order  to  assure  robustness  of  the  long-term  efficacy  and  safety analysis  results.  The  planned  number  of  subjects  to  be  treated  was  between  75  and  90.  Under the assumption of treating 90 subjects, the power for the non-inferiority analysis would be 85%, and for the final superiority analysis the power would be 56%.

## Randomisation

The study was a single arm study.

## Blinding (masking)

The study was an open-label study.

## Statistical methods

## General Methods

Analyses  and  summaries  were,  except  where  indicated  otherwise,  based  on  the  whole  target  study population, as well as on the following sub-populations:

- o Subjects treated with dasatinib tablets only (identified in table presentations as tablet only),
- o Subjects who at any time received dasatinib in the PFOS formulation (identified in table presentations as PFOS used)

## Efficacy Analyses

Efficacy analyses were based on all treated subjects and mainly consisted of response rates, KaplanMeier plots for time to event variables, and 3-year and 5-year EFS and DFS rates. The subjects who were enrolled in this study (CA180372) were considered Cohort 1 and the external historical controls AIEOP-BFM 2000 and Amended EsPhALL were considered Cohort 2 and Cohort 3, respectively.

Primary endpoint analyses were performed in hierarchical order as follows:

- Superiority of cohort 1 over cohort 2
- Non-inferiority of cohort 1 to cohort 3
- Superiority of cohort 1 over cohort 3

The differences in 3-year EFS rates were computed using binomial proportions of subjects who were free of events at 3 years over all treated subjects. Subjects lost to follow-up at any time without an event were considered event free in the primary analysis. Event rates were provided with exact 2sided  90%  Clopper-Pearson  CI's.  Differences  in  event  rates  were  tested  at  the  0.05  1-sided significance  level  using  a  Pearson  χ 2 test.  Non-inferiority  testing  against  the  study  treatment  in  the amended EsPhALL trial were carried out using the corresponding 2-sided 90% CI for the treatment difference  (3-year  EFS  rate  in  dasatinib+chemo  minus  3-year  EFS  rate  in  imatinib+chemo)  and comparing  the  lower  confidence  limit  to  the  non-inferiority  margin  of  -5%.  Next  to  performing  the above  analyses  on  all  treated  subjects,  the  same  analyses  were  performed  on  subjects  with

<div style=\"page-break-after: always\"></div>

uncontested Ph+ ALL diagnosis, meaning that any subject that was considered during treatment not to have Ph+ ALL was excluded.

## Results

## Participant flow

## Figure 7 Summary of Subject Disposition -Study CA180372

<!-- image -->

Abbreviations:DBL=data baselock;HR=highrisk;HSCT=hematopoietic stem cell transplant

<div style=\"page-break-after: always\"></div>

Table 10 Subject Disposition- Study CA180372

| Status (%)                                       | Tablet Only N=82   | PFOS Used N=24   | Total N=106   |
|--------------------------------------------------|--------------------|------------------|---------------|
| Completing the treatment period                  | 59 (72.0)          | 19 (79.2)        | 78 (73.6)     |
| Not completing the treatment period              | 23 (28.0)          | 5 (20.8)         | 28 (26.4)     |
| Reasonfornotcompleting thetreatment period       |                    |                  |               |
| Lack of efficacy                                 | 3 (3.7)            | 0                | 3 (2.8)       |
| Study drug toxicity                              | 2(2.4)             | 0                | 2 (1.9)       |
| Adverse event                                    | 8 (9.8)            | 0                | 8 (7.5)       |
| Withdrawal by subject                            | 4 (4.9)            | 0                | 4 (3.8)       |
| Death                                            | 0                  | 2 (8.3)          | 2 (1.9)       |
| Other                                            | 6 (7.3)            | 3 (12.5)         | 9(8.5)        |
| Continuing in the study                          | 78 (95.1)          | 22 (91.7         | 100 (94.3)    |
| Not continuing in the study                      | 4(4.9)             | 2 (8.3)          | 6 (5.7)       |
| Reason for not continuing in the study Death     | 4(4.9)             | 2 (8.3)          | 6 (5.7)       |
| Continuing in the follow-up period               | 67 (85.9)          | 20 (90.9)        | 87 (87.0)     |
| Not continuing in the follow-up period           | 11 (14.1)          | 2 (9.1)          | 13 (13.0)     |
| Reason for not continuing in thefollow-up period |                    |                  |               |
| Withdrawal by subject                            | 3 (3.8)            | 0                | 3 (3.0)       |
| Death                                            | 7(9.0)             | 2 (9.1)          | 9 (9.0)       |
| Lost to follow-up                                | 1(1.3)             | 0                | 1(1.0)        |

## Recruitment

Study initiation date: 13 April 2012. The last patient visit for this report was 28 May 2017 and the database lock was 26 July 2017.

<div style=\"page-break-after: always\"></div>

## Conduct of the study

## Changes to the protocol

Table 11 Summary of Changes to Protocol CA180372

<!-- image -->

| Document                                                                                                                                                                                     | Date of Issue                                                                                                                                                                                | Sunmary of Change                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amencment 04                                                                                                                                                                                 | 28-0ct-2013                                                                                                                                                                                  | This amendment: Provided updatesto theWOCBPlanguage tohanmonize thislanguagewith thecurentBMSdirectivesforWOCBP.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Amendment 03                                                                                                                                                                                 | 31-Jul-2013                                                                                                                                                                                  | This amendment: Increased thenumberof treatedsubjectsfrom75toatleast75andupto 90. Modified languageregardingpregnancy prevention. Incorporatedrecommendationsforsubjectmanagementandsupportive care duringHRBlocks1-3. Providedclarifications,fixed inconsistenciesacrosssections oftheprotocol andconrectedvarioustypographicalenrors.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Amendment02                                                                                                                                                                                  | 07-Dec-2012                                                                                                                                                                                  | This amendment Introducedanewpediaricformulationof dasatinib Addressed lackofavailabilityofnative-asparaginaseintheUnitedStates and allowed use of Peg-Asparaginase upfront in such instances aswell as providedmore detailedinshuction for dosemodifications of thevarious asparaginase formulations. IndicatedthattheBCR-ABLmutationstatuswillbereportedforbaseline and at time of progression as a secondary objective instead of as an exploratory objective. AllowedPhiladelphiachromosomepositivityfromperipheral bloodtobe acceptable for study entry. Expanded thewindowfor screening activitiesto2l days. Modified thedefinition of highriskgroup andlow/standard niskgroup in response toInductionlAtreatment. Providedclarifications,fixedinconsistenciesacrosssections of theprotocol and conrectedvarious typographical errors. |
| Amendment01                                                                                                                                                                                  | 20-Sep-2011                                                                                                                                                                                  | This amendment: Changed thestatistical designof thetial toallowcomparison tohistorical external controls.Specifically,the 3-yearEFSof dasatinibplus chemotherapytobecomparedtothe3-yearEFSofchemotherapy alone fromtheAIEOPBFM2000mialandthe3-yearEFSofimatinibplus chemotherapyfrom theEsPhALLstudy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Abbreviations:WOBCP=Women of ChildbearingPotential;HR=High Risk;BCR-ABL=Oncogenefusion protein;EFS=eventfreesurvival;AIEOPBFM=Associazione Italiana di Ematologia Pediamica-Berlin-Frankfut- | Abbreviations:WOBCP=Women of ChildbearingPotential;HR=High Risk;BCR-ABL=Oncogenefusion protein;EFS=eventfreesurvival;AIEOPBFM=Associazione Italiana di Ematologia Pediamica-Berlin-Frankfut- | Abbreviations:WOBCP=Women of ChildbearingPotential;HR=High Risk;BCR-ABL=Oncogenefusion protein;EFS=eventfreesurvival;AIEOPBFM=Associazione Italiana di Ematologia Pediamica-Berlin-Frankfut-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## Protocol deviations

Protocol deviations were identified via 1) on-site monitoring, 2) review of data listings and reported in monitoring visit reports and protocol deviation monitoring forms and 3) programmed checks based on data collected in the CRFs.

<div style=\"page-break-after: always\"></div>

Clinically  relevant  protocol  deviations  were  significant  protocol  deviations  that  were  prespecified, programmable, and defined as events that may have had considerable impact on the outcome of the study or interpretation of the results of the study.

Overall, there were 42 clinically relevant protocol deviations reported in 40 subjects: 40 deviations due to use of concomitant medications with potential to prolong QTc, and 2 deviations due to subjects with blast-phase CML who were misclassified with Ph+ ALL. Inclusion of these 2 subjects in analysis did not impact  interpretability  of  study  results.  Most  of  the  deviations  (30  subjects)  were  subjects  who received  short-term  prophylactic  antibiotics  with  a  macrolide  and/or  pentamidine.  Other  prohibited medications included droperidol, methadone, haloperidol, domepridone and chlorpromazine.

Table 12 Relevant Protocol Deviations Summary - All Treated Subjects- Study CA180372

|                                                   | Tablet Only N=82   | PEOSUsed N=24   | Total N=106       |
|---------------------------------------------------|--------------------|-----------------|-------------------|
| ATTEASTONE RELEVANTFROTOCOLDEVLATTON              | 32 (39.0)          | (33.3)          | 40 (37.7)         |
| Conccmitantmedsthatprolcng QT No diagmosis of ATL | 32 (068) 2 (2.4）   | (33.3)          | 40 (37.7) 2 （1.9) |

## Baseline data

A summary of baseline demographic characteristics is presented in Table 13 .

<div style=\"page-break-after: always\"></div>

Table 13 Demographic Characteristics Summary - All treated subjects- Study CA180372

|                                             | Tablet Only N=82   | PFOS Used N=24   | Total N=106   |
|---------------------------------------------|--------------------|------------------|---------------|
| Age(year's)atconsent                        |                    |                  |               |
| N                                           | 82                 | 24               | 106           |
| Mean                                        | 10.33              | 5.73             | 9.29          |
| Median                                      | 10.48              | 4.19             | 9.37          |
| Min, max                                    | 2.6, 17.9          | 1.6,14.0         | 1.6,17.9      |
| Q1,q3                                       | 6.15, 13.60        | 2.57,8.67        | 5.08,12.87    |
| Sd                                          | 4.160              | 3.612            | 4.467         |
| Age(years)atinitialall diagnosis            |                    |                  |               |
| N                                           | 82                 | 24               | 106           |
| Mean                                        | 10.30              | 5.70             | 9.26          |
| Median                                      | 10.46              | 4.16             | 9.34          |
| Min, max                                    | 2.6,17.9           | 1.6,13.9         | 1.6, 17.9     |
| Q1,q3                                       | 6.12,13.56         | 2.54,8.65        | 5.06,12.83    |
| Sd                                          | 4.160              | 3.614            | 4.467         |
| Agecategorization(Oo)atinitialall diagnosis |                    |                  |               |
| >1to2                                       | 0                  | 4 (16.7)         | 4 (3.8)       |
| >=2to<7                                     | 21 (25.6)          | 11 (45.8)        | 32 (30.2)     |
| >=7to<12                                    | 27 (32.9)          | 8 (33.3)         | 35 (33.0)     |
| >=12to<18                                   | 34 (41.5)          | 1 (4.2)          | 35 (33.0)     |
| Gender (%)                                  |                    |                  |               |
| Male                                        | 45 (54.9)          | 12 (50.0)        | 57 (53.8)     |
| Female                                      | 37 (45.1)          | 12 (50.0)        | 49 (46.2)     |
| Race (%)                                    |                    |                  |               |
| White                                       | 66 (80.5)          | 19 (79.2)        | 85 (80.2)     |
| Blackkor African American                   | 9 (11.0)           | 4 (16.7)         | 13 (12.3)     |
| Asian                                       | 5 (6.1)            | 0                | 5 (4.7)       |
| AmericanIndianorAlaskanative                | 0                  | 1 (4.2)          | 1 (0.9)       |
| Native Hawaiian or other pacific islander   | 1 (1.2)            | 0                | 1 (0.9)       |
| Other                                       | 1 (1.2)            | 0                | 1 (0.9)       |
| Ethnicity(%)                                |                    |                  |               |
| Hispanic or Latino                          | 19 (23.2)          | 5 (20.8)         | 24 (22.6      |
| Not Hispanic or Latino                      | 40 (48.8)          | 15 (62.5)        | 55 (51.9)     |
| Not reported                                | 23 (28.0)          | 4 (16.7)         | 27 (25.5)     |

<div style=\"page-break-after: always\"></div>

A summary of baseline disease characteristics is presented in Table 14.

Table 14 Disease History Summary - All treated Subjects- Study CA180372

|                                                                     | Tablet Only N=82   | PEOS Used N=24   | Total N=106   |
|---------------------------------------------------------------------|--------------------|------------------|---------------|
| TIEEROMINITIALIEUKEMIADIAGNOSIS TO FIRST IASATINIB DOSINGDATE(DAYS) |                    |                  |               |
| N                                                                   | 82                 | 24               | 106           |
| MEDIAN                                                              | 16.0               | 16.0             | 16.0          |
| MMN,MAX                                                             | 8,19               | 15,17            | 8,19          |
| IMMINOEHENOTYEEDISEASEDIAGNOSIS（)                                   |                    |                  |               |
| PREOURSORB-CELLALL                                                  | 82 (100.0)         | 22 （91.7）        | 104(98.1)     |
| T-CETL ALL                                                          | 0                  | 2(6.3)           | 2(1.9)        |
| BASELINE CNS IEUKEMTADISEASESTATUS                                  |                    |                  |               |
| CNS1                                                                | (67.1)             | (83.3)           | (70.8)        |
| CN52                                                                | 4）                 |                  |               |
| CNS2A                                                               | 0                  | 22               |               |
| CN52B                                                               | 9.8 8              |                  |               |
| CNS2C                                                               | 4                  |                  | 1 9           |
| CN53                                                                |                    |                  | 8)            |
| CNS3A                                                               | 1.2)               |                  | (6:0          |
| CN53C                                                               |                    |                  | 0.9)          |
| NOTASSESSED                                                         | 1.2                |                  | (6:0          |
| PHILADELPHIABOSITIVITY（)                                            |                    |                  |               |
| FLUORESCENT INSITUHYBRIDIZATION (EISH)CNLY                          | 21(25.6)           | 5(20.8)          | 26(24.5)      |
| RT-FCR ONLY                                                         | (l:3)              | 18 (8:8)         | 器 (182:3      |
| BOTH                                                                |                    |                  |               |
| BCR-ARLIRANSCRIPT()                                                 |                    |                  |               |
| P190                                                                | 09 (73.2)          | (62.5)           | 75 (70.8)     |
| P210                                                                | 1Ⅱ1 (13.4)         | (20. 8           | (15.1)        |
| NOTAVAILABIE                                                        | (13.4)             | (16. 7           | 15 (14.2)     |
| WBCCOUNTATDISEASEDIAGNOSIS(X1000 CELLS/uL)                          |                    |                  |               |
| N                                                                   | 82                 | 24               | 106           |
| MEAN                                                                | 113.40             | 138.89           | 119.17        |
| MEDIAN                                                              | 37.31              | 55.05            | 40.30         |
| XNNI                                                                | 0.6,1098.0         | 1.9,1074.0       | 0.6,1098.0    |
|                                                                     | 16.50,162.30       | 21.30,177.15     | 18.87,165.80  |
|                                                                     | 173.71             | 230.82           | 187.25        |
| VBCCOUNTAT DISEASE DIAGNOSIS（%)                                     |                    |                  |               |
| <50,000/mm3                                                         | (58.5)             | (45.8)           |               |
| 50,000-100,000/mm3                                                  | (11.0)             | 16.7             | 3             |
| >100,000/mm3                                                        | (30.5)             | (37.5)           | (32 1         |

## Numbers analysed

- All enrolled subjects: all subjects who had a signed informed consent form (N = 109).
- All treated/evaluable subjects: all subjects who received at least 1 dose of dasatinib (N = 106).
- Mutation data set: all treated subjects who had mutation data available (N = 80).

## Outcomes and estimation

- Primary endpoint: 3-year binomial EFS rates vs. historical controls

The  3-year  binomial  EFS  rate  with  dasatinib  plus  chemotherapy  was  66.0%  (90%  CI:  57.7,  73.7) compared to 49.2% (90% CI: 38.0, 60.4) observed with chemotherapy alone in AIEOP-BFM 2000 and to 59.1% (90% CI: 51.8, 66.2) observed with continuous imatinib plus chemotherapy in the amended EsPhALL trial in all treated subjects.

<div style=\"page-break-after: always\"></div>

Table 15 Difference in 3-Year binomial EFS Response Rates vs Historical Controls (AIEOPBFM 2000 and EsPhALL)

|                                   | Response Rate (°)   | Response Rate (°)   | Response Rate (°)   | DifferenceinResponseRates   | DifferenceinResponseRates   | DifferenceinResponseRates   | DifferenceinResponseRates   | DifferenceinResponseRates   | DifferenceinResponseRates   |
|-----------------------------------|---------------------|---------------------|---------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                   | n/N (%)             | 90%CI(%）(1)         |                     | Diff (%)                    | 90%CI(%)                    |                             | P-value (2)                 |                             |                             |
| Historical ControlAIEOP-BFM2000   | 30/ 61 (49.2)       | 38.0,               | 60.4)               |                             |                             |                             |                             |                             |                             |
| ALLTREATEDSUBJECTS                | 70/106 (66.0)       | 57.7,               | 73.7)               | 16.86                       | 3.9,                        | 29.8)                       | 0.032                       |                             |                             |
| TABLET ONLY                       | 54/ 82 (65.9)       | 56.3,               | 74.5)               | 16.67                       | （ 3.1,                      | 30.3)                       | 0.045                       |                             |                             |
| PEOS USED(AT LEAST 1DOSE)         | 16/ 24 (66.7)       | 47.9,               | 82.2)               | 17.49                       | -1.5,                       | 36.5)                       | 0.145                       |                             |                             |
| Historical ControlAmended EsPhALL | 81/137 (59.1)       | 51.8,               | 66.2)               |                             |                             |                             |                             |                             |                             |
| ALLTREATEDSUBJECTS                | 70/106 (66.0)       | 57.7,               | 73.7)               | 6.91                        | -3.3,                       | 17.2)                       | 0.271                       |                             |                             |
| TABLET ONLY                       | 54/ 82 (65.9)       | 56.3,               | 74.5)               | 6.73                        | (-4.3,                      | 17.8)                       | 0.322                       |                             |                             |
| PEOS USED (AT LEAST 1 DOSE)       | 16/ 24 (66.7)       | 47.9,               | 82.2)               | 7.54                        | -9.7,                       | 24.8)                       | 0.486                       |                             |                             |

Difference in response rate: dasatinib response rate - historical control response rate. DataSource:ADRS

- Secondary endpoint: 3-year binomial EFS rates vs COG study (AALL0031)

Table 16 Difference in 3-year binomial EFS Response Rate versus COG Study AALL0031

|                                      | Response Rate ()   | Response Rate ()   | DifferenoeinRespcnseRates   | DifferenoeinRespcnseRates   | DifferenoeinRespcnseRates   | DifferenoeinRespcnseRates   | DifferenoeinRespcnseRates   | DifferenoeinRespcnseRates   | DifferenoeinRespcnseRates   |
|--------------------------------------|--------------------|--------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                                      | n/N (%)            | 90%CI（%）（1)        |                             |                             | Diff（8）90%CI（8）             | P-value                     | (2)                         |                             |                             |
| Historical Control Stucy COGAAIL0031 | 43/56(76.8)        | (65.6, 85.7)       |                             |                             |                             |                             |                             |                             |                             |
| ALL TREATED SUBJECTS                 | 70/106(66.0)       | (57.7,73.7)        |                             | -10.75                      | (-22.7,1.2)                 |                             | 0.157                       |                             |                             |
| TABLET ONLY                          | 54/82(65.9)        | (56.3,74.5)        |                             | -10.93                      | (-23.6,1.7)                 |                             | 0.168                       |                             |                             |
| FEOS USED (ATIEAST1DOSE)             | 16/24(66.7)        | (47.9,82.2)        |                             | -10.12                      | （-28.5,8.2)                 |                             | 0.346                       |                             |                             |

Differenceinrespcnserate:dasatinibresocnserate-historicaloontrolrespcnserate. (1)Exact Clogper-Pearson confidence interval.(2) Fearson Chi-souare 1-sided test. LataSource:AiRs

- Secondary endpoint: yearly EFS rates

Table 17 Kaplan-Meier Estimates of Event Free Survival at Yearly Intervals- Study CA180372

|           | Event-freeSurvival(%o)with95%ConfidenceInterval   | Event-freeSurvival(%o)with95%ConfidenceInterval   | Event-freeSurvival(%o)with95%ConfidenceInterval   |
|-----------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Timepoint | Tablet Only N=82                                  | AtLeast1DoseofPFOs N=24                           | Total N=106                                       |
| Year 1    | 95.1 (87.5, 98.1)                                 | 91.7 (70.6, 97.8)                                 | 94.3 (87.8,97.4)                                  |
| Year 2    | 85.3 (75.5, 91.4)                                 | 83.3 (61.5, 93.4)                                 | 84.8 (76.4, 90.4)                                 |
| Year 3    | 65.1 (53.6,74.4)                                  | 66.7, (44.3, 81.7)                                | 65.5 (55.5,73.7)                                  |
| Year 4    | 56.5 (44.2, 67.1)                                 | 53.3 (29.4, 72.4)                                 | 55.8 (44.9, 65.4)                                 |
| Year 5    | 54.1 (41.4, 65.1)                                 | 53.3 (29.4, 72.4)                                 | 48.7 (34.8, 61.2)                                 |

<div style=\"page-break-after: always\"></div>

Figure 8 Kaplan-Meier Plot of Event Free Survival - All treated Subjects- Study CA180372

<!-- image -->

Figure 9 Kaplan Meier Plot of Event Free Survival - Tablet Only- Study CA180372

<!-- image -->

- Secondary endpoint: yearly EFS rates Historical Control Studies

Table 18 EFS Rates over Time in Historical Control Studies

|                                       | AIEOP-BEM200O N=61   | AIEOP-BEM200O N=61   | AIEOP-BEM200O N=61   | AmendedEsPhALL N=137   | AmendedEsPhALL N=137   | AmendedEsPhALL N=137   | COGAALL0031 N=56   | COGAALL0031 N=56   | COGAALL0031 N=56   |
|---------------------------------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|--------------------|--------------------|--------------------|
| KAPLAN-MEIERESTIMATES OFEFSRATE（95CI) |                      |                      |                      |                        |                        |                        |                    |                    |                    |
| YEAR1                                 | 78.7（                | 66.1,                | 87.0)                |                        | 81.8（71.4              | 88.7)                  | 89.3               | (77.7,             | 95.0)              |
| YEAR2                                 | 54.1                 | 40.9,                | 65.6)                | 67.9                   | 9（56.4，                | 76.9)                  | 80.2               | （67.2,             | 88.5)              |
| YEAR3                                 | 49.2                 | 36.2,                | 60.9)                | 59.0（4                 | 47.4,                  | 68.9)                  | 76.6               | ? 63.1,            | 85.7)              |
| YEAR4                                 | 49.2                 | 36.2,                | 60.9)                | 55.4                   | 43.6,                  | 65.7)                  | 69.1               | 55.1，              | 79.6)              |
| YEAR5                                 | 42.3                 | （29.8,               | 54.3)                |                        | 55.4(43.6,             | 65.7)                  |                    | 65.2（51.0,         | 76.2)              |

<div style=\"page-break-after: always\"></div>

## · Secondary endpoint: CRR

Table 19 Complete Remission Rates in Historical Control Studies

|                                        | ATFOP-BEM2000 N=61   | PmencedEsEhATL N=137   | COGAAIL0O31 N=56   |
|----------------------------------------|----------------------|------------------------|--------------------|
| OOMPLEIEREMISSTONRATE ATENDOEINLUUTION |                      |                        |                    |
| n/N (%)                                | 49/61 (80.3)         | 134/137 (97.8)         | 49/56 (87.5)       |

Ccmpleteremission:&lt;5slyyhcblastsinbonemarrowandinCSFwithoutevidenceofother extramerhillarvdiaaase.

Table 20 Summary of Complete Remission - Study CA180372

|                              | Number of Subjects （%) N=106   | Number of Subjects （%) N=106   | Number of Subjects （%) N=106   | Number of Subjects （%) N=106   | Number of Subjects （%) N=106   |
|------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                              | Induction IA                   | Induction IA                   | Induction IB                   | Induction IB                   | End Consolidation              |
| All Treated Subjects (N=106) |                                |                                |                                |                                |                                |
| COMPLETEREMISSION            | 69                             | 69 (65.1)                      | 94 25                          | (88.7)                         | 99(93.4) 8                     |
| FIRST CR CCR                 |                                |                                | 69                             |                                | 91 2                           |
| NOCR                         | 25                             | (23.6)                         | 6                              | (5.7)                          | (1.9)                          |
| UNABLETODETERMINE            |                                | 11  (10.4)                     | 4                              | (3.8)                          | 05                             |
| SUBJECTSNOTCOMPLETINGPERIOD  |                                | 1(0.9)                         |                                | 2(1.9)                         | (4.7)                          |
| Tablet Only (N=82)           |                                |                                |                                |                                |                                |
| COMPLETEREMISSION            | 53                             | 53 (64.6)                      | 72 19                          | (87.8)                         | 77 (93.9)                      |
| FIRST CR CCR                 |                                |                                | 53                             |                                | 7 70                           |
| NOCR                         |                                | 20(24.4)                       |                                | (7.3)                          | 1 (1.2)                        |
| UNABIETODETERMINE            |                                | (9.8)                          | 622                            | (2.4)                          | 04                             |
| SUBJECTSNOTCOMPLETINGPERIOD  |                                | 1( 1.2)                        |                                | 2.4)                           | (4.9)                          |
| PFOS Used (N=24)             |                                |                                |                                |                                |                                |
| COMPLETEREMISSION            |                                | 16 (66.7)                      | 22                             | (91.7)                         | 22 (91.7)                      |
| FIRST CR                     | 16                             |                                | 6                              |                                |                                |
| CCR                          |                                |                                | 16                             |                                | 12                             |
| NOCR                         | 5                              | (20.8)                         | 0                              |                                | (4.2)                          |
| UNABLETODETERMINE            |                                | (12.5)                         | 2                              | (8.3)                          |                                |
| SUBJECTSNOTCOMPLETING PERIOD | 0                              |                                | 0                              |                                | 1 （4.2）                        |

Completeremission:&lt;5%1ymphoblastsinbone marrow and in CsF without evidence of other extra medullarydisease.

achieved.

Data Source:ADRS

<div style=\"page-break-after: always\"></div>

## · Secondary endpoint: MRD

Table 21 MRD- Negative Rates Summary - Study CA180372

<!-- image -->

Table 22 MRD- Negative Rates Summary - All Treated Subjects with Evaluable Ig/TCR Assessments- Study CA180372

<!-- image -->

<div style=\"page-break-after: always\"></div>

## · Secondary endpoint: BCR-ABL mutation status

Table 23 Summary of BCR- ABL Mutations at Disease Progression or Relapse - Mutation Dataset- Study CA180372

|                                           | Eh+ALL              | Eh+ALL              | Eh+ALL            | Eh+ALL        |
|-------------------------------------------|---------------------|---------------------|-------------------|---------------|
|                                           | Tablet Only n/N (%) | Tablet Only n/N (%) | PEOS Used n/N (%) | Total n/N (%) |
| Number ofSuojects with                    |                     |                     |                   |               |
| Mitaticns                                 | 2/25                | (8.0)               | 0/ 6              | 2/31 (6.5)    |
| No Mitations*                             | 17/25               | (68.0)              | 3/ 6 (50.0)       | 20/31 (64.5)  |
| Not Reported                              | 6/25                | (24.0)              | 3/ 6 (50.0)       | 9/31 (29.0)   |
| Mtations in:                              |                     |                     |                   |               |
| P-Loop                                    | 0/2                 |                     |                   | 0/2           |
| Activaticn Loop                           | 0/ 2                |                     |                   | 0/ 2          |
| Other Location Only                       | 2/2(100.0)          |                     |                   | 2/2(100.0)    |
| Mutations with:                           |                     |                     |                   |               |
| IC50 todasatinib >3nM                     | 1/ 2                | (50.0)              |                   | 1/ 2 (50.0)   |
| IC50 todasatinib3nM件                      | 1/ 2                | (50.0)              |                   | 1/ 2 (50.0)   |
| IC50todasatinib<=3nMl#                    | 0/ 2                |                     |                   | 0/ 2          |
| IC50 toDasatinibUnlmowm###                | 0/ 2                |                     |                   | 0/ 2          |
| More than l Miitaticn Specific Miutation: | 0/2                 |                     |                   | 0/ 2          |
| F317L                                     | 1/2 2               | (50.0)              |                   | 1/ 2 (50.0)   |
| T315I                                     | 1/ 2                | (50.0)              |                   | 1/ 2 (50.0)   |

(）May include subjects with polymorghisms only （T240T,K247R,F311V,Y320C,andE499E).

#andnomtationswithIc50tocasatinib&gt;3nM.##andnomitationswith Ic50&gt;3nM.## andnomutations withlmown Ic50.

P-Loop:Subjects withatleast1mutationintheP-loop(248-256)andlpossihlymutationsinthe activaticn loop or other locaticns.

Activation Loop:Subjectswith&gt;=1mit.in the activaticn loop （379-398)andpossibly mutations intheP-loop/otherlocations.

Mitationswith IC50 todasatinib&gt;&gt;3nM:T315I/A.Miitations withIc50 todasatinib&gt;3nM: I248V,G250E,Q252H,E255K/V,V299L，F317L,L384M,Y253H,and F486S.M1itaticns with IC50 to dasatinib&lt;=3nM:M244V,Y253E,D276G,E279K,F311L,M351T，F359V,V379I，L387M,andH396P/R.

MitationswithunlmcwnIc5otodasatinib:allothermntations.DataSource:AnMl

<div style=\"page-break-after: always\"></div>

- Exploratory endpoints: EFS by MRD level

Figure 10 Landmark Kaplan-Meier Plot of EFS by MRD Level Based on Ig/TCR - All Treated Subjects at Risk of Event at MRD2- Study CA180372

<!-- image -->

Figure 11 Landmark Kaplan-Meier Plot of EFS by MRD level Based on Ig/TCR - All treated Subjects at Risk of Event at MRD3- Study CA180372

<!-- image -->

MRD-Neg=MRD negstive: MRD-PosINQ -MRD poaltive butnot qusntifisble, MRD-Pos=MRD posltive

<div style=\"page-break-after: always\"></div>

Figure 12 Landmark Kaplan-Meier Plot of EFS by MRD level Based on Ig/TCR - All treated Subjects at Risk of Event at MRD4- Study CA180372

<!-- image -->

- Exploratory endpoint: Correlation between 3 methods of assessing MRD

The proportion of subjects with non-evaluable results was lower with the FLOW method (2% to 6%) than with the Ig/TCR method (15% to 20%) and the BCR-ABL method (35% to 56%; subjects without MRD assessment because of treatment discontinuation were included as 'non-evaluable'). Concordance between MRD detection methods is summarized in Table 24.

Table 24 Numerical Concordance between MRD Methods - All treated Subjects with Available Data

|                         | %Concordance（MlethodAvsAfethodB)   | %Concordance（MlethodAvsAfethodB)   | %Concordance（MlethodAvsAfethodB)   |
|-------------------------|------------------------------------|------------------------------------|------------------------------------|
| MIRDTinepoint           | IC/TCRvsBCR-ABL                    | IG/TCRvsFLOW                       | BCR-ABLVSFLOIW                     |
| MIRD2                   | 89.5                               | 94.1                               | 72.1                               |
| MRD3                    | 87.0                               | 98.9                               | 88.3                               |
| MRD4                    | 95.0                               | 100.0                              | 89.4                               |
| AcrossMRD2.MRD3.andMRD4 | 90.1                               | 97.7                               | 82.3                               |

Abbreviations:MRD=minimalresidual disease;IG/TCR=immunoglobulinandT-cell receptorgene

reanrangements;FLoW =flow cytomety.

MRD2=EndofInductionperiodIA:MRD3=EndofInductionperiodIB/StaitofHighRiskBlock1;MRD4= EndofHigh RiskBlock3.

<div style=\"page-break-after: always\"></div>

## · Exploratory endpoint: DFS

Table 25 Kaplan Meier Estimates of Disease-free Survival at yearly intervals

| Timepoint   | TabletOnly N=82   | PFOSUsed N=24     | Total N=106       |
|-------------|-------------------|-------------------|-------------------|
| Year 1      | 93.9 (86.0,97.4)  | 91.7 (70.6, 97.8) | 93.4 (86.6, 96.8) |
| Year2       | 82.8(72.7,89.4)   | 83.3(61.5,93.4)   | 82.9 (74.3,88.9)  |
| Year3       | 65.0 (53.5, 74.4) | 66.7 (44.3, 81.7) | 65.4 (55.4, 73.7) |
| Year 4      | 56.4 (44.1, 67.0) | 53.3 (29.4, 72.4) | 55.7(44.8.65.3)   |
| Year5       | 53.8 (41.1, 65.0) | 0 (NE, NE)        | 48.5(34.7.61.1)   |

NE=notevaluable.

## · Exploratory endpoint: OS

Table 26 Kaplan Meier Estimates of Overall Survival at Yearly Intervals

| Timepoint   | TabletOnly N=82   | PFOSUsed N=24     | Total N=106       |
|-------------|-------------------|-------------------|-------------------|
| Year 1      | 96.3 (89.1,98.8)  | 91.7(70.6,97.8)   | 95.3(89.0.98.0)   |
| Year 2      | 93.9 (85.9,97.4)  | 87.5 (66.1, 95.8) | 92.4 (85.4, 96.1) |
| Year3       | 92.6 (84.3, 96.6) | 87.5(66.1,95.8)   | 91.5 (84.2,95.5)  |
| Year 4      | 83.2 (71.0, 90.5) | 87.5(66.1,95.8)   | 83.4 (72.7,90.1)  |
| Year 5      | 83.2(71.0, 90.5)  | 0 (NE, NE)        | 78.1 (62.1, 88.0) |

NE=notevaluable.

## Ancillary analyses

## Subjects who received dasatinib PFOS exclusively

Of the 24 subjects in the PFOS group (received at least 1 dose of PFOS), 8 (7.54%) subjects received PFOS exclusively. At the time of DBL, 5 of them were alive with no relapse, 2 had a bone marrow relapse  and  were  alive  after  receiving  subsequent  therapy.  One  subject  had  a  positive  MRD  and underwent  a HSCT,  reinitiated dasatinib until Month  5 post-transplantation; 3 months  after discontinuing dasatinib, the patient relapsed and died 2.5 months later. Hence, the OS rate was 7/8 (87.5%) and EFS rate was 5/8 (62.5%).

- Updated 3-year data, PFOS (only) vs. PFOS (once)

The Kaplan-Meier estimate of 3-year DFS of dasatinib plus chemotherapy treatment in the 8 patients who received PFOS exclusively was 62.5% (95% CI: 22.9, 86.1). The Kaplan-Meier estimate of 3-year DFS of dasatinib plus chemotherapy treatment in the patients who received both PFOS and tablets was 68.8% (95% CI: 40.5, 85.6).

<div style=\"page-break-after: always\"></div>

Table 27 Study CA180372 Kaplan-Meier estimates of DFS in subjects treated exclusively with PFOS

|                                                              |                    | Number of Subjects with Events   | Number of Subjects with Events   | Nunber of Subjects Censored   | Nunber of Subjects Censored   |        | Kaplan-Meier Estimates at Last Event   | Kaplan-Meier Estimates at Last Event   |
|--------------------------------------------------------------|--------------------|----------------------------------|----------------------------------|-------------------------------|-------------------------------|--------|----------------------------------------|----------------------------------------|
| Interval                                                     | #Subjects atRiskof | During                           |                                  | During Time                   |                               | Remain | in Time Interval                       | in Time Interval                       |
| (Month)                                                      | Event              | Interval                         | Cumllative                       | Interval                      | Cumlative                     | atRisk | DES                                    | 95%CI                                  |
| 0 0-3 3-6 6-9 9-12 12-15 15-18 18-21 21-24 24-27 27-30 30-33 | 888                | 000 0 0 10 D 0                   | 0 0 0 0 1 1                      | D                             | 000000                        |        | 100.0                                  | (100.0,100.0)                          |
|                                                              |                    |                                  |                                  | 0                             |                               |        |                                        |                                        |
|                                                              |                    |                                  |                                  | 0                             |                               |        |                                        |                                        |
|                                                              | 8                  |                                  |                                  |                               |                               | 7      | 87.5                                   | (38.7,98.1)                            |
|                                                              | 7                  |                                  |                                  |                               |                               | 7      |                                        |                                        |
|                                                              | 7                  |                                  | 1                                | D                             |                               | 7      |                                        |                                        |
|                                                              | 7                  |                                  | 1                                | 0                             | 0                             | 7      |                                        |                                        |
|                                                              |                    |                                  | 1                                | 0                             |                               |        |                                        |                                        |
|                                                              | 7                  | 0                                |                                  |                               |                               | 7      |                                        |                                        |
|                                                              | 7                  | 1                                |                                  |                               | 0                             | 6      | 75.0                                   | (31.5,93.1)                            |
|                                                              | 665                |                                  | 2333                             | 0                             |                               |        |                                        |                                        |
| 33-36                                                        |                    |                                  |                                  | 0                             | 00                            |        | 62.5                                   | (22.9, 86.1)                           |
| 36-39                                                        |                    | 100                              |                                  |                               | 1135                          | 654420 |                                        |                                        |
| 39-42                                                        | 4                  |                                  |                                  |                               |                               |        |                                        |                                        |
|                                                              |                    |                                  |                                  | 10                            |                               |        |                                        |                                        |
| 42-45                                                        |                    | 0                                |                                  |                               |                               |        |                                        |                                        |
| 45-48                                                        | 42                 | 0                                | 33                               | 22                            |                               |        |                                        |                                        |

<div style=\"page-break-after: always\"></div>

Figure 13 Study CA180372 Kaplan-Meier Plot of DFS All PFOS treated subjects

<!-- image -->

One patient who exclusively received PFOS died. The Kaplan-Meier estimate of 3-year OS was 87.5% (95% CI: 38.7, 98.1).

Two out of 16 patients who received both PFOS and tablets have died; the 3-year OS was 87.5% (95% CI: 58.6, 96.7).

## Summary of main study

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 28 Summary of Efficacy for trial CA180372

| Title: A Phase 2 multi-centre, historically-controlled study of dasatinib added to standard chemotherapy in paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia   | Title: A Phase 2 multi-centre, historically-controlled study of dasatinib added to standard chemotherapy in paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia   | Title: A Phase 2 multi-centre, historically-controlled study of dasatinib added to standard chemotherapy in paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                      | CA180372                                                                                                                                                                                                              | CA180372                                                                                                                                                                                                              |
| Design                                                                                                                                                                                                                | Open-label, multi-centre, single-arm, Phase 2, historically-controlled study                                                                                                                                          | Open-label, multi-centre, single-arm, Phase 2, historically-controlled study                                                                                                                                          |
| Design                                                                                                                                                                                                                | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                        | 3 Years (completed) not applicable 2 Years (ongoing)                                                                                                                                                                  |
| Hypothesis                                                                                                                                                                                                            | Superiority over chemotherapy alone of AIEOP-BFM 2000 Non-inferiority to imatinib plus chemotherapy of EsPhALL trial Superiority over continuous imatinib plus chemotherapy of EsPhALL trial                          | Superiority over chemotherapy alone of AIEOP-BFM 2000 Non-inferiority to imatinib plus chemotherapy of EsPhALL trial Superiority over continuous imatinib plus chemotherapy of EsPhALL trial                          |

<div style=\"page-break-after: always\"></div>

| Treatments group                                | paediatric Ph + ALL                                | paediatric Ph + ALL                                                     | dasatinib 60 mg/m 2 daily (Tablet or PFOS) + chemotherapy (ALL 2000 regimen) for a maximum duration of 2 years; 109 subjects enrolled, 106 treated.                     | dasatinib 60 mg/m 2 daily (Tablet or PFOS) + chemotherapy (ALL 2000 regimen) for a maximum duration of 2 years; 109 subjects enrolled, 106 treated.                     |
|-------------------------------------------------|----------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions                       | Primary endpoint                                   | 3-year event free survival (EFS) binomial rates vs. historical controls | The number of subjects without event after 3 years since the start of dasatinib divided by the number of treated subjects.                                              | The number of subjects without event after 3 years since the start of dasatinib divided by the number of treated subjects.                                              |
| Endpoints and definitions                       | Secondary endpoint                                 | MRD negative rate                                                       | The MRD levels are the proportion of leukemic cells in a sample at a specific time point. The limit of detection will be approximately 10 -4 - 10 -5 or 0.01% - 0.001%. | The MRD levels are the proportion of leukemic cells in a sample at a specific time point. The limit of detection will be approximately 10 -4 - 10 -5 or 0.01% - 0.001%. |
| Endpoints and definitions                       | Secondary endpoint                                 | Complete Remission Rate (CRR)                                           | Defined as < 5% lymphoblasts in the bone marrow (ie, M1 bone marrow) and CSF with no evidence of other extra medullary disease.                                         | Defined as < 5% lymphoblasts in the bone marrow (ie, M1 bone marrow) and CSF with no evidence of other extra medullary disease.                                         |
| Database lock 26-Jul-2017                       | Database lock 26-Jul-2017                          | Database lock 26-Jul-2017                                               | Database lock 26-Jul-2017                                                                                                                                               | Database lock 26-Jul-2017                                                                                                                                               |
| Results and Analysis                            | Results and Analysis                               | Results and Analysis                                                    | Results and Analysis                                                                                                                                                    | Results and Analysis                                                                                                                                                    |
| Analysis description                            | Primary Analysis                                   | Primary Analysis                                                        | Primary Analysis                                                                                                                                                        | Primary Analysis                                                                                                                                                        |
| Analysis population and time point description  | modified intention to treat                        | modified intention to treat                                             | modified intention to treat                                                                                                                                             | modified intention to treat                                                                                                                                             |
| Descriptive statistics and estimate variability | Treatment group                                    | Treatment group                                                         | dasatinib + chemotherapy                                                                                                                                                | dasatinib + chemotherapy                                                                                                                                                |
| Descriptive statistics and estimate variability | Number of subjects                                 | Number of subjects                                                      | 106                                                                                                                                                                     | 106                                                                                                                                                                     |
| Descriptive statistics and estimate variability | 3-year binomial EFS rate (%)                       | 3-year binomial EFS rate (%)                                            | 66.0                                                                                                                                                                    | 66.0                                                                                                                                                                    |
| Descriptive statistics and estimate variability | 90% exact CI                                       | 90% exact CI                                                            | (57.7 - 73.7)                                                                                                                                                           | (57.7 - 73.7)                                                                                                                                                           |
| Descriptive statistics and estimate variability | KM estimate of EFS at 3 years                      | KM estimate of EFS at 3 years                                           | 65.5%                                                                                                                                                                   | 65.5%                                                                                                                                                                   |
| Descriptive statistics and estimate variability | 95% CI                                             | 95% CI                                                                  | (55.5 , 73.7)                                                                                                                                                           | (55.5 , 73.7)                                                                                                                                                           |
| Descriptive statistics and estimate variability | Complete remission rates at End of Induction 1A    | Complete remission rates at End of Induction 1A                         | 65.1%                                                                                                                                                                   | 65.1%                                                                                                                                                                   |
| Effect estimate per comparison                  | Primary endpoint Comparison groups                 | Primary endpoint Comparison groups                                      | Primary endpoint Comparison groups                                                                                                                                      | AIEOP- BFM2000                                                                                                                                                          |
| Effect estimate per comparison                  | Dasatinib-Control                                  | Dasatinib-Control                                                       | Dasatinib-Control                                                                                                                                                       | 16.86                                                                                                                                                                   |
| Effect estimate per comparison                  | 3-year EFS rate 90% CI                             | 3-year EFS rate 90% CI                                                  | 3-year EFS rate 90% CI                                                                                                                                                  | [3.9 29.8]                                                                                                                                                              |
| Effect estimate per comparison                  | P-value (χ 2 test)                                 | P-value (χ 2 test)                                                      | P-value (χ 2 test)                                                                                                                                                      | 0.032                                                                                                                                                                   |
| Effect estimate per comparison                  | Primary endpoint Comparison groups                 | Primary endpoint Comparison groups                                      | Primary endpoint Comparison groups                                                                                                                                      | EsPhal                                                                                                                                                                  |
| Effect estimate per comparison                  | Pearson χ 2 test                                   | Pearson χ 2 test                                                        | Pearson χ 2 test                                                                                                                                                        | 6.91                                                                                                                                                                    |
| Effect estimate per comparison                  | 3-year EFS rate 90% CI                             | 3-year EFS rate 90% CI                                                  | 3-year EFS rate 90% CI                                                                                                                                                  | (-3.3, 172.2)                                                                                                                                                           |
| Effect estimate per comparison                  | P-value                                            | P-value                                                                 | P-value                                                                                                                                                                 | 0.271                                                                                                                                                                   |
| Effect estimate per comparison                  | Primary endpoint Comparison groups                 | Primary endpoint Comparison groups                                      | Primary endpoint Comparison groups                                                                                                                                      | COG ALL0031                                                                                                                                                             |
| Effect estimate per comparison                  | Pearson χ 2 test                                   | Pearson χ 2 test                                                        | Pearson χ 2 test                                                                                                                                                        |                                                                                                                                                                         |
| Effect estimate per comparison                  |                                                    |                                                                         |                                                                                                                                                                         | -10.75                                                                                                                                                                  |
| Effect estimate per comparison                  | 3-year EFS rate 90% CI P-value                     | 3-year EFS rate 90% CI P-value                                          | 3-year EFS rate 90% CI P-value                                                                                                                                          | (-22.7, 1.2) 0.157                                                                                                                                                      |
| Notes                                           | study CA180204 functioned as run-in for this study | study CA180204 functioned as run-in for this study                      | study CA180204 functioned as run-in for this study                                                                                                                      | study CA180204 functioned as run-in for this study                                                                                                                      |

Analysis performed across trials (pooled analyses and meta-analysis)

N/A

## Clinical studies in special populations

N/A

<div style=\"page-break-after: always\"></div>

## Supportive study

## Study CA180204

Study  CA180204  was  an  open-label,  multi-center,  single-arm  Phase  II  study  in  62  paediatric  and young adult patients with newly diagnosed Ph+ ALL. A total of 55 paediatric subjects were treated (35 in the discontinuous dasatinib group and 20 in the continuous dasatinib group; 3 non-eligible subjects were excluded from the efficacy analysis). A total of 33 (60%) paediatric subjects completed study treatment. The most common reason in paediatric subjects in the combined cohorts for not completing study treatment was bone marrow transplant (N = 13, 23.6%). Two paediatric subjects were reported to  have  disease  progression  during  the  study.  Reasons  for  not  continuing  in  the  study  included: enrolment  onto  another  COG  study  with  therapeutic  intent  (9.1%),  death  (12.7%),  and  3  (5.5%) subjects  considered  ineligible  after  having  started  treatment.  A  summary  of  key  demographic characteristics of study CA180204 is presented in Table 29.

Table 29 Summary of Key Demographic Characteristics-Study CA180204

|                                                  | CA180372Tablet Only and CA180204 ContinuousDasatinib N=99   | CA180372Tablet Only and CA180204Efficacy Sample N=132   | CA180372andCA180204 Efficacy Sample (Total) N=156   |
|--------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------|-----------------------------------------------------|
| Demographics                                     |                                                             |                                                         |                                                     |
| Median age, years (min-max)                      | 10.36 (1.8, 17.9)                                           | 9.72 (1.5, 17.9)                                        | 9.11 (1.5,17.9)                                     |
| Median age at initial diagnosis, years (min-max) | 10.34 (1.8, 17.9)                                           | 9.69 (1.5, 17.9)                                        | 9.10 (1.5, 17.9)                                    |
| Age categonization at diagnosis, n (%)           |                                                             |                                                         |                                                     |
| >1year-<2years                                   | 1 (1.0)                                                     | 2 (1.5)                                                 | 6 (3.8)                                             |
| ≥2 years -c7 years                               | 26 (26.3)                                                   | 40 (30.3)                                               | 51 (32.7)                                           |
| ≥7years -c12 years                               | 33 (33.3)                                                   | 42 (31.8)                                               | 50 (32.1)                                           |
| ≥ 12 years - ≤ 18 years                          | 39 (39.4)                                                   | 48 (36.4)                                               | 49 (31.4)                                           |
| Sex, n (%)                                       |                                                             |                                                         |                                                     |
| Male                                             | 57 (57.6)                                                   | 79 (59.8)                                               | 91 (58.3)                                           |
| Female                                           | 42 (42.4)                                                   | 53 (40.2)                                               | 65 (41.7)                                           |
| Race, n (%)                                      |                                                             |                                                         |                                                     |
| White                                            | 77 (77.8)                                                   | 100 (75.8)                                              | 119 (76.3)                                          |
| Black/African American                           | 12 (12.1)                                                   | 17 (12.9)                                               | 21 (13.5)                                           |
| Asian                                            | 6 (6.1)                                                     | 7 (5.3)                                                 | 7 (4.5)                                             |
| Other                                            | 4 (4.0)                                                     | 8 (6.1)                                                 | 9 (5.8)                                             |

Note: Pediahic Efficacv Sample = nediatic subiects treated with at least 1 dose of dasatinib.

The  median  duration  of  dasatinib  therapy  from  first  through  last  dasatinib  dose  date  was  31.31 months.

Subjects were categorized by risk: Standard Risk was defined as M1 (bone marrow status of &lt; 5% lymphoblasts/complete response in bone marrow) with MRD &lt; 1% at end Induction and MRD &lt; 0.01% at end Consolidation Block 2; High Risk was defined as MRD ≥ 1% at end Induction or MRD ≥ 0.01% at end Consolidation Block 2. Any Risk is both groups combined.

A summary of efficacy results in Study CA180204 is presented in Table 30.

<div style=\"page-break-after: always\"></div>

Table 30 Summary of Efficacy in Study CA180204

| Endpoint                         | Discontinuous Dasatinib AnyRisk N=33   | Continuous Dasatinib AnyRisk N=19   | Continuous + DiscontinuousDasatinib AnyRisk N=52   |
|----------------------------------|----------------------------------------|-------------------------------------|----------------------------------------------------|
| K-Mestimateof3-yearEFS % (95%C1) | 87.9 (76.9,98.8)                       | 68.4(48.3,88.6)                     | 80.8 (70.2,91.4)                                   |
| K-Mestimateof3-yearOS %(95%C1)   | 97.0 (91.2,100)                        | 89.5(76.1,100)                      | 94.2(88.0,100)                                     |
| MRD positive, n/N (%)a           |                                        |                                     |                                                    |
| EndofInduction                   | 11/32(34.4)                            | 9/19 (47.4)                         | 20/51 (39.2)                                       |
| I%06                             | (17.9,50.8)                            | (24.9, 69.8)                        | (25.8,52.6)                                        |
| Endof Consolidation              | 2/33 (6.1)                             | 3/19 (15.8)                         | 5/52 (9.6)                                         |
| I%06                             | (2.0, 16.8)                            | (6.5,33.6)                          | (4.8,18.5)                                         |

PediauicEfficacySample=pediatricsubjectsreatedwithatleastldoseofdasatinib.

A summary of EFS from pooled CA180204 and CA180372 data are presented below.

Table 31 Kaplan Meier Estimates Event-free Survival

|                           | CA180372TabletOnly andCA180204 ContinuousDasatinib N=99   | CA180372Tablet OnlyandCA180204 Efficacy Sample N=132   | CA180372and CA180204Efficacy Sample (Total) N=156   |
|---------------------------|-----------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------|
| K-MEstimateofEFS.%(95%CI) |                                                           |                                                        |                                                     |
| 3-Yearestimate            | 65.1 (54.7, 73.6)                                         | 70.8 (62.2, 77.9)                                      | 70.2(62.3.76.8)                                     |
| 5-Yearestimate            | 52.4 (40.7,62.8)                                          | 55.2 (45.3, 64.0)                                      | 52.6(43.0, 61.3)                                    |

Figure 14 Kaplan-Meier plot of Event-free survival - Total Pooled CA180204 and CA 180372

<!-- image -->

NumberofSubjectsatRisk

156156153150147142141138132126122117105887566574539 Z 19

Dasatinib（events:65/156).medianand95%Cl:62.36(48.56.N.A.) Censored

ProgramSource:/projects/bms235555/stats/ScE/prog/figures

ProgramName:rg-ef-os-gtl.sas

03OCT2017:09:48:56

Time(Months)

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical efficacy

## Design and conduct of clinical studies

This  application  is  based  on  two  studies.  The  main  study  CA180372  is  a  Phase  2,  open-label,  multicenter single-arm, historically-controlled study in children and adolescents with newly diagnosed Ph+ ALL.  Included  patients  were  given  continuous dasatinib  added  to  a  Ph+  ALL chemotherapy  regimen, based  on  regimens  from  the  AIEOP-BFM  ALL  2000  study  and  the  amended  EsPhALL.  The  primary objective was to compare the 3-year EFS of dasatinib in combination with chemotherapy with external historical controls.

The supportive  study  CA180204  was  a  Phase  2,  open-label,  multi-center,  single-arm  study  including children and young adults with newly diagnosed Ph+ ALL to be treated also with dasatinib 60 mg/m 2 daily by oral tablet. Study CA180204 was based on a different chemotherapy backbone therapy than that  used  in  CA180372,  and  the  number  of  subjects  in  study  CA180204  who  received  dasatinib continuously was limited to 20 subjects. This study was terminated early due to the opening of the main study.

The  clinical  studies  were  performed  with  few  amendments,  withdrawals  or  lost  to  follow-up. Introduction of an oral suspension of medication for the ALL, otherwise only available as tablet and not for  parenteral  use,  will  definitely  meet  an  unmet  medical  need in  children.  Likewise,  this  PFOS  may also  be  of  interest  in  some  adult  patients,  who  may  have  difficulties  swallowing  tablets  for  various reasons.

The clinical development program for dasatinib in paediatric ALL includes single-arm studies. Imatinib was  the  first  TKI  to  be  developed  and  therefore  also  the  first  introduced  as  targeted  therapy  in childhood leukemia. The trials included randomization of chemotherapy to treatment with and without imatinib  and  demonstrated  the  superiority  of  the  combination  therapy.  The  design  of  the  main  and supportive studies introducing dasatinib were single-arm studies because activity of dasatinib against Ph+  ALL  in  adults  and  of  imatinib  against  Ph+  ALL  in  children  has  been  established  and  hence comparing the activity of dasatinib in combination to chemotherapy alone is acceptable. However, the review  and  interpretation  of  previous  advice  is  accepted.  It  is  noticed  that  in  the  introduction  of imatinib in paediatric ALL, trials did include a randomization in subgroups between chemotherapy plus imatinib versus chemotherapy alone but were amended to all patients receiving imatinib shortly after favourable results of other paediatric trials with imatinib became known [2].

The patient population included in the dasatinib clinical studies are representative for paediatric Ph+ ALL, with very few patients below the age of 7, and the majority up to the age of 18. Patients often present severe leucocytosis and two T-ALL were included. Some more characteristics may influence the prognosis, and treatment progress in all acute leukaemia therapy has emphasized the importance of the cytogenetic aberrations. The secondary genetic abnormalities have not been included in previous advice, nor have data been collected later, e.g. from conventional chromosome analysis, which it is anticipated  have  been  performed  in  many  patients,  because  the  banding  technique  is  a  standard analysis.  The  importance  of  secondary  clonal  aberrations  was  known  before  2005  [3],  but  it  is accepted that the information was not collected and consequently not included in the interpretation of results of dasatinib in paediatric ALL.

## Efficacy data and additional analyses

The Performance status is not commented in reviews on paediatric ALL (Ph-positive and -negative), but the symptoms involves fever, recurrent infections, organomegaly, bleeding, weight loss, bone pain etc [7]. The PS is not mentioned in the criteria for the EsPhALL study, which states that the patient should  be  eligible  for  the  current  local  prospective  therapeutic  study  of  childhood  ALL  (link:

<div style=\"page-break-after: always\"></div>

https://clinicaltrials.gov/ct2/show/NCT00287105).  However,  only  1  subject  out  of  109  screened patients in study CA180372 was excluded due to an active infection.

In study CA180372, the 3-year binomial EFS rate with dasatinib plus chemotherapy was 66.0% (90% CI:  57.7,  73.7)  compared  to  49.2%  (90%  CI:  38.0,  60.4)  observed  with  chemotherapy  alone  in AIEOP-BFM  2000  and  to  59.1%  (90%  CI:  51.8,  66.2)  observed  with  continuous  imatinib  plus chemotherapy in the amended EsPhALL trial in all treated subjects.

Regarding the secondary endpoints, the OS rate was 91.5% (95% CI: 84.2 - 95.5) at 3 years and the CR was 93.4% (99/106) after consolidation chemotherapy. The results of 3-year DFS are in the same range to results obtained with imatinib.

The inferior CR rate at the end of Induction IA vs AIEOP-BFM 2000 and the Amended EsPhALL trial showed a relevant flaw  in  the  CA180372  study  design  and  conduct,  as  patients  undergoing  the  CR assessment not in the last day of Induction IA, as determined, but on the following day, just prior to start Induction IB, were not recognised, as per protocol criteria, to be in CR. However, the CR data with one day extension is clinically acceptable, as that extra day is not expected to significantly change the patient's CR status and allows for the inclusion of CR cases excluded for lack of information. The CR analyses results with one extra day are in line with historical trials, including AIEOP-BFM 2000 and Amended EsPhALL.

Not  all  patients  were  assessed  for  MRD-negativity  by  Ig/TCR  PCR  technique,  mainly  due  to  poor baseline  samples,  e.g.  no  clones  identified,  no  reliable  targets,  primers  failed  to  amplify  target, inadequate volume of BM at DX, etc. The MRD negativity rate assessed by Ig/TCR rearrangement was 71.7% by the end of consolidation in all treated patients. When this rate was based on the 85 patients with evaluable Ig/TCR assessments, the estimate was 89.4%. The MRD-negativity rates at the end of induction and consolidation as measured by flow cytometry were 66.0% and 84.0%, respectively.

The results of the oral suspension, which may be very valuable in the treatment of young children - or perhaps adult patients with Ph+ ALL for reasons like mucositis, swallowing disturbances and more are presented in 24 patients, who all had the PFOS at least once. Eight patients are characterized as treated exclusively by PFOS. The OS rate was 7/8 (87.5%) and EFS rate at 3 years was 5/8 (62.5%). The  relapse  and  survival  rates  in  the  PFOS  subgroup  of  subjects  are  consistent  with  the  overall population. It may be anticipated that children may use PFOS and tablets intermittently. Updated data for PFOS (only) and PFOS (once) treated patients are restricted by low numbers, as expected, but are comparable  demographically,  and  seems  to  show  similar  results  and  clinically  meaningful  on  the endpoint DFS, EFS and OS.

The  study-design  did  not  include  previously  imatinib-treated  children,  and  the  experience  in  the molecular  biological  details  in  such  patients  is  also  limited.  However,  it  appears  that  eight  of  nine samples from imatinib-treated patients in the COGAALL0031 trial showed no BCR-ABL1 kinase domain mutation, only one presenting an acquired mutation [9].

It is a concern if long-term outcome is reduced by insufficient dosing, even if the initial effect may still be high response rates and encouraging results. Acute leukaemia may in most cases be sensitive to treatment,  and  it  is  important  to  maintain  the  efficacy  by  the  successive  therapies.  The  results obtained  in  the  main  single  arm  study  must  be  assessed  in  the  context  of  the  data  from  historical controls. Induction of deeper remissions are obtained more rapidly by dasatinib in CML than obtained by imatinib [10]. A survival advantage has not been demonstrated clearly in CML by any TKI, but the disease  biology  in  the  acute  leukaemia  is  different,  and  a  more  rapid  and  deep  remission  may  be valuable for survival. The efficacy results on dasatinib treatment are interpreted as a contribution to

<div style=\"page-break-after: always\"></div>

reduce  the  need  for  HSCT  as  second-line  treatment  in  paediatric  Ph+  ALL.  This  implication  is  very encouraging due to risks for fatal outcome or morbidity by HSCT.

In the supportive study CA180204, the 3-year EFS rate was 80.8% (95% CI: 70.2, 91.4) in the 52 paediatric  patients  considered  evaluable  for  efficacy  and  68.4%  (95%  CI:  48.3,  88.6)  in  the  19 subjects on continuous dasatinib.

## 2.5.2. Conclusions on the clinical efficacy

The main study CA180372 showed a clinically relevant effect in terms of the 3-year binomial EFS rate compared to historical controls treated without dasatinib by the same combination chemotherapy backbone. This was supported by improvements on all relevant secondary endpoints.

Therefore, clinically relevant efficacy of dasatinib in combination with chemotherapy in newly diagnosed Ph+ ALL was demonstrated in the paediatric population.

## 2.6. Clinical safety

## Introduction

Dasatinib was combined with 2 different multi-agent chemotherapeutic 'backbone' regimens to treat a total  of  161  paediatric  subjects  with  Ph+  ALL:  the  COG  AALL0031  treatment  regimen  in  Study CA180204,  and  the  Associazione  Italiana  di  Ematologia  Paediatrica  -  Berlin-Frankfurt-  Muenster (AIEOP-BFM) ALL 2000 regimen in Study CA180372. In Study CA180204, the COG AALL0031 regimen was combined with dasatinib treatment as a 'discontinuous' regimen (ie, 2-week periods of dasatinib treatment followed by 1 to 2 weeks off) in the first cohort and a 'continuous' regimen in the second cohort.  Study  CA180372 also used the dasatinib powder for oral suspension (PFOS) formulation for subjects who could not swallow tablets.

Subject  disposition,  exposure,  adverse  events  (AEs),  and  AEs  of  special  interest  (AEOSIs)  were analyzed  from  paediatric  subject  data  pooled  from  Studies  CA180204  and  CA180372  and  are presented by the following categories of dasatinib treatment:

- Discontinuous dasatinib: N = 35 (exclusively from CA180204)
- Continuous dasatinib tablet only: N = 102 (20 from CA180204, and 82 from CA180372)
- Continuous dasatinib: N = 126 (20 from CA180204, and 106 from CA180372)
- All treated subjects: N = 161 (55 from CA180204, and 106 from CA180372)

<div style=\"page-break-after: always\"></div>

## Patient exposure

## Table 32 Extent of exposure of Dasatinib Summary - All Treated Subjects in the Pooled Population

|                                                                         | Discontinucus Dasatinib N = 35                 | Continugus Dasatinib Tablet omly N=102   | Cantinugus Dasatinib N = 126   | Al1 Treated N 161                         |
|-------------------------------------------------------------------------|------------------------------------------------|------------------------------------------|--------------------------------|-------------------------------------------|
| DURATION OE THERAPY (-ONTHS) EAN BBBBB 一 MAX) 百百 11                     | (14.306) i 28.6) 08 34.96) 11.4) (60.0)        | 23: 8 (965 33.02)                        | 23 337) 41 33.02) 58:          | 23: 351525564 T6 900) 8 353 34.96) .2     |
| AVERHGE MEAN (SD) IAILYDOSE(MG/M2/LAY) MEDIAN(MMN-MAX)                  | 38:82 (22.35) - 46.66)                         | 5:88 (31589)- 76.12)                     | 58:88 (31189 - 76.12)          | 58:88 (2:8942 76.12)                      |
| NUMBEROFDASATINIB DOSE DAYS (MONTHS) MEAN (SD) MAX) B                   | 10.35 15. 940100 (6.675) 2 64 16.23) 11. 60.0) | 18. 22. 98 8 352) 31.77)                 | 18 22 (8. 097) 31.77)          | 17.11 19559325 (8.571) 0 6) 31.77) 32o 10 |
| MEAN MEDIAN(MN-MAX) (SD)                                                | 58:28  (8677 66.84)                            | 58:40  一 92.13)                          | 68:43  (46561) - 92.13)        | 60.51 (4:288 - 92.13)                     |
| NUMBEROFDASATINIBTABTET DOSE TAYS (-CINHS) 二 MAX) CTS                   | 38040200 16.23) 60.0)                          | 80 31.77) 8 13: 9                        | 29: 38220955 90 rnon 31.77)    | 18: 08319351 31.77) 6                     |
| NUMEEROF TASATINB PEOS DOSE DAYS (MONTHS) AN (SD 品品品品品品 2886886 MAX) 15 | 0. 00 0.00)                                    | 0.08 (0.000) (100.0) 00 0.00)            | H4645 23.52)                   | (6.076) 23.52)                            |

<div style=\"page-break-after: always\"></div>

## Adverse events

Table 33 Summary of Safety Results Pooled  from  CA180372 and CA180204 - All treated Paediatric Subjects

|                                                                        | DiscontinuousDasatinib N=35                                            | DiscontinuousDasatinib N=35                                            | ContinuousDasatinib TabletOuly N=102                                   | ContinuousDasatinib TabletOuly N=102                                   | Continuous Dasatinib N=126                                             | Continuous Dasatinib N=126                                             | All Treated N=161                                                      | All Treated N=161                                                      |
|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Number of Subjects(%)                                                  | All                                                                    | Grade 3-4                                                              | All                                                                    | Grade 3-4                                                              | All                                                                    | Grade3-4                                                               | Al                                                                     | Grade3-4                                                               |
| Adrerse Events(pooled population)                                      |                                                                        |                                                                        |                                                                        |                                                                        |                                                                        |                                                                        |                                                                        |                                                                        |
| All causality                                                          | 34(97.1)                                                               | 33(94.3)                                                               | 101 (99.0)                                                             | 100 (98.0)                                                             | 125 (99.2)                                                             | 122 (96.8)                                                             | 159 (98.8)                                                             | 155 (96.3)                                                             |
| Dasatinib-related                                                      | 27 (77.1)                                                              | 27 (77.1)                                                              | 88(86.3)                                                               | 76(74.5)                                                               | 106 (84.1)                                                             | 91(72.2)                                                               | 133 (82.6)                                                             | 118(73.3)                                                              |
| Dasatinib-related AdverseErents of SpecialInterest (pooled population) | Dasatinib-related AdverseErents of SpecialInterest (pooled population) | Dasatinib-related AdverseErents of SpecialInterest (pooled population) | Dasatinib-related AdverseErents of SpecialInterest (pooled population) | Dasatinib-related AdverseErents of SpecialInterest (pooled population) | Dasatinib-related AdverseErents of SpecialInterest (pooled population) | Dasatinib-related AdverseErents of SpecialInterest (pooled population) | Dasatinib-related AdverseErents of SpecialInterest (pooled population) | Dasatinib-related AdverseErents of SpecialInterest (pooled population) |
| Fluidretention                                                         | 0                                                                      | 0                                                                      | 13 (12.7)                                                              | 8 (7.8)                                                                | 15 (11.9)                                                              | 8(6.3)                                                                 | 15 (9.3)                                                               | 8(5.0)                                                                 |
| Superficial edema                                                      | 0                                                                      | 0                                                                      | 7 (6.9)                                                                | 3(2.9)                                                                 | 8 (6.3)                                                                | 3 (2.4)                                                                | 8(5.0)                                                                 | 3(1.9)                                                                 |
| Pleuraleffusion                                                        | 0                                                                      | 0                                                                      | 6 (5.9)                                                                | 4(3.9)                                                                 | 7 (5.6)                                                                | 4(3.2)                                                                 | 7(4.3)                                                                 | 4(2.5)                                                                 |
| Generalized edema                                                      | 0                                                                      | 0                                                                      | 2 (2.0)                                                                | 1 (1.0)                                                                | 3 (2.4)                                                                | 1 (0.8)                                                                | 3(1.9)                                                                 | 1 (0.6)                                                                |
| Ascites                                                                | 0                                                                      | 0                                                                      | 3(2.9)                                                                 | 2(2.0)                                                                 | 3(2.4)                                                                 | 2(1.6)                                                                 | 3(1.9)                                                                 | 2(1.2)                                                                 |
| Pericardial effusion                                                   | 0                                                                      |                                                                        | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
| CHF/Cardiac dysfunction                                                | 0                                                                      | 0                                                                      | 1 (1.0)                                                                | 1 (1.0)                                                                | 1(0.8)                                                                 | 1 (0.8)                                                                | 1 (0.6)                                                                | 1 (0.6)                                                                |
| Pulmonary edema                                                        | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
| Pulmonary hypertension                                                 | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
| Respiratory disorders                                                  | 1 (2.9)                                                                |                                                                        | 4(3.9)                                                                 | 0                                                                      | 7 (5.6)                                                                | 0                                                                      | 8(5.0)                                                                 | 0                                                                      |
| Chest pain                                                             | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 1 (0.8)                                                                | 0                                                                      | 1 (0.6)                                                                | 0                                                                      |
| Non-productive cough                                                   | 0                                                                      | 0                                                                      | 3 (2.9)                                                                | 0                                                                      | 5 (4.0)                                                                | 0                                                                      | 5 (3.1)                                                                | 0                                                                      |
| Shoitness ofbreath                                                     | 1 (2.9)                                                                | 0                                                                      | 2(2.0)                                                                 | 0                                                                      | 4(3.2)                                                                 | 0                                                                      | 5(3.1)                                                                 | 0                                                                      |
| Cardiac disorders                                                      | 1(2.9)                                                                 | 0                                                                      | 5 (4.9)                                                                | 0                                                                      | 8(6.3)                                                                 | 0                                                                      | 9(5.6)                                                                 | 0                                                                      |
| Pulmonary arterial hypertension                                        | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
| Hemonhage                                                              | 2 (5.7)                                                                | 2 (5.7)                                                                | 15 (14.7)                                                              | 6 (5.9)                                                                | 18 (14.3)                                                              | 7 (5.6)                                                                | 20 (12.4)                                                              | 9 (5.6)                                                                |
| GI bleeding                                                            | 1 (2.9)                                                                | 1(2.9)                                                                 | 9(8.8)                                                                 | 3(2.9)                                                                 | 11(8.7)                                                                | 4(3.2)                                                                 | 12 (7.5)                                                               | 5 (3.1)                                                                |
| CNS bleeding                                                           | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      |
| Other hemonhage                                                        | 1 (2.9)                                                                | 1 (2.9)                                                                | 9 (8.8)                                                                | 3(2.9)                                                                 | 12 (9.5)                                                               | 3(2.4)                                                                 | 13 (8.1)                                                               | 4(2.5)                                                                 |
| Pediatic growth and development                                        | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 1(0.8)                                                                 | 0                                                                      | 1(0.6)                                                                 | 0                                                                      |
| Osteopenia                                                             | 0                                                                      | 0                                                                      | 0                                                                      | 0                                                                      | 1 (0.8)                                                                | 0                                                                      | 1 (0.6)                                                                | 0                                                                      |

Source:Appendix 5.1,Appendix 5.3,Table 12

Note:dasatinib was dosed at 60 mg/mper scheduled treatment dayinboth studies.

Table 34 Summary of Safety Results from Individuals studies - CA180372 and CA180204 All treated Subjects

| SafetyResnlesfromSmdyCA180372 Number of Subjects(%)   | DasatinibTablet Only (N=82)                         | DasatinibPFOSUsed (N=24)   | All Treated Subjeets (=106)   |
|-------------------------------------------------------|-----------------------------------------------------|----------------------------|-------------------------------|
| Deaths                                                | 11 (13.4)                                           | 4(16.7)                    | 15 (14.2)                     |
| Primary reason of death:                              |                                                     |                            |                               |
| Disease                                               | 1(1.2)                                              | 1(4.2)                     | 2(1.9)                        |
| HSCT                                                  | 2(2.4)                                              | 0                          | 2(1.9)                        |
| Other                                                 | 8(9.8)                                              | 3(12.5)                    | 11(10.4)                      |
| In Continued CompleteRemission                        | 6(7.3)                                              | 3(12.5)                    | 9(8.5)                        |
| Within30daysfromlastdose                              | 3(3.7)                                              | 2(8.3)                     | 5 (4.7)                       |
|                                                       | A!I Grade3-5                                        | A!I Grade3-5               | AII Grade3-5                  |
| SAEs                                                  |                                                     |                            |                               |
| All causalitya                                        | 79 (96.3) 79 (96.3)                                 | 22(91.7) 22(91.7)          | 101(95.3) 101 (95.3)          |
| Dasatinib-related                                     | 36(43.9)                                            | 8(33.3)                    | 44 (41.5) 42(39.6)            |
| AEs leading to discontinuation                        | 34(41.5) 4(4.9)                                     | 8(33.3)                    | 7 (6.6)                       |
| All causality                                         | 7 (8.5)                                             | 0 0                        | 4(3.8)                        |
| Dasatinib-related                                     | 2(2.4) 1(1.2)                                       | 0 0                        | 2(1.9) 1(0.9)                 |
| SefetyResuirsfromAll IreatedStbjectsinSmdyCA180204b   | SefetyResuirsfromAll IreatedStbjectsinSmdyCA180204b |                            |                               |
| Number of Subjects(%)                                 | Discontinuous Dasatinib (N=40)                      | ContinuousDasatinib (N=22) | All Treated Subjects (N=62)   |
| Deaths                                                |                                                     |                            |                               |
| Atany time                                            | 4(10.0)                                             | 4(18.2)                    | 8(12.9)                       |
| Within30 daysfrom lastdose                            | 0                                                   | 0                          | 0                             |
| SAEs(based on primary event)c                         |                                                     |                            |                               |
| All causality                                         | 19 (47.5)                                           | 10 (45.5)                  | 29 (46.8)                     |
| Dasatinib-related                                     | 14(35.0)                                            | 7(31.8)                    | 21 (33.9)                     |

Source:CA180204final CSRTable7.1(overall safety summary);CA180372finalCSRTable8.1-1(Overall SafetySummary)andTableS.6.2(deaths)

<div style=\"page-break-after: always\"></div>

## · Common AEs

Table 35 Summary of On-treatment adverse Events Reported for at least 10% of subjects by CTC grade - All treated Paediatric Subjects in the Pooled Population

| SKINIEECTION                                                                                  |                         | 7) 6）           | 16 7) 15 14. 7) 17 16.7)   | 8) 7) 11 10.8 8)            | 14 3) 15 9) 15. 12 7)              | 8. 7) 14.3) 11. 9)   |            | 14 3) 13. 7) 13.7)   |                    |
|-----------------------------------------------------------------------------------------------|-------------------------|-----------------|----------------------------|-----------------------------|------------------------------------|----------------------|------------|----------------------|--------------------|
| LUNG INFECTION URINARY TRACT INEECTION                                                        |                         |                 |                            |                             |                                    |                      |            |                      |                    |
| PNEUMONIA                                                                                     |                         |                 |                            | 7)                          | 1）                                 |                      |            |                      |                    |
| SINUSITIS                                                                                     |                         | 3） 9)           | 13 12.7)                   |                             |                                    | 11.1)                | 20         | 13.0) 12.4) 11.2)    |                    |
| CELLULITIS                                                                                    |                         |                 | 17.6)                      | (8'8                        |                                    | 7.9) 3.2)            | 18         |                      |                    |
|                                                                                               |                         |                 | 18 12 11.8)                | 3.9)                        | 1) 10.3)                           |                      |            | 11                   |                    |
| OTITIS MEDIA EVIEROOOLITIS                                                                    | 8.6 6) 11.4)            | 9.8 11.4)       | 12.7)                      | 47 9)                       | 11 9) ot 3)                        | 6.3) 5. 6)           | 18         | 11.2) 10.6) 9.3)     |                    |
| INEECTIOUS BACTERAEMTA                                                                        |                         |                 | 11.8)                      | 9) 12 11.8                  | 11 (6                              |                      | 15         |                      |                    |
| CIOSTRIDIUM CILE                                                                              | 2.9)                    |                 | 11.8)                      | 8)                          |                                    | 11.9)                |            |                      |                    |
| CLOSTRTDTUM BIRSICTLE SIITIOO INEECTION CONJUNCTIVITIS                                        |                         |                 | 66                         | 77 18                       | 9                                  |                      |            | 7)                   |                    |
| ORAL CANDIDIASIS                                                                              |                         |                 |                            |                             |                                    | 8) 8)                |            |                      |                    |
| RHINITIS                                                                                      | 5.7)                    |                 | 1331                       | 1104                        |                                    |                      |            | 7                    |                    |
|                                                                                               |                         | 5.7)            |                            |                             |                                    |                      |            |                      |                    |
| CANDIDA INEECTION                                                                             |                         |                 | i1 8)                      |                             |                                    |                      |            | 1）                   |                    |
|                                                                                               |                         |                 |                            | 3.9)                        | 5)                                 |                      |            |                      |                    |
|                                                                                               |                         |                 |                            |                             |                                    | 3.2)                 |            |                      |                    |
| INWESTIGATICNS NEUIROBHILCOUNT DECREASED ALANINEAMTINOIRANSFERASE INCREASED                   | 32321718 88.6) 65.73 6) |                 | 84997                      | 51326                       | 35554 7275                         | 2569915 77-0)        | 68乳8折      | 8944 7               | 84232 9198 28. 6)  |
| PLATELET COUNT TECRDASED ASDARTATEAMMNOIRANSBERASE INCREASED WHITE BLOOD CETL COUNT LECREASED | 51.4)                   | 48.6)           |                            |                             | 32 5)                              | 23.0)                |            | 36 6)                | C                  |
| WEIGHT DECREASED                                                                              | 13 37.1)                | 13 37.1)        | 2321 657                   |                             |                                    | 8                    |            | 8469                 | 5                  |
| BLOOD BTLIRUBIN INCREASED BLOOD CREATININEINCREASED                                           |                         | 5.7) 2.9)       | 7                          | 698                         |                                    | 2. 4)                |            |                      |                    |
| CARDIACMURMUR                                                                                 |                         |                 | 10.8)                      |                             | 9.5)                               |                      |            |                      |                    |
|                                                                                               | 0m10 8.6)               | 0210            |                            |                             |                                    |                      |            |                      |                    |
|                                                                                               | 2.9)                    |                 |                            | 9）                          |                                    | 9 33                 |            |                      |                    |
| GASTROINIESTINAL DISORDERS                                                                    | 57 16 8.                |                 | 25 72.5 5) 68. 6)          | 7) 122 7)                   | 28 -3 69. 66. 61 49                | 32 37                |            | 5)                   | 19282628626        |
| VOMITING NAUSEA DIARRHOEA ABDOMTINALDAIN                                                      | 11                      | 962             | 60.8 8                     |                             | (0                                 |                      |            | 7336                 |                    |
| SIO-ATITIS CONSTIPATICN                                                                       |                         |                 |                            |                             | 9) 46.0) 2) 22 2)                  |                      |            | 18                   |                    |
| ORAL PAIN COLITIS                                                                             | 9)                      |                 | 45.11 24. 5) 18 6)         | 30.4) 10.                   | 18 3) .1)                          |                      |            |                      |                    |
|                                                                                               |                         |                 |                            | 0) 9) 8                     | 15.                                | 0566636586           |            |                      |                    |
| ABDOMTINAL PAIN UPPER                                                                         | 99                      |                 | 16. 7) 8)                  | 8)                          | 11 1）                              |                      |            |                      |                    |
| NEUTROFENICCOLITIS PROCTALGIA                                                                 | 11.4)                   | 11.4)           | 1 7                        | 9)                          | 12 11                              |                      |            | 98297                |                    |
| HADMATOCHEZIA                                                                                 |                         |                 | 11.8)                      | 1.6)                        | 7)                                 | 8)                   |            |                      |                    |
|                                                                                               | 24 68.6) 51 4)          | 62.9) 48 . 6)   | 53. 78.4 4) 9)             | 63.7) 44. 1)                | 77-0) 50                           | 61                   |            |                      | 566                |
| METABOLISMAND NUTRITION DISORDERS HYROKALADMTA DELREASED APPETITE HYPOAIBUMTNAEMIA            | 125 391                 | 11 693 4) 11 4) | 225 33 3) 4) 5) 19. 6)     | 19.6) 14. 7) 7) 10.8) 4. 9) | 5222128696 (8 34 1) 0) 24. 19. 19. | 88 76                |            | 19224311             |                    |
| HYRONATRAEMTA HYROCATARMTA DEHYTRATICN HYFERGLYCAETA                                          |                         | 11 4)           | 17. 6)                     | 10. 8)                      | 19                                 |                      |            |                      | 1861231896 0996626 |
|                                                                                               | 11.4 11 4)              |                 | 17. 6)                     |                             | 6)                                 | 1                    |            | 17                   |                    |
|                                                                                               | 11.4)                   | 11.4)           |                            |                             | 15                                 |                      | 6888461587 |                      |                    |
| HYTOPHOSPHATAEMTA HYROMAQNESADTA                                                              |                         |                 | 180228868                  |                             | .0)                                |                      |            | 8)                   | (2.9               |
|                                                                                               |                         |                 | 13.7)                      | 1.0)                        | .0) .1) 0)                         |                      |            |                      |                    |
|                                                                                               |                         |                 | 86 （                       | 42                          | 86.5)                              | 09                   | 47.6)      | （ 70.2)              |                    |
|                                                                                               |                         | 1 （ 2.9)        |                            | 41.2)                       | 109                                |                      | 113        |                      | 61 37.9)           |
| SITE CONDITIONS                                                                               | 4(11.4)                 |                 | 84.3)                      |                             |                                    |                      |            |                      |                    |
| PIREXTA INETAMMATION                                                                          | 5.7)                    |                 |                            |                             |                                    |                      | 1机6622666  | 26897887             |                    |
| MUOOSAL FATIGUE                                                                               | 20011                   |                 |                            |                             |                                    |                      |            |                      | S9276              |
| PAIN                                                                                          |                         |                 |                            |                             |                                    |                      |            |                      |                    |
| CHTLLS                                                                                        | 2:3                     | 0000N0OOO 2.9)  |                            |                             |                                    |                      |            |                      |                    |
| NON-CARDIAC CHEST CELEMA APERIDHERAL                                                          |                         |                 |                            | 2:83                        |                                    |                      |            |                      |                    |
| DAIN CATHETER SITE                                                                            | 10000                   |                 |                            |                             | 16611666                           |                      | 1:3        |                      |                    |
|                                                                                               |                         |                 |                            |                             | 8.7)                               |                      |            |                      |                    |
| ASTHENIA                                                                                      |                         |                 |                            |                             |                                    |                      |            | 6.8)                 |                    |
|                                                                                               |                         |                 | 9.8) 10.8)                 |                             |                                    |                      |            |                      |                    |

<div style=\"page-break-after: always\"></div>

| HEATACHE PERIPHERALMOTOR NEUROPATHY PERIPHERAL SENSORY NEUROPATHY DIZZINESS   | 361 8 6 （ 17.1)       | 93210 9)       | 91 ir 284 10            | 47.9           | 237                              | 8728          | 172215                 | 7) 4.3)   | 7) 4.3)   |
|-------------------------------------------------------------------------------|-----------------------|----------------|-------------------------|----------------|----------------------------------|---------------|------------------------|-----------|-----------|
| OROEHARYNGEAL BAIN EPISTAXIS NASAL CONGESTION DYSENOEA PLEURAL EFHUSION       |                       | 5 14.3)        | 79 77.5) 2.9) 2.9) 2.9) | 29 28.4) 99    | 98 77.8) 7)                      | 33 26.2)      | 104 64.6)              | 38 C      | 38 C      |
| RESPIRATORY,THORACIC AND MEDIASTINALDISORDERS HE0OO RHINORRHOEA BACK PAIN     | 860 33:3              | 4 （ 00HO000    |                         | (0             | 39822                            |               |                        | 23.6)     | 23.6)     |
| VASOULAR DISORDERS HYPOTENSION                                                |                       | 18-85          | 134                     | 128            | 39.7)                            | 29-3 11 1)    |                        | 188 3:    | 188 3:    |
| HYPERTENSION                                                                  |                       |                | 40.2)                   |                |                                  |               | 31.1)                  | 8.7)      | 8.7)      |
| INJURY,FOISONING AND PROCEDURAL COMPLICATIONS CONIUSION                       | 00                    |                | 52 51.0)                | 11 （ 10.8)     | 3 38:3 4)                        | 14 0.8) 3. 2) | 3                      | 15        | 15        |
| CARDIAC DISORDERS TACHYCARDIA SINUS TACHYCARDIA                               | 5.7) 5.7)             | 10 2.9)        | 24. 18 6)               | 11 10.8        |                                  |               |                        | 228 757   | 228 757   |
| PSYCHIATRIC DISORDERS ANXIETY                                                 |                       | 8.6)           |                         |                | 165                              |               |                        |           |           |
|                                                                               | 11.4)                 |                |                         |                |                                  |               |                        |           |           |
| DEPRESSION                                                                    |                       |                | 3233                    | 6211           | 9555                             |               |                        |           |           |
| INSOMNIA                                                                      |                       |                |                         |                |                                  |               |                        | 6)        | 6)        |
| EYE DISCRIERS                                                                 | 11 2: 3               |                |                         |                |                                  |               |                        |           |           |
| VISICN BLURRED                                                                |                       |                | 39 2） 14. 7)            |                | 39.                              |               | 31. 7)                 |           |           |
|                                                                               | 5.7)                  |                |                         |                |                                  |               |                        |           |           |
|                                                                               |                       | 1 2.9)         | 77 75.5)                | 301101O        | 94 74.6) 52 38 4）                |               |                        | 34 21.1)  | 34 21.1)  |
| HYEOXTA WHEEZING                                                              | 202                   | OOO0OOOHO 2.9) | 8)                      | 1. 0) 27 26.5) | 14. 3) 10.3)                     | 686088338     |                        | 262765876 | 262765876 |
| CONECTIVE                                                                     | OOONONONO 5.7) 3 8.6) |                |                         |                |                                  | 33 26.        | 1) 97 60.2)            |           |           |
| MUSOULOSKELETALAND TISSUE DISORLERS PADN IN EXTREMITY                         | HNOOOOOO 2:3 8(22.9)  |                |                         | husl 10. 8)    | 54628868 12. 7) 89 70.6) K 38.9) | .2) 10. 3)    | T4628669 41. 123786 9) |           |           |
| MUSCULAR NEAKNESS DAIN IN JAW MYALGIA MUSCULOSKEIETAL PAIN                    |                       | 2.9)           |                         | 9) 8.8) 2.9)   | 4822226                          |               |                        |           |           |
| ARTHRAUGIA BONE PAIN                                                          |                       | OHO0OOOO       | 92367671                | 999980         | 903515                           | 69889         |                        |           |           |
|                                                                               |                       |                | 7)                      |                |                                  | 4)            |                        | 13        | 13        |
|                                                                               |                       |                |                         |                |                                  | 9 7.1)        |                        | 8.1)      | 8.1)      |
| DISORDERS                                                                     |                       | 11.4)          | 72 70.6)                |                |                                  |               | 97 60.2) 30.           | 1.9)      | 1.9)      |
| RASH PRURIIUS                                                                 | 11.4)                 | 2.9)           | 37.3)                   |                |                                  | 2.4)          | 18: 4)                 | 1.2) (9:0 | 1.2) (9:0 |
| RASH MACULO-DAPULAR ERYTHENA ALODECIA                                         | 0040000               |                | 17. 6)                  | 1.83           | 5)                               | (8-0 (8.0     | 7                      | 3021010   | 3021010   |
|                                                                               |                       |                |                         | 1.0)           |                                  | 3011010 (8'0  | 1622226                | 0.6)      | 0.6)      |
| DRY SKIN                                                                      |                       |                |                         |                |                                  |               |                        |           |           |
| PETECHIAE                                                                     |                       |                | 67                      |                |                                  |               |                        |           |           |
|                                                                               | 1( 2.9)               | 1 2.9) 00      | 2 23.5)                 | 12 2.8)        | 65 （ 51.6)                       | 14 C 11.1)    | 66 41.0) 19.9)         | 9.3)      | 9.3)      |
| AILERGIC TRANSFUSION REACTION                                                 |                       |                | 9.8)                    | 8)             |                                  |               | 8.1)                   | 14 2.3)   | 14 2.3)   |
|                                                                               |                       |                |                         | 44 99          | 2988                             |               |                        |           |           |
|                                                                               |                       | 2.9)           |                         |                |                                  |               |                        |           |           |
|                                                                               |                       |                |                         |                |                                  |               |                        | 896       | 896       |
|                                                                               | 4110                  |                |                         |                |                                  | 311 3488      | 3226                   | 1311      | 1311      |
|                                                                               |                       |                |                         | 2.0)           |                                  |               |                        |           |           |
|                                                                               |                       |                |                         |                | 7) 12. 7                         | 2O 1.6)       | 57 10. 6)              | 31 9)     | 31 9)     |
| IMMINE                                                                        |                       |                |                         | 18             |                                  |               |                        | 6)        | 6)        |
| DRUG HYPERSENSITIVITY                                                         |                       | 5.7)           | 34 3 7                  |                | 558                              | 17.5          |                        |           |           |
|                                                                               |                       | 2O1            |                         | 698            |                                  |               |                        | 387       | 387       |
| ANAPHYLACTIC REACTION                                                         | 2.9)                  | 2.9)           |                         |                |                                  |               |                        |           |           |
| RENAL AND URINARY DISORIERS HADMATURIA                                        | 000                   | 000            |                         |                | 333                              | 024 962       |                        | 024 225   | 024 225   |
| ACUTE KTLNEY INJURY                                                           |                       |                |                         |                |                                  |               |                        |           |           |
|                                                                               |                       | 5.7)           | 24.5)                   |                |                                  |               |                        |           |           |
|                                                                               |                       | 20             |                         |                |                                  |               | 2                      |           |           |
|                                                                               |                       |                |                         |                | 2号3                              | 10            |                        | 30        | 30        |
|                                                                               |                       |                |                         | 00             |                                  |               |                        |           |           |
|                                                                               |                       |                | 20.6)                   |                |                                  |               |                        |           |           |
| EAR AND LABYRINIH DISORIERS                                                   | 20                    |                |                         |                |                                  |               |                        |           |           |
| EAR DAIN                                                                      |                       |                |                         |                |                                  |               |                        |           |           |
|                                                                               |                       |                |                         |                |                                  |               |                        | 15.5)     |           |
|                                                                               |                       |                |                         |                |                                  | 0.8)          |                        |           |           |
|                                                                               |                       |                |                         |                | 3.:8)                            |               |                        |           |           |
|                                                                               |                       |                |                         |                |                                  |               |                        | 1.9)      | 1.9)      |
|                                                                               |                       | 19.3)          |                         |                |                                  |               |                        |           |           |
|                                                                               |                       | 5.7)           |                         |                |                                  |               |                        |           |           |
|                                                                               |                       | 2#             |                         |                |                                  |               |                        |           |           |

<div style=\"page-break-after: always\"></div>

## · On-Treatment Dasatinib-related Adverse Events

Table 36 Summary of On-Treatment Dasatinib-related Adverse Events Reported for at least 10% of Subjects by CTC Grade - All Treated Subjects in the Pooled Population-CA180372

| Class （号）                                                                                                                                                             | Disocntinuous Desatinib N=35   | Disocntinuous Desatinib N=35   | Continuous Dasatinib Tablet only N = 102   | Continuous Dasatinib Tablet only N = 102   | Continucus Dasatinib N=126   | Continucus Dasatinib N=126   | All Treated N=161   | All Treated N=161   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------------------|--------------------------------------------|------------------------------|------------------------------|---------------------|---------------------|
| Freferred Texm                                                                                                                                                        | Any Grade                      | Grade 3-4                      | Any Grade                                  | Gradle 3-4                                 | Any Gradle                   | Gradle3-4                    | Grade               | Gradle 3-4          |
| TOTAL SUBJECTS WITH ANEVENT                                                                                                                                           | 27 77.1)                       | 27 77.1)                       | 88 86.3)                                   | 76 74.5)                                   | 106 84.1)                    | 91 72.2)                     | 133 82.6)           | 118 (73.3)          |
| INWESTIGATIONS AIANINE AMINOTRANSPERASE INCREASED ASPARTAIEAMINOIRANSRPRASE NEUIROEHIL OOUNT TECREASED IOREASED PIATSTETC COUNTLDLREASSD WHTIE BLOODCETLCOUNTELREASED | 275207 844482                  | 2155197 854322                 |                                            | 278928 onnaom                              | 633229 534577                | 643329 824017 4oom5n         |                     |                     |
| BLOODANDLYMEHATICSYSTEMDISORIERS FEERILE NEUIROPENIA ANOD-ITA NEUIROPENIA THRO-BOCYTOPENIA                                                                            |                                | 0048 34                        | 2686 4728215                               | T2225 Hnnor                                | 57342624                     | 72281                        | 23510               | 43251 07            |
| GASTRONIESTINAL DISORIERS NAUSEA VOIITING DIARRHOEA ARDO-MNAL BAIN NEUIROFENICCOLITIS                                                                                 |                                | 911414                         | 222224 429113                              |                                            |                              | 308824                       |                     | 287057 903213       |
| METABOLISMANDNUIRITIONDISORIERS HYPORATADMA TECREASEDAPPETTTE HYROAIBOMMNADMA HYPOEHOSEHATADMTA                                                                       |                                | 44151                          | 21063 29052 58899                          | 59422                                      | 24375                        | 81624 37802                  | 84686               | 69250               |
| INRDCTIONS AND INFESTATIONS SEPSIS                                                                                                                                    | 69 28:73                       | 16 维线:3                        | 9 12.                                      | 79                                         | 28 53                        | 17.8                         | 37 28: 66           | 37 38.8 56          |
| GNERALDISORIERSANDAIMINISTRATION SITE OINDITIONS                                                                                                                      |                                | 000                            | 28 27. .5)                                 | 13 12 7)                                   | 35 27.8)                     | 17 13 3.5)                   | 35 7)               | 17 10.6)            |
| FATIGUE                                                                                                                                                               | 00                             |                                | 8:83                                       | 50 4.9)                                    | 18:3                         | 70 5.6)                      | 含:3                 | 4.3)                |
| NERVOUSSYSTPMDISORIERS HEADACHE                                                                                                                                       | 52 9:33                        | 5:3                            | 21 28:83                                   | 号:8                                        | 11:3                         | 7:83                         | 30 1号:83            | # g:83              |

## · Dasatinib-related Adverse Events of Special Interest

Table 37 Summary of On-treatment Dasatinib-related Adverse Events of special interest - All Treated Subjects in the pooled Population- CA180372

|                                                                                                                                                                 | Discontinucus Dasatinib N=35   | Discontinucus Dasatinib N=35   | Contimuous Dasatinib Tablet Only N=102   | Contimuous Dasatinib Tablet Only N=102   | Continuous Dasatinib N=126               | Continuous Dasatinib N=126             | All Treaved N=161   | All Treaved N=161       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|----------------------------------------|---------------------|-------------------------|
| AE Special Interest                                                                                                                                             | Any Grade                      | Severe (3-4)                   | Any Grade                                | Severe （3-4）                             | Any Grade                                | Severe (3-4)                           | Any Grade           | Severe （3-4）            |
| FLUID ROIENTION SUPERFICIAL EDEMA PISURALEREUSION OTHER FLUID RELATED ASCITES GENERALIZED EIEMA PERICARDIAL EBFUSICN CONGESTIVEHEART FAILURE/CARDIACDYSEUNCTICN | 00000000                       | 0000 00 0                      | 13 7652301 12. 999 7) 22 0 9) 1.0)       | 83441201 7.8) 99 9) 2.83 0) 1.0)         | 15 87633 11. 16542 368 9) 2. 4) 4 《 0.8) | 83441201 6.3) 4 2) 2） 1.6) 0. .8) 0.8) | 9) 0.6)             | 5955 0) 1. 2) 6) 1 0.6) |
| PUIMONARY ELEMA PUIMONARYHYPERTENSION                                                                                                                           | o0                             | 0 0                            | 00                                       |                                          |                                          | 00                                     | 00                  | 00                      |
| RESPIRATORY DISORLERS NON-PRODUCTIVE COUGH CHEST BAIN SHORTNESS OE BREATH                                                                                       | 1001 （ 2.9) 2.9)               | 0000                           | 3.9) 2:83 9)                             | 0000                                     | 6666                                     | 0000                                   | 0) 3.1)             | 0000                    |
| CARDIAC DISORDERS                                                                                                                                               | 1 2.9)                         | 0                              | 5 4.9)                                   | 0                                        | 8 6.3)                                   |                                        | 9 5.6)              |                         |
| DULMONARYARTERIALHYPERTENSION                                                                                                                                   | 0                              | 0                              | 0                                        | 0                                        | 0                                        | 0                                      | 0                   | 0                       |
| DIARRHEA                                                                                                                                                        | 4 11.4)                        | 4 （ 11.4)                      | 12 (11.8)                                | 5 4.9)                                   | 16 （ 12.7)                               | 6 4.8)                                 | 20 12.4)            | 10 （ 6.2)               |
| NAUSEA/VOMITING                                                                                                                                                 | 3 8.6)                         | 2 5.7)                         | 28 (27.5)                                | 8.8)                                     | 34 (27.0)                                | 9 7.1)                                 | 37 23.0)            | 11 6.8)                 |
| FATIGUE                                                                                                                                                         |                                |                                | 10 9.8)                                  | 0                                        | 14 11.1)                                 | 0                                      | 14 8.7)             | 0                       |
| MYALGIAS/ARTHRAIGIAS                                                                                                                                            |                                |                                | 7 C 6.9)                                 | 2 （ 2.0)                                 | 9 7.1)                                   | 2 1.6)                                 | 9 5.6)              | 2 1.2)                  |
| RASH                                                                                                                                                            | （ 8.6)                         | 1 2.9)                         | 12 （ 11.8)                               |                                          | 16 （ 12.7)                               |                                        | 19 11.8)            | 1 （ 0.6)                |
| HEMORRHAGE GI BLEEDING ONS BLEEDING OTHER HEMORRHAGE                                                                                                            | 7) 9) 2.9)                     | 2101 2:3 2.9)                  | 14.7) (8'8 8.8)                          | 6303 2.9) 5.9) 2.9)                      | 14.3) 8.7) 9.5)                          | 3.2) 5.6) 2.4)                         | 12. 7.5) .4) ( 8.1) | 5.6) 3.1) 2.5)          |

seautoads-ae-at/setce/boxd/sos/saeas/ssssezsuc/saoafoxd/:aoxoswrexboxd

29SED2017:04:38:21

<div style=\"page-break-after: always\"></div>

## · All-causality Adverse Events of Special Interest

## Table 38 Summary of On-treatment Adverse Events of Special Interest - All Causality - All treated Subjects in the Pooled population

<!-- image -->

|                                                                                                                                                                                                          | Discontinuous Dasatinib N=35   |                                | Contimuous Dasatinib Tablet Only N=102                                                        |                                                                         | Continucus Dasatinib N=126                                                                              |                                                                               | All Treated N=161                                                                                          |                                                                  |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|------|----|-------|--------|------|-------|--------|----|----|----|-------|------|---------|----|------|----|-------|
| AE Special Interest                                                                                                                                                                                      | Any Grade                      | Severe （3-4）                   | Any Grade                                                                                     | Severe （3-4)                                                            | Any Grade                                                                                               | Severe (3-4)                                                                  | Any Grade                                                                                                  | Severe （3-4)                                                     |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
| ELUID RETENTION SUPERFICIAL ELEMA PLEURAL EERUSION OTHER FLUID RELATED GENERALTZED EIEMA ASCITES PERICARDTAL ERHUSION CONGESTIVE HEART FAILURE/CARDIACDYSEUNCTION PUTMONARY EDEMA FULMONARY HYPERTENSION | 00000000 o0                    | 0 0 0 o00 0 0 0 0 0000 1（ 2.9) | 35 48 C 47.1) 34 .3) 17 16. 7) 24 23 16 15 -7) 7 6.9) 62 5.9) 2.01 3.9) 0 988 69 17 40 （39.2） | 14 13.7) 9) 6 9) 12 1.0) 2.0) 0 2 2.0) 30 C 2.9) 11.8) 392 9 8) 10 9.8) | 39 56 31.0) 44.4) 21 16.7) 28 22.2) 18 14.3) 7 5.6) 7 2 1.6) 5.6) so 4.0) 85 61.5 67.5) 28 22 51 （40.5） | 16 12.7) 4.0) 6.3) 4.8) 2 0.8) 1.6) 12 1.6) 0.8) 30 2.4) 13 420 10.3) 11 8.7) | 39 56 2 34.8) 2) (O-ET 17.4) 18 11.2 2) 7 4.3) 2 7 4.3) 1.2) （ 3.1) （ 13.0) 53.4) 48.4) 29 18.0) 53 （32.9) | 16 5 3.1 (6'6 86 5.0) 3.7) 12 0.6) C 1.2) 1.2) 0.6) 1.9) 13 8.1) |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
| RESPIRATORY DISORDERS NON-BRODUCTIVE OOUGH CHEST PAIN SHORTNESS OE BREATH CARDTAC DISORLERS                                                                                                              | 2.9) 2.9)                      |                                | 67.6) 8 5                                                                                     |                                                                         | (2-91 9) .2)                                                                                            | 2 3)                                                                          |                                                                                                            | 5) 2)                                                            |      |    |       |        |      |       |        |    |    |    |       |      |         | 12 |      |    | 7.5)  |
| PULMONPRY ARTERTALHYPERTENSION                                                                                                                                                                           | 2 5.7) 0                       | 0                              | 0                                                                                             | 0                                                                       | 0 66.7)                                                                                                 | 0                                                                             | 0 88 54.7)                                                                                                 | 0                                                                |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
| DIARRHOEA NAUSEA/VOMTTING                                                                                                                                                                                | 6 （17.1)                       | 5(14.3)                        | 83 81.4)                                                                                      | 26 25.5)                                                                | 20 100 79.4)                                                                                            | 30 23.8)                                                                      | 106 65.8)                                                                                                  | 33 （20.5）                                                        |      |    | 68.6) | (19.6) |      |       | (11.4) | 70 | 29 | 84 | 23.0) |      | 4（11.4) | 35 |      | 4  | 21.7) |
| MYAUGIAS/ARIHRAIGIAS                                                                                                                                                                                     | 0                              |                                |                                                                                               | 5 4.9)                                                                  | 48 （ 38.1)                                                                                              | 6                                                                             |                                                                                                            |                                                                  |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
| RASH                                                                                                                                                                                                     | 5 （ 14.3)                      |                                | 61 59.8)                                                                                      | 7                                                                       | 76 60.3)                                                                                                |                                                                               | 81 50.3)                                                                                                   | 10                                                               |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
| GIBL5EDING QNS BIBEDING                                                                                                                                                                                  | 5.                             |                                |                                                                                               | 6. 9)                                                                   |                                                                                                         |                                                                               |                                                                                                            |                                                                  |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
| OTHER HEMORRHAGE                                                                                                                                                                                         |                                |                                |                                                                                               |                                                                         |                                                                                                         |                                                                               |                                                                                                            |                                                                  |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
| FATIGUE                                                                                                                                                                                                  | 14.3)                          | 0                              | 42 41.2)                                                                                      | 15.7)                                                                   |                                                                                                         | 2 1.6)                                                                        |                                                                                                            |                                                                  |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
| HEMORRHAGE                                                                                                                                                                                               |                                | 2                              | 54.                                                                                           |                                                                         |                                                                                                         | 8 6.3)                                                                        |                                                                                                            |                                                                  |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          |                                | 11.                            |                                                                                               |                                                                         |                                                                                                         |                                                                               | 44-7)                                                                                                      | 14.3)                                                            |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          |                                |                                |                                                                                               |                                                                         |                                                                                                         | 15. 1)                                                                        |                                                                                                            |                                                                  |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          |                                | 5.7)                           |                                                                                               |                                                                         |                                                                                                         |                                                                               | 61 37.9)                                                                                                   | 2 1.2)                                                           |      | 2  | 47.1) |        |      | 48.4) |        | 48 |    | 61 |       |      |         |    | 2.0) |    |       |
|                                                                                                                                                                                                          |                                | 0                              |                                                                                               | 6.9)                                                                    |                                                                                                         | 4.8)                                                                          | 48 29.8)                                                                                                   | 6 3.7)                                                           |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          |                                |                                |                                                                                               |                                                                         |                                                                                                         |                                                                               |                                                                                                            | 6.2)                                                             |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          |                                | 5.71                           |                                                                                               |                                                                         |                                                                                                         | 7.1)                                                                          |                                                                                                            |                                                                  |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          | 5204                           | 4203                           |                                                                                               |                                                                         | 6538                                                                                                    |                                                                               | 2736                                                                                                       |                                                                  |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          |                                |                                |                                                                                               |                                                                         |                                                                                                         |                                                                               |                                                                                                            | 6.8)                                                             |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          |                                |                                |                                                                                               |                                                                         |                                                                                                         |                                                                               |                                                                                                            | 41.0)                                                            |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          | 11.4)                          |                                |                                                                                               |                                                                         |                                                                                                         |                                                                               |                                                                                                            |                                                                  |      |    |       |        |      |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          |                                |                                |                                                                                               |                                                                         |                                                                                                         |                                                                               |                                                                                                            |                                                                  | 9.8) |    | 8.6)  |        | 8.7) |       |        |    |    |    |       |      |         |    |      |    |       |
|                                                                                                                                                                                                          |                                |                                |                                                                                               |                                                                         |                                                                                                         |                                                                               |                                                                                                            |                                                                  |      |    |       |        |      |       |        |    |    |    |       | 8.7) |         |    |      |    |       |

## · Safety in Ph+ ALL paediatric vs. adult

Table 39 Selected &gt;=10% Drug-related Non-Hematologic AE

| System Organ Class Preferred Term               | Pooled Paediatric Ph+ALL (N=161)                | Pooled Paediatric Ph+ALL (N=161)                | Adult START-L study i (N=46)                    | Adult START-L study i (N=46)                    | Adult Ph+ ALL population CA180-035 study ii     | Adult Ph+ ALL population CA180-035 study ii     | Adult Ph+ ALL population CA180-035 study ii     | Adult Ph+ ALL population CA180-035 study ii     |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                                 | Combination                                     | Combination                                     | Monotherapy                                     | Monotherapy                                     | Monotherapy                                     | Monotherapy                                     | Monotherapy                                     | Monotherapy                                     |
|                                                 | %of Subjects                                    | %of Subjects                                    | %of Subjects                                    | %of Subjects                                    | %of Subjects                                    | %of Subjects                                    | %of Subjects                                    | %of Subjects                                    |
| Drug-related AE                                 | Any Grade                                       | Grade 3- 4                                      | Any Grade                                       | Grade 3- 4                                      | QD (N=40)                                       | QD (N=40)                                       | BID (N=44)                                      | BID (N=44)                                      |
|                                                 |                                                 |                                                 |                                                 |                                                 | Any Grade                                       | Grade 3-4                                       | Any Grade                                       | Grade 3-4                                       |
| Gastrointestinal Disorders                      | Gastrointestinal Disorders                      | Gastrointestinal Disorders                      | Gastrointestinal Disorders                      | Gastrointestinal Disorders                      | Gastrointestinal Disorders                      | Gastrointestinal Disorders                      | Gastrointestinal Disorders                      | Gastrointestinal Disorders                      |
| Diarrhea                                        | 12.4                                            | 6.2                                             | 33                                              | 9                                               | 35                                              | 5                                               | 27.3                                            | 4.5                                             |
| Nausea                                          | 17.4                                            | 5                                               | 22                                              | 0                                               | 27.5                                            | 2.5                                             | 25                                              | 4.5                                             |
| Vomiting                                        | 16.8                                            | 4.3                                             | 11                                              | 0                                               | 20                                              | 0                                               | 18.2                                            | 2.3                                             |
| Abdominal Pain                                  | 11.8                                            | 3.1                                             | 2                                               | 0                                               | 0                                               | 0                                               | 2.3                                             | 2.3                                             |
| General Disorders                               | General Disorders                               | General Disorders                               | General Disorders                               | General Disorders                               | General Disorders                               | General Disorders                               | General Disorders                               | General Disorders                               |
| Pyrexia                                         | 9.9                                             | 4.3                                             | 22                                              | 2                                               | 15                                              | 0                                               | 15.9                                            | 0                                               |
| Asthenia                                        | 1.2                                             | 0                                               | 15                                              | 7                                               | 10                                              | 0                                               | 6.8                                             | 2.3                                             |
| Fatigue                                         | 8.1                                             | 0                                               |                                                 |                                                 | 10                                              | 0                                               | 13.6                                            |                                                 |
| Peripheral edema                                | 3.1                                             | 1.2                                             | 13                                              | 0                                               | 17.5                                            | 2.5                                             | 31.8                                            | 13.6                                            |
| Skin and Subcutaneous Tissue Disorders          | Skin and Subcutaneous Tissue Disorders          | Skin and Subcutaneous Tissue Disorders          | Skin and Subcutaneous Tissue Disorders          | Skin and Subcutaneous Tissue Disorders          | Skin and Subcutaneous Tissue Disorders          | Skin and Subcutaneous Tissue Disorders          | Skin and Subcutaneous Tissue Disorders          | Skin and Subcutaneous Tissue Disorders          |
| Rash                                            | 6.8                                             | 0                                               | 15                                              | 2                                               | 2.5                                             | 0                                               | 6.8                                             | 0                                               |
| Nervous System Disorders                        | Nervous System Disorders                        | Nervous System Disorders                        | Nervous System Disorders                        | Nervous System Disorders                        | Nervous System Disorders                        | Nervous System Disorders                        | Nervous System Disorders                        | Nervous System Disorders                        |
| Headache                                        | 9.9                                             | 5                                               | 13                                              | 0                                               | 10                                              | 0                                               | 6.8                                             | 2.3                                             |
| Respiratory, Thoracic and Mediastinal Disorders | Respiratory, Thoracic and Mediastinal Disorders | Respiratory, Thoracic and Mediastinal Disorders | Respiratory, Thoracic and Mediastinal Disorders | Respiratory, Thoracic and Mediastinal Disorders | Respiratory, Thoracic and Mediastinal Disorders | Respiratory, Thoracic and Mediastinal Disorders | Respiratory, Thoracic and Mediastinal Disorders | Respiratory, Thoracic and Mediastinal Disorders |
| Pleural effusion                                | 4.3                                             | 2.5                                             | 24                                              | 7                                               | 17.5                                            | 5                                               | 31.8                                            | 13.6                                            |
| Dyspnoea                                        | 2.5                                             | 0                                               | 15                                              | 4                                               | 10                                              | 2.5                                             | 20.5                                            | 0                                               |
| Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  |
| Weight Decreased                                | 3.7                                             | 0                                               | 13                                              | 2                                               | 5                                               | 0                                               | 2.3                                             | 0                                               |
| Blood and Lymphatic system disorders            | Blood and Lymphatic system disorders            | Blood and Lymphatic system disorders            | Blood and Lymphatic system disorders            | Blood and Lymphatic system disorders            | Blood and Lymphatic system disorders            | Blood and Lymphatic system disorders            | Blood and Lymphatic system disorders            | Blood and Lymphatic system disorders            |
| Febrile Neutropenia                             | 32.3                                            | 31.7                                            | 8.7                                             | 8.7                                             | 12.5                                            | 12.5                                            | 6.8                                             | 6.8                                             |

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious Adverse Events (SAEs)

## · Study CA180372

Table 40 Dasatinib-related Serious Adverse Event Summary by CTC Grade in Study CA180372 - All Treated Subjects

| System Organ Class （3) Preferred Term （6）                                 |               |                  | AllTreated Subjects (=106)   | AllTreated Subjects (=106)   | Grade5   |                     |
|---------------------------------------------------------------------------|---------------|------------------|------------------------------|------------------------------|----------|---------------------|
|                                                                           | Grade1        | Grade2           | Grade3                       | Grade4                       |          | Total               |
| TOTAL SUBJECTS WITH AN EVENT                                              | 1(0.9）        | 1(0.9)           | 22(20.8)                     | 20(18.9)                     | 0        | 44（41.5)            |
| BLOOD AND LYMDHATICSYSTEM DISORDERS EERRTLE NEUIROPENIA                   | （ 0.9) ( 0.9) | 0                | 2 (11.3) (19.8)              | 14 (13.2) (0.9)              |          | 732 (25.5) (21.7 7) |
| NEUIROFENIA                                                               |               | 0                | OSHOHO                       | (11.3)                       |          | 12 (11.3)           |
| ANAEIA                                                                    | 00000         |                  | 4.7)                         | (0.9)                        | 0        | 5.7                 |
| THROMBOCYTOFENIA                                                          |               | 000              | （ 0.9)                       | 3.8)                         | 0        | 2                   |
| LEUKOPENIA                                                                |               |                  |                              | (2.8)                        | 00       | 6531 (6'0           |
| HAEMORRHAGICANAEMIA                                                       |               |                  | (0.9)                        |                              |          |                     |
| PANCYTOPENIA                                                              | 0             | 0                |                              | (0.9）                        | 0        | （ 0.9)              |
| GASTROINTESTINAL DISORDERS                                                | 1 (0.9)       | 1.9)             | 10 9.4)                      | 0000000                      |          | 13 (12.3)           |
| COLITIS                                                                   | o             | 1.9)             | 8)                           |                              |          | 4.7)                |
| DIARRHOEA                                                                 | NO 1.9)       |                  |                              |                              |          | 4.7)                |
| VOMITIING LONER GASTROINTESTINAL HAEMORRHAGE                              | 1 (0.9)       | 0.9) 0.9)        | 0.9) (6                      |                              | 0        | 3 2.8) 2.8)         |
| ABDOMMNAL PATN                                                            | 00            | 0.9)             | 0.9) 19)                     |                              |          | 1.9) 1.9)           |
| ASCITES                                                                   | 1 0.9)        |                  | （ 0.9)                       |                              | 0        | 1.9)                |
| NAUSEA ANAL HAEMORRHACE                                                   | 0.9)          |                  |                              |                              |          | 2221 0.9)           |
| ENVIEROOOLITIS                                                            |               |                  | (0.9)                        |                              |          | 0.9)                |
| GASIRIC HAEMORRHAGE                                                       | 10000000      | 0.9)             |                              |                              |          | 0.9)                |
| GASIRITIS GASTROINTESTINAL HAEMORRHAGE                                    |               | （ 0.9)           |                              |                              |          | 111 0.9)            |
|                                                                           |               | OOOOHHOOOOHHHONN | (0.9）                        |                              |          | 0.9)                |
| PANCREATTTIS ACUTE RECTAL HAEMORRHAGE                                     |               |                  | 11 8.2) 8.33                 |                              | 00       | 9.2) 0.9)           |
|                                                                           |               |                  | 1                            |                              | 0        | 1                   |
| UPPER GASTROINTESTINAL HAEMORRHARE                                        |               |                  | (0.9)                        | 000000000                    |          | (0.9)               |
| GENERAL DISORDERS AND AIIMTNISTRATION SITE OONDITIONS                     | 3 2.8)        | 1 0.9)           | 7.5)                         | (0.9)                        |          | (12.3)              |
| PYREXTA                                                                   | 2.8)          | 1.9)             |                              | (0.9)                        | 00000    |                     |
| IOCALISED CEDEA                                                           |               |                  | 0.9)                         |                              |          | 0.9)                |
| MUUOSAL INELAMATION OETEMA                                                | o0o           | 2OOO             | 841111 0.9)                  |                              |          | 0.9)                |
| OEDEMA PERIPHERAL                                                         | 0             | 0                | 0.9)                         | HHOOOO                       | 0        | 0.9)                |
| INEDCTIONS AND INEESTATIONS                                               | 0 0           |                  | 5. 7) 9)                     | (2.8) 2.8)                   | 00       | 8.5)                |
| SEPSIS CLOSTRIDIUM DIFFICILE COLITIS                                      | 0             | 0                | (6 9)                        |                              | 0        | 9)                  |
| HERDES ZOSTER LEVICE RETATED INFDLTION                                    | 0             | 0                | 0.9)                         |                              |          | 0.9)                |
| ENVTEROOOLITIS INEECTIOUS                                                 |               | 0                | 0.9)                         | 300000                       | 000      | 9422111 0.9)        |
|                                                                           | 0             |                  | 6122111 （                    |                              |          | 0.9)                |
| LUNG INEECTION                                                            | 0             | 0                | 0.9)                         |                              | 0        |                     |
| OTITIS MEDIA                                                              | 0             | 1 (0.9) 0        |                              | 00000                        |          |                     |
| DNEUMONTA                                                                 |               |                  | 0.9) 9)                      |                              | 00000    | 1111 99             |
| PNPUMONIA VIRAL SKIN INEECTION                                            | oo            | 00 0             |                              |                              |          | 9                   |
|                                                                           |               |                  | 9)                           |                              |          | 0.9)                |
|                                                                           | 0             |                  | (6'0 0.9)                    |                              |          |                     |
| INVESTIGATIONS NEUIROBHILCOUNT LECREASED ALANINEAMTNOTRANSEERASEINCREASED | o0 0          | o0 0             | HOOHHOIO                     | 1.9) 0.9)                    |          | 0422111 58 999      |
| ASPHRTATE AMTNOIRANSRERASE INCREASED                                      | 0 0           | 0                | 0.9) 0.9)                    | 74210101                     |          |                     |
| PLATELET COUNT LECREASED                                                  | 0             | 0                |                              | (0.9)                        |          |                     |
| URDNE OUTPUT LECREASED                                                    |               | 0 0              | 0.9)                         |                              | 00000000 | 9                   |
|                                                                           | 0             | 0                |                              | （0.9）                        |          | 9) （ 0. 9)          |
| WHITE BLOOD CETL OOUNT LECREASED METABOLISMAND NUIRITION DISORDERS        | 0 0           |                  | 8)                           | （0.9）                        |          |                     |
| HYPOALBUMTNAETA HYPOKALAEMTA                                              |               | 000000           | 421111 999                   | 101000 (0.9)                 |          | 79999               |
| DECREASED APPETITE                                                        |               |                  | 9)                           |                              |          |                     |
| TEHYDRATION                                                               |               |                  |                              |                              | 000000   | 2211                |
| HYPONATRAEMTA                                                             | 0000          |                  | 0. 9)                        |                              |          | 0. 9)               |
|                                                                           | (0.9）         | 1 （0.9） 0        | 1.9) 0.9)                    |                              |          | 8                   |
| LEPRESSED IEVEL OE OONSCIOUSNESS EACIAL PARESIS                           | 100           | 1 (0.9)          |                              | 000000                       | 000000   | 4111 99999          |
| HEADACHE                                                                  | 1 (0.9) 10o   |                  |                              |                              |          |                     |
| PERIPHERAL MOTOR NEUROPATHY DERIPHERAL SENSORY NEUROPATHY                 |               |                  | 0.9) 0.9)                    |                              |          | 9)                  |
| RESPIRATORY,THORACIC AND MEDIASTINAL DISORTERS PLEURAL EFBUSION           |               | 0 0              | 3 （ 2.8) 2.8)                |                              |          | 8) 898              |
| CHYTOTHORAX                                                               | ooo (0.9)     | 10 （0.9)         | 30o                          | 0000                         | 0000     | 3311                |
| HAEMOTHORAX                                                               | 1             |                  |                              |                              |          | 9)                  |
| PSYCHTAIRIC DISCRDERS DELIRIUM                                            | o00           | o0o              | 2 9)                         | 000                          | 000      | 2                   |
| PERSONALITY CHANGE                                                        |               |                  | 0.9)                         |                              |          |                     |
| VASOULAR DISORDERS                                                        | 0 0           | 1(0.9)           | 00                           | 1(0.9)                       |          | 2 (1.9) 2 (1.9)     |
|                                                                           |               | 1(0.9)           |                              | 1(0.9）                       | 0        |                     |
| HYEOTENSION                                                               |               |                  |                              |                              |          |                     |

<div style=\"page-break-after: always\"></div>

| CARDTACDISORDERS CARDTACEATLURE                       |         | 1 (8:3)   |     | 1(8:3   |
|-------------------------------------------------------|---------|-----------|-----|---------|
| RENALAND URINARY DISORIERS ACUIEKTLNEYINJURY          | 1 (8:3) |           | D 口 | 1 (8:3) |
| REPRODUCTIVE SYSTEM AND BREASTDISORDERS OEDEMAGENITAL |         | 1(8.3)    |     | (8:3    |

## · Study CA180204

Table 41 Summary of SAEs by CTCAE Category regardless of relationship to Dasatinib in study CA180204 - All Treated Paediatric and Adult Subjects

|                                                  |                                                  | Number(So)ofDasatinib-treated Subjects   | Number(So)ofDasatinib-treated Subjects   | Number(So)ofDasatinib-treated Subjects   |
|--------------------------------------------------|--------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| CTCAE Category                                   | SAE                                              | Discontinuous N=40                       | Continuous N=22                          | Total N=62                               |
| Bloodand LymphatieSystemDisorders                | Bloodand LymphatieSystemDisorders                |                                          |                                          |                                          |
|                                                  | Febrileneutropenia                               | 0                                        | 1(4.5)                                   | 1(1.6)                                   |
| Cardine                                          |                                                  |                                          |                                          |                                          |
|                                                  | Hypotension                                      | 1 (2.5)                                  | 0                                        | 1 (1.6)                                  |
|                                                  | LeftVentricularSystolicDysfunction               | 0                                        | 1 (4.5)                                  | 1 (1.6)                                  |
|                                                  | QTcProlongation                                  | 1 (2.5)                                  | 0                                        | 1 (1.6)                                  |
| Dermatology/Slin                                 |                                                  |                                          |                                          |                                          |
|                                                  | Rash (Hand-footskin reaction)                    | 1(2.5)                                   | 0                                        | 1 (1.6)                                  |
| Gastrointestinal                                 |                                                  |                                          |                                          |                                          |
|                                                  | Colitis                                          | 2 (5.0)                                  | 2 (9.1)                                  | 4 (6.5)                                  |
|                                                  | Dehydration                                      | 1 (2.5)                                  | 0                                        | 1 (1.6)                                  |
|                                                  | Dianhea                                          | 1(2.5)                                   | 0                                        | 1 (1.6)                                  |
|                                                  | Nausea                                           | 0                                        | 1 (4.5)                                  | 1 (1.6)                                  |
| General DisordersandAdministrationSiteConditions | General DisordersandAdministrationSiteConditions |                                          |                                          |                                          |
|                                                  | Infusionrelated reaction                         | 0                                        | 1 (4.5)                                  | 1 (1.6)                                  |
| Hemorrhage,Bleeding                              |                                                  |                                          |                                          |                                          |
|                                                  | AbdominalHemonhage                               | 1(2.5)                                   | 0                                        | 1 (1.6)                                  |
| ImmuneSystemDisorder                             |                                                  |                                          |                                          |                                          |
|                                                  | Allergicreaction                                 | 1 (2.5)                                  | 1(4.5)                                   | 2 (3.2)                                  |
| Infectionsand Infestations                       |                                                  |                                          |                                          |                                          |
|                                                  | Cellulitis                                       | 1(2.5)                                   | 0                                        | 1 (1.6)                                  |
|                                                  | Colitis,infectious                               | 1 (2.5)                                  | 0                                        | 1 (1.6)                                  |
|                                                  | Febrileneutropenia                               | 2 (5.0)                                  | 0                                        | 2 (3.2)                                  |
|                                                  | Neutrophildecreased                              | 2 (5.0)                                  | 0                                        | 2 (3.2)                                  |
|                                                  | Periorbitalinfection                             | 1 (2.5)                                  | 0                                        | 1 (1.6)                                  |
|                                                  | Upper airway infection                           | 1(2.5)                                   | 0                                        | 1 (1.6)                                  |
|                                                  | Sepsis                                           | 1 (2.5)                                  | 0                                        | 1 (1.6)                                  |
| Investigations                                   |                                                  |                                          |                                          |                                          |
|                                                  | Blood bilinubinincreased                         | 1 (2.5)                                  | 0                                        | 1 (1.6)                                  |
|                                                  | Creatinine increased                             | 0                                        | 1 (4.5)                                  | 1 (1.6)                                  |
| Lymphaties                                       |                                                  |                                          |                                          |                                          |
|                                                  | Edema limb                                       | 0                                        | 1(4.5)                                   | 1 (1.6)                                  |

<div style=\"page-break-after: always\"></div>

| Metabolie,Laboratory Albumin-serumlow        | 1 (2.5)   | 1(4.5)   | 2 (3.2)   |
|----------------------------------------------|-----------|----------|-----------|
| Hypokalemia                                  | 0         | 2 (9.1)  | 2 (3.2)   |
| Hyponatremia                                 | 0         | 1 (4.5)  | 1 (1.6)   |
| MfusculoskeletalandConnectireTissueDisorders |           |          |           |
| Back Pain                                    | 0         | 1 (4.5)  | 1 (1.6)   |
| Nerrous SystemDisorder                       |           |          |           |
| Ifosfamidenewrotoxicity                      | 1(2.5)    | 0        | 1 (1.6)   |
| Mood alteration-agitation                    | 1(2.5)    | 0        | 1 (1.6)   |
| Neurologyy-Motor                             | 1 (2.5)   | 1(4.5)   | 2 (3.2)   |
| Neturology-Sensory                           | 0         | 1(4.5)   | 1 (1.6    |
| Personality/Behavioral                       | 1(2.5)    | 0        | 1 (1.6)   |
| Seizure                                      | 2 (5.0)   | 0        | 2 (3.2)   |
| Pain Headache                                | 1(2.5)    | 0        | 1(1.6)    |
| Pulmonary,UpperRespiratory                   |           |          |           |
| Dyspnea                                      | 0         | 1 (4.5)  | 1 (1.6)   |
| Hypoxia                                      | 1 (2.5)   | 0        | 1 (1.6)   |
| Renal/Genitourinary                          |           |          |           |
| Renal Dysfunction                            | 1 (2.5)   | 0        | 1(1.6)    |
| Vascular                                     |           |          |           |
| Hypeitension                                 | 1(2.5)    | 0        | 1 (1.6)   |
| Superiorvenacava syndrome                    | 1(2.5)    | 0        | 1 (1.6)   |
| Thrombosis/thrombus/embolism                 | 2 (5.0)   | 0        | 2 (3.2)   |

<div style=\"page-break-after: always\"></div>

## Deaths

## · Study CA180372

As of the 26 July 2017 DBL, 15 (14.2%) treated subjects died, with most on-study deaths occurring post HR3 (12 subjects, 11.3%). No deaths were considered related to dasatinib.

Table 42 Summary of Deaths - All Treated Subjects

|                                                                                | Number of Subjects Treated （)   | Number of Subjects Treated （)   | Number of Subjects Treated （)   | Number of Subjects Treated （)   |
|--------------------------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                                                | During Inducticn n(5)           | During HR1-3 n(e)               | On-study PostHR3 n（5）           | Across the Studly n（）           |
| All TreatedSubjects(I=106)                                                     |                                 |                                 |                                 |                                 |
| N OE DEATHS                                                                    | 0                               | 3 (2.8）                         | 12 (11.3)                       | 15 (14.2)                       |
| PRIMARY REASON OE IEATH DISEASE                                                | 0                               | 0                               | 2 (1.9)                         | 2 (1.9)                         |
| HSCT                                                                           |                                 |                                 | 1.9)                            | 2 (1.9)                         |
| OTHER                                                                          | 0                               | 103 (2.8)                       | 20 (7.5)                        | 11 (10.4)                       |
| N OE DEATHS IN SUBJECTS IN OLR                                                 | 0                               | 3 (2.8)                         | 6 (5.7)                         | 9 (8.5)                         |
| NDEATHS WITHIN 3O DAYS ERO LAST DASATINIB DOSE PRIMARY REASON OF IEATH         | 0                               | 3 (2.8)                         | 2 (1.9)                         | 5 (4.7)                         |
| OTHER                                                                          | 0                               | 3 (2.8)                         | 2 (1.9)                         | 5 (4.7)                         |
| TabletOnly(l=82)                                                               |                                 |                                 |                                 |                                 |
| N OF DEATHS                                                                    | 0                               | 2 （2.4)                         | 9 (11.0)                        | 11 (13.4)                       |
| FRIMARY REASON OE LEATH DISEASE                                                |                                 |                                 | (1.2)                           | (1.2)                           |
| HSCT                                                                           |                                 | o0                              | 2                               | 2 (2.4)                         |
| OTHER                                                                          |                                 | 2 （2.4)                         | 6 (7.3)                         | 8 (9.8)                         |
| N OE DEATHS IN SUBJECTS IN OCR                                                 | 0                               | 2 (2.4）                         | 4 (4.9)                         | 6 (7.3)                         |
| N DEATHS WITHIN 3O DAYS ETOM LAST DASATINIB DOSE PRIMARY REASON OF DEATH       | 0                               | 2 (2.4)                         | 1 (1.2)                         | 3 (3.7)                         |
| OTHER                                                                          | 0                               | 2 (2.4)                         | 1 (1.2)                         | 3 (3.7)                         |
| PFUSUsed(=24)                                                                  |                                 |                                 |                                 |                                 |
| N OF DEATHS                                                                    | 0                               | 1 (4.2)                         | 3 (12.5)                        | 4 (16.7)                        |
| PRINGRY REASON OE IEATH DISEASE                                                | 0                               | 9                               | 2 4.2)                          | 1 4.2)                          |
| OTHER                                                                          |                                 | 1 (4.2）                         | 8.3)                            | 3 (12.5)                        |
| N OE DEATHS IN SUBJECTS IN OCR                                                 | 0                               | 1 (4.2)                         | 2 (8.3）                         | 3 (12.5)                        |
| N DEATHS WITHIN 3O DAYS EROM LAST DASATINIB DOSE PRIMARY REASON OE LEATH OTHER | 0 0                             | 1 (4.2) 1 (4.2)                 | 1 (4.2) 1 (4.2）                 | 2 （8.3） 2 (8.3)                 |

OcR=Continued CcnpleteRemission

On-studv post-HR3:suoiects on or off treatment who had not died.withdlrawn consent or weze lost to follow-uo bv the end of HR3.

## · Study CA180204

Among all treated paediatric subjects in Study CA180204 (N = 55), 7 (12.7%) deaths were reported, including 3 (8.6%) in Cohort 1 (N = 35) and 4 (20.0%) in Cohort 2 (N =20). No death was reported within 30 days of the last dose of treatment, and none was related to dasatinib treatment. Overall, 2 deaths  were  due  to  disease  progression,  and  the  remaining  5  were  due  to  'other  cause':  cardiac failure, acute critical upper airway obstruction,  MLL-rearranged  therapy-related acute myeloid leukemia, injuries resulting from being hit by a school bus, and infection due to complication of graft vs host disease following HSCT.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## · Haematology

Table 43 Summary of Grade 3-4 Hematology Laboratory Test Results at Baseline, any Time on Treatment, Beyond Induction, and Beyond Consolidation - All Treated Subjects - Study CA180372

| Lab Test Description Toxicity Grade   | At Baseline               | Any Time on Treatment     | Beyond                         | Indiction                 | Beyord Consolidation             |
|---------------------------------------|---------------------------|---------------------------|--------------------------------|---------------------------|----------------------------------|
| Leukocytes                            |                           |                           |                                |                           |                                  |
| GRATE GRALE4                          | 34/106(32.1) 46/106(43.4) | 17/106(16.0) 83/106(78.3) |                                | 15/104(14.4) 79/104(76.0) | 12/93(12.9) 13/93(14.0)          |
| AbsoluteNeutroghilCoumt               |                           |                           |                                |                           |                                  |
| GRALE3                                | 14/103(13.6)              | 9/106(8.5)                |                                | 11/104(10.6)              | 11/92 (12.0)                     |
| GRALE4                                | 73/103(70.9)              | 94/106(88.7)              |                                | 85/104(81.7)              | 13/92(14.1)                      |
| PlateletComt                          |                           |                           |                                |                           |                                  |
| GRAIE3                                | 26/106(24.5)              |                           | 13/106(12.3)                   | 11/104(10.6)              | 5/93(5.4)                        |
| GRADE4                                | 14/106(13.2)              |                           | 80/106 (75.5)                  | 74/104(71.2)              | 12/93(12.9)                      |
| Hemoglobin                            |                           |                           |                                |                           |                                  |
| GRALE3                                | 19/106(17.9)              |                           | 88/106(83.0)                   | 80/104(76.9)              | 15/93(16.1)                      |
| Leukocytes                            |                           |                           |                                | Baseline                  |                                  |
| EROM ANY GRADE AT: Grade3-4           | Baseline 100/106(94.3)    | Beseline 94/104（90.4)     | End of Inchucticn 94/104(90.4) | 25/93(26.9)               | End of Consolidation 25/93(26.9) |
| AbsoluteNeutrophilCount               |                           |                           |                                | Baseline                  |                                  |
| EROM ANY GRADE AT: Grade 3-4          | Baseline 101/103(98.1)    | Baseline 94/101(93.1)     | End of Incucticn 96/104(92.3)  | 23/89(25.8)               | End of Consolidation 24/92(26.1) |
| Platelet Coumt                        |                           |                           |                                | Baseline                  |                                  |
| EROM ANY GRAIE AT: Grade3-4           | Baseline 93/106(87.7)     | Baseline 85/104(81.7)     | End of Incucticn 85/104(81.7)  | 17/93(18.3)               | End of Consolidation 17/93(18.3) |
| Hemoglcbin                            |                           |                           |                                | Baseline                  |                                  |
| EROM ANY GRADE AT: Grade 3-4          | Baseline 88/106(83.0)     | Baseline 80/104(76.9)     | End of Inchucticn 80/104(76.9) | 15/93(16.1)               | End of Consolidation 15/93(16.1) |

Toxicity Scale:CTCversicn 4.0

Note: Grade 3 is the hiahest Dossible tcwicity arade for hemoalcbin test results.

<div style=\"page-break-after: always\"></div>

## · Serum chemistry

Table 44 Summary of Grade 3-4 Serum Chemistry Laboratory Abnormalities at any Time on Treatment - Any grade at Baseline - All Treated Subjects - Study CA180372

| Lalb Test Category Lel Test                  | EROMANYRESULTATBASEIAINE n/N subjects ()   |
|----------------------------------------------|--------------------------------------------|
| LiverFimction                                |                                            |
| ALT(high) GRADE 3-4                          | 53/105 (50.5)                              |
| AST(high) GRAIE3-4                           | 28/100 (28.0)                              |
| Totalbilirubin (high) GPADE3-4               | 9/105 (8.6)                                |
| Renal Fumction                               | (high)                                     |
| Serum creacinine GRADE3-4                    | 2/106 (1.9)                                |
| Electrolytes                                 |                                            |
| Calcium (low) GRAIE3-4                       | 18/104 (17.3)                              |
| Bhosphorus (low) GRADE3-4                    | 13/104 (12.5)                              |
| Potassium (Low) GPADE3-4                     | 43/106 (40.6)                              |
| Toxicicy Scale: CTC version 4.0 TITNT 1 TTMT |                                            |

<div style=\"page-break-after: always\"></div>

## · Liver function tests

Table 45 Serum Liver Function Test Summary of Worst Toxicity Grade on Treatments Relative to Baseline ( Any Grade) - All Treated Subjects

<!-- image -->

| Nof subjects (5)    | Tablet Only N=82    | PEOS Used N=24      | Total N=106         |
|---------------------|---------------------|---------------------|---------------------|
| ALT                 | ALT                 | ALT                 | ALT                 |
| ANYCRADEATBASELTINE | ANYCRADEATBASELTINE | ANYCRADEATBASELTINE | ANYCRADEATBASELTINE |
| GRADEO              | 3(3.7)              | 0                   | 3(2.9)              |
| GRADE 1-2           | 40(49.4)            | 9(37.5)             | 49(46.7)            |
| GRADE3-4            | 38(46.9)            | 15(62.5)            | 53(50.5)            |
| TOTAL               | 81 (100.0)          | 24(100.0)           | 105(100.0)          |
| AST                 | AST                 | AST                 | AST                 |
| ANYCRAIE ATBASELINE | ANYCRAIE ATBASELINE | ANYCRAIE ATBASELINE | ANYCRAIE ATBASELINE |
| GRADEO              | 7(8.9)              | 0                   | 7(7.0)              |
| GRACE1-2            | 51(64.6)            | 14(66.7)            | 65(65.0)            |
| GRADE3-4            | 21 (26.6)           | 7(33.3)             | 28 (28.0)           |
| TOTAL               | 79(100.0)           | 21(100.0)           | 100(100.0)          |
| Totalbilirubin      | Totalbilirubin      | Totalbilirubin      | Totalbilirubin      |
| ANYCRAIEATBASELTNE  | ANYCRAIEATBASELTNE  | ANYCRAIEATBASELTNE  | ANYCRAIEATBASELTNE  |
| GRADEO              | 54(66.7)            | 21(87.5)            | 75(71.4)            |
| GRADE 1-2           | 18(22.2)            | 3(12.5)             | 21(20.0)            |
| GRALE 3-4           | 9(11.1)             | 0                   | 9(8.6)              |
| TOTAL               | 81 (100.0)          | 24(100.0)           | 105(100.0)          |

Towieitr Srale·CTc uereian4n

Table 46 Dasatinib-related Grade 3-4 AEs of Elevated ALT, AST, GGT, or Total Bilirubin Investigations - All Treated Subjects - Study CA180372

| PreferredTermn                     | Numberof subjects （5)（N=106) Grade3 Grade4   | Numberof subjects （5)（N=106) Grade3 Grade4   |
|------------------------------------|----------------------------------------------|----------------------------------------------|
| ALANTNEAMTNOTRANSEERASETNCREASED   | 16 (15.1)                                    | 6.6)                                         |
| ASPARTATEAIDNOIRANSEERASETCRCASED  | (8.5)                                        | 1.9)                                         |
| BLOODBTLIRUBININCREASED            | 990 (2.8)                                    | 7211 0.9)                                    |
| GAMMA-GLUTAMYLTRANSEEDASEIMCREASED |                                              | 0.91                                         |

MecnBA:2O.0

Subjects mayhavemorethan leventwithin aclass.

<div style=\"page-break-after: always\"></div>

## · Kidney function

Table 47 Serum Kidney Function Test Summary of Worst Toxicity Grade on Treatment Relative to Baseline ( Any Grade) All Treated Subjects

| N of subjects (④)      | Tablet Only N=82       | PEOS Used N=24         | Total N=106            |
|------------------------|------------------------|------------------------|------------------------|
| BUN/Urea               | BUN/Urea               | BUN/Urea               | BUN/Urea               |
| ANY RESULT AT BASELDNE | ANY RESULT AT BASELDNE | ANY RESULT AT BASELDNE | ANY RESULT AT BASELDNE |
| =UIN                   | 49 (59.8)              | 17 (70.8)              | 66 (62.3)              |
| >UEN                   | 33 (40.2)              | (29.2)                 | 40 37. 7)              |
| TOT-L                  | 82(100.0)              | 24(100.0)              | 106(100.0)             |
| UILN AT BASEIINE       | UILN AT BASEIINE       | UILN AT BASEIINE       | UILN AT BASEIINE       |
| =ULN                   | 31 122:83              | 1.81:3                 | 12(22:2)               |
| >UIN                   |                        |                        |                        |
| TOTAL                  | 40(100.0)              | 14(100.0)              | 54(100.0)              |
| UIN AT BASELINE        | UIN AT BASELINE        | UIN AT BASELINE        | UIN AT BASELINE        |
| <=ULN                  | 18（42.9)               | 6(60.0)                | 24 (46-2)              |
| >ULN                   | 24 (57 .1)             | 4 (40.0)               | 28 (53. 8              |
| TOTAL                  | 42(100.0)              | 10 (100.0)             | 52 (100.0)             |
| Serumcreatinine        | Serumcreatinine        | Serumcreatinine        | Serumcreatinine        |
| ANY GRALE AT BASELINE  | ANY GRALE AT BASELINE  | ANY GRALE AT BASELINE  | ANY GRALE AT BASELINE  |
| GRALEO                 | 58 (70-7)              | (91-7)                 | 80                     |
| GRALE 1-2              | (26. 8                 | 8.3)                   |                        |
| GRATE 3-4              | 2 4                    |                        |                        |
| TOTAL                  | 82(100.0)              | 24(100.0)              | 0)                     |
| GRADEO AT BASELTINE    | GRADEO AT BASELTINE    | GRADEO AT BASELTINE    | GRADEO AT BASELTINE    |
| GRALE                  | 57 (70 4)              | 22 (95.7)              | 79 176 0)              |
| 0 GRADE 1 -2           | 22 (27                 | 1O (4.3)               | 23 22                  |
| GRATE 3- 4             | 2 5)                   |                        | 2 1. 9)                |
| TOTAL                  | 81(100.0)              | 23 (100.0)             | 104(100.0)             |
| GRADE1-2 AT BASELINE   | GRADE1-2 AT BASELINE   | GRADE1-2 AT BASELINE   | GRADE1-2 AT BASELINE   |
| GRADE 0                | 1 (100.0)              | 0                      | 1 (50.0)               |
| GRALE 1-2              |                        | 1 (100.0)              | HO (50.6)              |
| GRALE 3-4              | 00                     | 0                      |                        |
| TOTAL                  | 1(100.0)               | 1(100.0)               | 2 (100.0)              |

Toxicity Scale: CTC versicn 4.0 TITN = 1imit. T.TN =

## · Vital signs

Table 48 Electrocardiogram Summary of Categories - All treated Subjects

| EoGMeasurement (Units) Category (5)                      | Tablet Only N=82                        | PEOS Used N=24                  | Total N=106   |
|----------------------------------------------------------|-----------------------------------------|---------------------------------|---------------|
| Meximal QIc[E]Intervals (msec) <450                      | 80 (97.6) 1 (1.2) 1 (.1:2) 82 (100.0) 0 | 24 (100.0) 0 19 (79.2) 5 (20.8) | 104 (98.1) 1  |
| 450-500                                                  |                                         | 24(100.0) 0                     | (0.9)         |
| 00S                                                      |                                         |                                 |               |
| NOTREPORTED                                              |                                         |                                 | 1 (.0.9)      |
| TOTAL                                                    |                                         |                                 | 106 (100.0)   |
| QIc[E] changes frcm baseline （msec) 09-> -60-<-30 -30-<0 | 0 0                                     |                                 | 0             |
|                                                          |                                         |                                 | 85 (80.2)     |
| 0-30                                                     | 66 (80.5)                               |                                 | (13.2)        |
| >30-60                                                   | (11.0)                                  |                                 | 14            |
| >60                                                      | 2 (2.4)                                 | 0                               | 2 (1.9)       |
|                                                          |                                         | 0                               | (4.7)         |
| NOT REPORTED                                             | 5 (6.1)                                 |                                 |               |
| TOTAL                                                    | 82 (100.0)                              | 24 (100.0)                      | 106(100.0)    |

Table 49 Summary of Echocardiogram Results on Treatment - All Treated Subjects

|                    | Tahlet Only N=82   | PEOSUsed N=24   | Total N=106   |
|--------------------|--------------------|-----------------|---------------|
| INIERDRETATION     |                    |                 |               |
| NORMDL             | (74.4)             | 18 (75.0)       | 79 (74.5)     |
| ATTRASTCNEAENOPMAL | (9.9               | (4.2)           | (8.5)         |
| NOTREPORTED        | (15.9)             | (20.8）          | (17.0         |

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Intrinsic factors

- Age

Table 50 Summary of On Treatment Dasatinib-related Serious Adverse Events by Age (years) in ≥ 2 Subjects - All Treated Subjects in Study CA180372

| System Organ Class (6) Preferred Term (t)                                                              | <7 N=36            | >=7and<12 N=35       | 12and<18 N=35   |
|--------------------------------------------------------------------------------------------------------|--------------------|----------------------|-----------------|
| TOTAL SUBJECTS WITH AN EVENT                                                                           | 9（25.0)            | 17(48.6)             | 18 （51.4)       |
| BLOOD AND LYMEHATIC SYSTEMDISORIERS                                                                    | 13.9)              | 21 34.3) 31.4) 20.0) | 28-6)           |
| FEBRILENEUIROPENIA NEUIROFENIA                                                                         | 41111 11.1)        | 7342 8.6) 11.4) 5.7) | .9) 5.7)        |
| INVESTIGATIONS                                                                                         | 2H000000 5.6) 2.8) | 3667                 | 17 1 SP         |
| ANADMTA THROYBOCYTOFENIA LEUKOPENIA                                                                    |                    |                      |                 |
| GASTROINTESTINAL DISORDERS COLITIS DTARRHOEA LONERGASTROINTESTINAL HAEMORRHAEE VOMITING ABDOMMNAL PAIN | 2.8)               | 53322111 312 一       |                 |
|                                                                                                        | 000                | 20.0) 6)             | 6121111         |
| NEUIROBHIL OOUNT DECRDASED                                                                             |                    |                      |                 |
| METABOLISMAMD NUTRITION DISORIERS HYPOALBUDTNAEMTA HYPORATAEMTA                                        |                    |                      | 7)              |
|                                                                                                        |                    |                      | 11.             |
|                                                                                                        |                    | 9                    | 11.4)           |
|                                                                                                        | 11                 |                      |                 |
|                                                                                                        |                    | 311                  |                 |
|                                                                                                        |                    |                      | 9)              |
| ASCITES NAUSEA                                                                                         |                    |                      |                 |
| GENERALDISORLERS AND AIMTNISTRATION SITE CONDITIONS PYREXIA                                            | 22 5.6)            | 14.3)                | 8.6)            |
|                                                                                                        | 5.6)               |                      |                 |
|                                                                                                        | 8.3)               | 14.3)                | (6              |
| SEPSIS CLOSTRIDIUM DIEFICIIE COLITIS                                                                   | mooo               | 9                    | -O 9) 9)        |
| HERDES ZOSTER                                                                                          |                    |                      |                 |
|                                                                                                        | 2111               | 2OOO 5.7)            | 69              |
| ALANINE AMINOIRANSFERASE INLREASED                                                                     |                    |                      | (6              |
| ASPARTATEAMTNOTRANSFERASE INCREASED                                                                    |                    | 8.6)                 |                 |
|                                                                                                        |                    |                      | 9               |
| RESPIRATORY,THORACIC AND MEDTASTINALDISORTERS                                                          |                    | 00                   | 3 8.6)          |
|                                                                                                        |                    |                      | 3               |
| VASOULAR DISORDERS                                                                                     |                    |                      |                 |
| PLEURAL EEFUSICN                                                                                       |                    |                      | 8.6)            |
|                                                                                                        | 2.6)               | #2:3                 |                 |
| HYEOTENSICN                                                                                            |                    |                      | o0              |

Subiects mav have more then levent within a class.

MedLRA:20.0

<div style=\"page-break-after: always\"></div>

## · Gender

Table 51 Summary of On Treatment Dasatinib-related Serious Adverse Events by Gender in ≥ 2 Subjects - All Treated Subjects in Study CA180372

| System Organ Class （b) Preferred Term (o)                                                              | Female 6=N                                     | Male N=57                                      |                                     |
|--------------------------------------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------|
| TOTAL SUBJECTS WITHAN EVENT                                                                            | 22(44.9)                                       | 22(38.6)                                       |                                     |
| BLOOD AND LYMFHATIC SYSTEM DISORLERS FERRILENEUIROPENIA NEUIROFENIA ANADMA THROMBOCYTOPENIA LEUKOPENIA | 13 （26.5) 10 C 20.4) 8.2) 1 2.0) 1 2.0) 1 2.0) | 14 (24.6) 13 22.8) 8 14.0) 5 8.8) 4 7.0 2 3.5) |                                     |
| GENERALDISCRTERSAND AIIINISTRATIONSITECONDITIONS PYREXTA                                               | 5 (10.2) 3 6.1)                                | 8 (14.0) (12.3)                                |                                     |
| INEDCTIONS AND INEESTATIONS SEPSIS                                                                     | 10.2) 4.1)                                     | 7.0) 3.5)                                      |                                     |
| INVESTIGATIONS NEUIROFHILCOUNT DELREASED ALANINEAMINOIRANSEERASEINCREASED                              | 4.1)                                           | 6 (10.5)                                       |                                     |
|                                                                                                        | 2HOO 2.0)                                      | 32 5.3) 3.5) 2                                 |                                     |
| HYPOAIBUMMNAE-IA                                                                                       | 4.1)                                           | 3 5.3)                                         |                                     |
|                                                                                                        | 4.1)                                           |                                                |                                     |
| RESPIRATORY,THORACICAND MEDIASTINAL DISORIERS                                                          |                                                | 2                                              |                                     |
| PLEURAL EERUSION                                                                                       |                                                |                                                |                                     |
|                                                                                                        | 2.0)                                           |                                                |                                     |
|                                                                                                        |                                                | 3.5)                                           |                                     |
| HYPOKALAEMTA                                                                                           | 2.0)                                           |                                                |                                     |
| METABOLISMAND NUTRITION DISORIERS                                                                      |                                                |                                                |                                     |
|                                                                                                        |                                                | 3.5)                                           |                                     |
|                                                                                                        |                                                | 3.5)                                           |                                     |
|                                                                                                        |                                                | 20                                             |                                     |
|                                                                                                        |                                                | 3.5)                                           |                                     |
|                                                                                                        | 202                                            |                                                |                                     |
|                                                                                                        |                                                |                                                | ASDARTATE AMTNOIRANSFERASEINCREASED |

MedDRA:20.0

Subjects may have more than l event within a class.

## · Race

Table 52 Summary of On Treatment Dasatinib-related Serious Adverse Events by Race in ≥ 2 Subjects - All Treated Subjects in Study CA180372

| System Organ Class (e)                                      | White     | Black or African Hmerican   | Asian   | Other N=3   |
|-------------------------------------------------------------|-----------|-----------------------------|---------|-------------|
| Preferred Termm （o)                                         | S8=N      | N=13                        | S=N     |             |
| TOTAL SUBJECTS WITH AN EVENT                                | 36(42.4)  | 3(23.1)                     | 3（60.0） | 2(66.7)     |
| BLOOD AND LYMPHATIC SYSTEM DISORIERS                        | 25.9)     | 3311 23-12                  |         | 33.3)       |
| FEERTLENEUTROFENIA                                          |           | 1                           |         | HOO 33.3)   |
| NEUIROFENIA                                                 | 8)        | 7)                          |         |             |
| ANAEMTA                                                     | 4.71      | 7. 7)                       | 20.0)   |             |
| THROMEOCYTOFENIA                                            | 4.7)      | 1 7.7)                      |         | 0           |
| LEUKOPENIA                                                  | 2 2.4)    | 1 7.7)                      |         | 0           |
| GASTROINTESTINAL DISORDERS                                  | 12 (14.1) | 0                           | (20.0)  | 0           |
| COLITIS                                                     | 5.9)      | 0                           |         | 0           |
| DIARRHOEA                                                   | 4.7)      |                             | （20.0)  | 0           |
| LONER GASTROINTESTINAL HAEMORRHAGE                          | 3.5)      |                             | O1OOOO  | 0           |
| VOMTING                                                     | 3.5)      |                             |         | O           |
| ABDOMINAL PAIN                                              | C 2.4)    |                             |         |             |
| NAUSEA                                                      | 2.4)      |                             |         | 0           |
| GENERAL DISORDERS AND AIMINISTRATION SITE CONDITIONS        | 11(12.9)  | 0                           | 2（40.0) | 0           |
| PYREXIA                                                     | 9(10.6)   | 0                           | 1（20.0) | 0           |
| INEDCTICNS AND INEESTATIONS                                 | 7 8.21    | 2 （15.4)                    |         | 0           |
| SEPSIS                                                      |           |                             |         | 0           |
| CLOSTRIDIUM DIFEICIIE COLITIS                               | 2.4)      | 0                           | o00     | 0           |
| INVESTIGATIONS                                              | 7 2)      | 000                         | 20.0)   | 0           |
| NEUIROEHIL COUNT DECREASED ALANINEAMTNOIRANSEERASEINCREASED | 4)        |                             | 20.0}   | 000         |
| ASDARTATE AMINOIRANSEERASE INCREASED                        |           |                             | 1100    |             |
| RESPIRATORY,THORACIC AND MEDIASTINAL DISORIERS              |           | 0                           | 20.0)   |             |
| PLEURAL EEBUSICN                                            | 2.4)      | 0                           | 20.0)   | 0 0         |
|                                                             | 2.4)      |                             |         | 0           |
| VASOULAR DISORDERS HYEOTENSION                              | 2.4)      | 0 0                         | 0 0     | 0           |

MedLRA:20.0

Subiects mav have more than l event within a class.

<div style=\"page-break-after: always\"></div>

## Extrinsic factors

## · Geographic region

Though most subjects on treatment were in North America, and fewer subjects were in Europe or Rest of  World.  AEs  and  SAEs,  AEs  leading  to  discontinuation  of  study  treatment  were  observed  at comparable frequencies across geographic region subgroups of the pooled or CA180372 Ph+ ALL study population.

In Study CA180372, most subjects on treatment were in North America (N = 78), and fewer subjects were in Europe (N = 25) or Rest of World (N = 3). In the pooled population from Studies CA180372 and CA180204, most subjects on treatment were in North America (N = 130), and fewer subjects were in Europe (N = 25) or Rest of World (N = 6).

## · ECOG

Table 53 Summary of On Treatment Dasatinib-related Serious Adverse Events by Performance Status in ≥ 2 Subjects - All Treated Subjects in Study CA180372

| System Organ Class (B)                            | EOOG=0      | D0OG=1    | EO0G=2    |
|---------------------------------------------------|-------------|-----------|-----------|
| Preferred Term (6)                                | N=39        | N=50      | N=14      |
| TOTAL SUBJECTS WITH AN EVENT                      | 11(28.2)    | 24(48.0)  | 7(50.0)   |
| BLOODANDLYMEHATICSYSTEMDISORDERS                  | 23.1)       | 13 (26.0) | 21:4)     |
| BEERTLENEUIROPENIA                                | 20-53       | 11 22.0)  |           |
| NEUIROEENTA                                       | 2.7         | 14.0)     |           |
| ANAEMTIA                                          | 10.3)       | 2.0)      |           |
| THROMBOCYTOFENTA                                  | 5.1)        | 7121 4.0) | 7.1)      |
| LEUKOPENIA                                        | 903422 5.1) | 2.0)      |           |
| GASTROINTESTINALDISORIERS                         | 7.7)        | 7 14.0)   | 21.4)     |
| COLITIS                                           | 6           | 4.0)      | 14.3)     |
| DIARRHOEA                                         | 3.:3        | 211       | 14.3)     |
| LONER GASTROINTESTINAL HAEMORRHAGE                | 3120        | 8         | 14.3)     |
| GENERALDISORDERS AND AIMINISTRATIONSITECONDITIONS | 12.8)       | 8.0)      | 28.6)     |
| PYREXIA                                           | 12.8)       | 6.0)      | 92 14.3)  |
| INEDCTIONS AND INEESTATIONS                       | 300 7.7)    | 4.0)      | C 21.4)   |
| SEPSIS                                            |             | 210 2.0)  | 3m2 21.4) |
| CIOSTRIDIUM DIEFICILE COLITIS                     |             |           | 14.3)     |
| INVESTIGATIONS                                    | 21 7-7      | 3 6.0)    | 14.3)     |
| NEUIROEHIL COUNT DECREASED                        | 5.1         | 2.0)      | 7.1)      |
| METABOLISMAND NUIRITIONDISORIERS                  | 2(5.1)      | 30 6.0)   | o0        |
| HYPOKALAEMA                                       | 0           | 264.0)    |           |
| RESPIRATORY,THORACICANDMEDTASTINLDISORIERS        | 22 （ 5.1)   | 3 2.0)    |           |
| PLEURALEFRUSION                                   | 5.1)        | 2.0)      | 0o        |

MedLRA:20.0

Karmofsky/Lansky scores collected in study CA180372 were magped to Eo0G scores per Appendix 8 in the CA180372 protocol. Subfectsmavhave more thanleventwithin aclass.

## Safety related to drug-drug interactions and other interactions

No new information in paediatric subjects is available.

## Discontinuation due to adverse events

## Study CA180372

## All-causality AEs leading to discontinuation

In Study CA180372, AEs that led to treatment discontinuation were reported in 7 (6.6%) out of 106 subjects. All subjects who discontinued treatment took dasatinib tablet only, and no subject who took dasatinib PFOS at least once discontinued treatment due to an AE.

<div style=\"page-break-after: always\"></div>

Grade 3-5 AEs leading to treatment discontinuation were reported in 4 (3.8%) out of 106 subjects and included Grade 4 enteritis, Grade 5 fungal sepsis, Grade 3 lung infection, and Grade 3 thrombocytopenia.

## Dasatinib-related AEs leading to discontinuation

Dasatinib-related AEs that led to treatment discontinuation occurred in 2 (1.9%) subjects: 1 subject with  a  Grade 1  AE  of  drug  hypersensitivity,  and  1  subject  with  a  Grade  3  AE  of  thrombocytopenia. These 2 subjects took dasatinib tablet only, and no subjects who took dasatinib PFOS at least once discontinued due to a dasatinib-related AE.

## Study CA180204

In  CA180204,  'action  taken'  regarding  study  drug  was  not  collected  as  part  of  AE  reporting,  and therefore no summaries of AEs leading to discontinuation of study treatment were generated. Based on investigator  reports  after  database  lock,  2  subjects  were  identified  with  on-treatment  toxicities  or complications leading to discontinuation of treatment: 1 subject with persistent QTc prolonged, and 1 subject with methotrexate-related leukoencephalopathy.

## Post marketing experience

Dasatinib  was  first  approved  for  the  treatment  of  adults  with  CML  or  Ph+  ALL  who  are  resistant  or intolerant to imatinib on 28 June 2006 by the US FDA. Dasatinib was subsequently approved in other countries and is marketed worldwide for these indications in over 60 international countries including the EU, Japan, and Canada:

- Dasatinib  is  indicated  for  the  treatment  of  adults  with  chronic,  accelerated,  or  myeloid  or lymphoid blast phase CML with resistance or intolerance to prior therapy including imatinib.
- Dasatinib is indicated for the treatment of adults with Ph+ ALL with resistance or intolerance to prior therapy.
- Dasatinib  is  indicated  for  the  treatment  of  adult  subjects  with  newly  diagnosed  Ph+  CML  in chronic phase.

As reported in Periodic Benefit-Risk Evaluation Report No. 5 (28-Jun-2016 through 27-Jun-2017), the cumulative  number  of  patients  exposed  to  dasatinib  from  28-Jun-2006  through  31-Mar-2017  is estimated  to  be  63,960,  and  the  cumulative  exposure  is  estimated  to  be  127,690  patient-years.13 Cumulatively, of the approximately 6,773 subjects assigned to treatment (ie, assigned to treatment with  the  investigational  medicinal  product,  active  comparator,  and/or  placebo  control)  in  BMSsponsored clinical trials, approximately 5,389 subjects have been exposed to dasatinib. Approximately 1,214  total  subjects  have  been  exposed  to  dasatinib  under  Expanded  Access  Programs  (EAPs; CA180325).  Cumulatively,  3,300  subjects  have  been  exposed  to  dasatinib  while  participating  in  an ISR/ISTs supported by BMS. Therefore, in total, approximately 9,903 subjects have been exposed to dasatinib from 04-Nov-2003 through 27-Jun-2017.

## 2.6.1. Discussion on clinical safety

The safety of dasatinib has been characterised in CML patients and appears similar in Ph+ALL in adults and overall in  paediatric ALL.  The  safety  results  reported  in  the  main  and  supportive  study  did  not reveal any new concern in combination with poly-chemotherapy backbone.

<div style=\"page-break-after: always\"></div>

Dasatinib's characteristic effect of effusions in pleura or pericardium, observed as a dose-dependent adverse event in adult CML, was not observed in the discontinued treatment or PFOS (used) group, and in all grades in 5.9% in the tablet (only) group. Considering the complexity of the disease and treatment this result is acceptable. Pleural effusions were not observed in childhood CML treatment. The incidence of pleural (or pericardial) effusions is not expected to be underestimated as the clinical monitoring of patients was very thorough.

There  were  two  studies  in  a  total  of  161  paediatric  patients  with  Ph+  ALL  in  which  Sprycel  was administered  in  combination  with  chemotherapy.  In  Study  1,  of  55  paediatric  patients,  35  received Sprycel  in  combination  with  chemotherapy  on  a  discontinuous  dosing  regimen  (two  weeks  on treatment  followed  by  one  to  two  weeks  off)  and  20  received    Sprycel  in  combination  with chemotherapy on a continuous dosing regimen. In Study 2, 106 paediatric patients received Sprycel in combination with chemotherapy on a continuous dosing regimen. Among the 126 Ph+ ALL paediatric patients  treated  with  Sprycel  on  a  continuous  dosing  regimen,  the  median  duration  of  therapy  was 23.6 months (range 1.4 to 33 months) (SmPC, section 4.8).

Adverse  reactions  reported  in  the  two  paediatric  studies  in  which  Sprycel  was  administered  in combination with chemotherapy were consistent with the known safety profile of Sprycel in adults, and expected  effects  of  chemotherapy.  Of  the  126  Ph+  ALL  paediatric  patients  on  a  continuous  dosing regimen, 2 (1.6%) experienced adverse reactions leading to treatment discontinuation(SmPC, section 4.8).

The adverse events were less frequently reported in the group of patients treated by 'discontinuous' dasatinib, compared to the continuous (tablet only) group. This is in line with a dose relation, which therefore add uncertainty to interpretation of results obtained in the group of PFOS (used, n=24) and PFOS (exclusively, n = 8) group, because the bioavailability is estimated to be 19% less by the 60 mg/m2 dose with PFOS. A new analysis showed a similar exposure distribution between disease types in both adult and paediatric patients. In addition, the results showed that the intestinal permeability did not change between chronic and acute leukaemia (see discussion on clinical pharmacology).

Dasatinib treatment of paediatric ALL-patients appears to have limited clinically significant impact on growth  and  development,  but  it  is  difficult  to  draw  definitive  conclusions  due  to  the  concomitant treatment of dose-intense combination chemotherapy and without a longer follow-up period.

The adherence to treatment was not optimal, with 25-30% of patients receiving less than 18 dasatinib doses  /  month.  The  risk  for  interaction  with  concomitant  medication  and  simultaneous  AEs  e.g. mucositis may be partly responsible..

Cardiac  events  had  an  impact  on  clinically  relevant  protocol  deviations  reported  in  40  subjects:  40 deviations due to use of concomitant medications with potential to prolong QTc, and two deviations due to  subjects  with  blast-phase  CML  who  were  misclassified  with  Ph+  ALL.  Inclusion  of  these  two subjects in analysis did not impact interpretability of study results. Most of the deviations (30 subjects) were subjects who received short-term prophylactic antibiotics with a macrolide, pentamidine or other prohibited medications, which included droperidol, methadone, haloperidol, domepridone and chlorpromazine.  The  use  of  the  prohibited  concomitant  therapy  did  not  impact  the  efficacy  of  the treatment with dasatinib plus chemotherapy; none of these subjects had a QTc &gt;450msec.

The  adverse  events  affect  mainly  bone-marrow  function,  skin  and  mucosa  -  in  particular  in  the gastrointestinal  tract,  manifested  as  vomiting  and  diarrhoea.  Sepsis  and  infections  may  be  a consequence of neutropenia and barrier defect, because contagious infections rarely are observed in leukaemia patients.  In  addition,  all  may  be  serious  in  grade,  and  in  a  few  cases  lead  to  treatment discontinuation. The number of all-causality related AEs leading to discontinuation was 8.5% (grade 3-

<div style=\"page-break-after: always\"></div>

5 was 4.9%) in the tablet (only) group, and 2.4 % (1.2 % grade 3-5) were interpreted as dasatinibrelated. No discontinuation were registered due to AE, all causality or dasatinib-related in the PFOS (once) group in the main study.

As  of  last  data-base  lock,  15  (14.2%)  treated  subjects  died.  Twelve  of  15  while  on-study  deaths occurring post HR3. No deaths were considered related to dasatinib. Nine (8.5%) subjects who were in CCR died and 5 (4.7%) subjects died less than 30 days after discontinuation from dasatinib treatment. Of the 11 deaths reported in the category of 'Other,' 9 deaths were attributed primarily to infections. However, for a more meaningful comparison, the paediatric Ph+ ALL population was compared with the adult Ph+ ALL population and with  the paediatric population studied for the CP-CML indication.

It is acknowledged that even focusing the analyses in the Ph+ ALL population, the setting is different between  children  and  adults.  In  the  paediatric  population  dasatinib  was  used  in  association  with chemotherapy and in the adult population it was used as monotherapy in patients with resistance or intolerance to prior therapies. In the heavily pretreated adult population, the overall safety profile was influenced  by  the  advanced  stage  of  the  disease  and  the  use  of  prior  therapies.  In  the  paediatric population  it  was  influenced  by  the  concomitant  use  of  chemotherapy.  Dasatinib's  safety  profile  is notably consistent across these groups, being in general more favourable in the paediatric population, namely with less pleural effusion and peripheral edema. There is some more abdominal pain (maybe related to age groups) and much more febrile neutropenia (in probable relation with the ALL backbone chemotherapy  treatment).  Nevertheless,  in  general,  the  safety  profile  of  dasatinib  in  the  paediatric Ph+ ALL study population was comparable to that in the adult trials.

The adverse events observed in treatment of acute leukaemia may be related. It is also noted in tables of  AEOSI  and  SAE  that  patients  may  have  more  than  one  event  within  a  class.  A  trend  has  been observed  towards  more  frequent  SAEs  in  the  age-group  12-18  years  compared  to  the  youngest patients, below the age of 7 years.

In  paediatric  patients  with  Ph+  ALL  treated  with  dasatinib  in  combination  with  chemotherapy, CBCs should be performed prior to the start of each block of chemotherapy and as clinically indicated. During the  consolidation  blocks  of  chemotherapy,  CBCs  should  be  performed  every  2  days  until  recovery (SmPC, section 4.4).

In paediatric trials of Sprycel in combination with chemotherapy in newly diagnosed Ph+ ALL paediatric patients after a maximum of 2 years of treatment, treatment-related adverse events associated with bone growth and development were reported in 1 (0.6%) patient. This case was a Grade 1 osteopenia (SmPC, section 4.4).

In  the  paediatric  ALL  studies,  the  rates  of  laboratory  abnormalities  were  consistent  with  the  known profile for laboratory parameters in adults, within the context of an acute leukaemia patient receiving a background chemotherapy regimen (SmPC, section 4.8).

The introduction of the oral suspension, PFOS, in ALL will be a great treatment advantage in order to dispense the medication to a young child. Results on safety were pooled with tablet treated patients, and do not indicate specific safety issues or adverse events.

## 2.6.2. Conclusions on clinical safety

The safety profile of Sprycel administered in combination with chemotherapy in paediatric patients with Ph+ ALL was consistent with the known safety profile of Sprycel in adults and the expected effects of chemotherapy, with the exception of a lower pleural effusion rate in paediatric patients as compared to adults.

<div style=\"page-break-after: always\"></div>

## 2.6.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Risk management plan

The CHMP endorsed RMP version 16.1 with the following content:

## Safety concerns

Table 54 Summary of the safety concerns

| Important idennified risks   | Myelosuppression Fluid Retention Bleeding Related Events QT Prolongation PAH Pregnancy Related Malfonmative or Foeto/ Neonatal Toxicity                                                                                                                      |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Severe Hepatotoxicities Direct Cardiotoxic Effects (eg, Cardiomyopathy) Growth and development disorders and bone mineral metabolism disorders in the paediatic population Toxic Skin Reactions CYP3A4 Drug Interactions HBV Reactivation Nephrotic Syndrome |
| Missing information          | Carcinogenicity Paediatic data Children ≤ 1 year of age Reproductive and lactation data                                                                                                                                                                      |

## Pharmacovigilance plan

No additional pharmacovigilance activities are planned.

## Risk minimisation measures

<div style=\"page-break-after: always\"></div>

Table 55 Summary table of risk minimisation measures by safety concern

| Safety Concern                           | Risk Mfinimisation Mfeasures                                       | Pharmacovigilance Activities                                                                       |
|------------------------------------------|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                          | Additional risk minimisation measur'es: DHPC issued in EU Apr-2016 | Additional pharmacovigilance activities: None                                                      |
| Nephrotic Syndrome                       | Routine risk minimisation measl'es: SmPC Section 4.8               | Routine pharmacovigilance activities beyond adverse reactions reporting and sigual detection: None |
|                                          | Additional riskminimisation measures: None                         | Additional pharmacovigilance activities: None                                                      |
| Carcinogenicity                          | Routine risk minimisation measwres: SmPC Section 5.3               | Routine pharmacovigilance activities beyond adverse reactions reporting and sigual detection: None |
|                                          | Additionalriskminimisation measures: None                          | Additionalpharmacovigilance activities: None                                                       |
| Paediamic data: Children < 1 year of age | Routine risk minimisation measures: SmPC Section 4.2.              | Routine pharmacovigilance activities beyond adverse reactions reporting and sigual detection: None |
|                                          | Additional risk minimisation meast'es: None                        | Additional pharmacovigilance activities: None                                                      |
| Reproductive and lactation data          | Routine risk minimisation measlres: SmPC Sections 4.6 amd 5.3      | Routine pharmacovigilance activities beyond adverse reactions reporting and sigual detection: None |
|                                          | Additional riskminimisation measwres: None                         | Additional pharmacovigilance activities: None                                                      |

## Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

The applicant also removed the text allowing constitution of the powder for oral suspension by patients or caregivers at the end of the Package Leaflet to ensure that constitution is limited to pharmacists or qualified healthcare professionals.

In addition, the list of local representatives in the PL has been revised to amend contact details for the representative of Island.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The applied indication is as follows:

Sprycel is indicated for the treatment of paediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy.

## 3.1.2. Available therapies and unmet medical need

In the EU, imatinib is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.

The survival rate among subjects with Ph+ ALL still lags behind most other cytogenetic subgroups in paediatric ALL. Until recently, HSCT in first complete remission offered the best opportunity for longterm EFS for children with Ph+ ALL, with an improvement in disease free survival of up to 65% and OS 72%. This strategy is limited by the availability of a suitably matched donor, by the risk of posttransplant-related morbidity and mortality and by relapses after HSCT, particularly in those who are MRD positive prior to transplantation. Paediatric patients with no suitable donor for HSCT have an even more critical unmet need for disease management.

## 3.1.3. Main clinical studies

The clinical package of Sprycel for the paediatric ALL indication was primarily supported by data from a Phase II, open-label, multi-centre, single-arm, historically-controlled study of dasatinib added to standard chemotherapy in paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Study CA180372).

## 3.2. Favourable effects

In study CA180372 the 3-year binomial EFS rate with dasatinib plus chemotherapy was 66.0% (90% CI:  57.7,  73.7).  As  an  indirect  comparison,  to  the  EFS  rate  was  49.2%  (90%  CI:  38.0,  60.4)  with chemotherapy alone in AIEOP-BFM 2000 and to 59.1% (90% CI: 51.8, 66.2) with continuous imatinib plus chemotherapy in the amended EsPhALL trial in all treated subjects.

Regarding the secondary endpoints, the OS rate was 91.5% (95% CI: 84.2 - 95.5) at 3 years and the CR  was  93.4%  (99/106)  after  consolidation  chemotherapy.  In  addition,  the  MRD  negativity  rate assessed  by  Ig/TCR  rearrangement  was  71.7%  by  the  end  of  consolidation  in  all  treated  patients. When this rate was based on the 85 patients with evaluable Ig/TCR assessments, the estimate was 89.4%.  The  MRD-negativity  rates  at  the  end  of  induction  and  consolidation  as  measured  by  flow cytometry were 66.0% and 84.0%, respectively.

<div style=\"page-break-after: always\"></div>

In the supportive study CA180204, the 3-year EFS rate was 80.8% (95% CI: 70.2, 91.4) in the 52 paediatric  patients  considered  evaluable  for  efficacy  and  68.4%  (95%  CI:  48.3,  88.6)  in  the  19 subjects on continuous dasatinib.

## 3.3. Uncertainties and limitations about favourable effects

For CP-CML a PFOS dose of 90 mg/m 2  has been proposed and endorsed by CHMP, but bioequivalence will  be  investigated  in  a  PK  window  study  in  CP-CML  conducted  post-approval.  As  the  PK,  including bioavailability, of dasatinib appear to be comparable across disease status, the PFOS dose used in CPCML has also been endorsed for the Ph+ ALL indication. The MAH was committed to provide the results of this PK-window study post-approval. In relation to this it needs to stressed that although (based on the  mechanistic  understanding,  the  analysis  of  efficacy  versus  GI  toxicity,  formulation  and  patient populations, and the analysis of PK in the different patient populations) the PBPK model is considered to provide reassuring data on the extrapolation of PK across the patient populations, the PBPK model is not  fully  validated.  The  CHMP  recommended  the  MAH  to  confirm  (post-approval)  that  the  postapproval  analysis  will  be  conducted  to  demonstrate  that  the  PBPK  model  adequately  captures  the effects of chemotherapy on absorption in line with the existing guideline on Reporting and Qualification of PBPK models..

## 3.4. Unfavourable effects

Dasatinib-related AEs were reported in 86.3% and 72.2% had grade 3-4 AEs in the studied population. No new concerns were observed. Similar manifestations are observed treating ALL paediatric patients with PFOS.

The pattern of AEs are similar to treatment by dasatinib in paediatric and adult CML and adult ALL, dominated by all grade myelosuppression, mucositis / gastrointestinal manifestations and infections but not any particular microbiological agent.

The pattern of SAEs in general follows the same manifestations. The AEs and SAEs are recognized in this patient population and manageable, and the pattern also reflects the lack of co-morbidity in the paediatric patient population.

No deaths have been related to dasatinib treatment.

## 3.5. Uncertainties and limitations about unfavourable effects

There are no uncertainties and limitations about unfavourable effects.

## 3.6. Effects Table

Table 56 Effects Table for dasatinib in paediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy (Study CA180372- data cut-off: 26 July 2017)

| Effect             | Short description           | Unit   | Treatment   | Historical control     | Uncertaint ies / Strength of evidence   | References                |
|--------------------|-----------------------------|--------|-------------|------------------------|-----------------------------------------|---------------------------|
| Favourable Effects | Favourable Effects          |        |             |                        |                                         |                           |
| 3-Year binom       | number of pts without event | %      | 66          | - AIEOP-BFM 2000: 49.2 | - Study CA180372                        | See ''clinical efficacy'' |

<div style=\"page-break-after: always\"></div>

| Effect                | Short description                                                                    | Unit                 | Treatment            | Historical control   | Uncertaint ies / Strength of evidence                                                   | References              |
|-----------------------|--------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|-----------------------------------------------------------------------------------------|-------------------------|
| ial EFS rate          | after 3 years since the start of dasatinib divided by the number of treated subjects |                      |                      | - EsPhALL : 59.1     | 90% CI: 57.7, 73.7 - AIEOP- BFM 2000: 90% CI: 38.0, 60.4 - EsPhALL : 90% CI: 51.8, 66.2 | section                 |
| Unfavourable Effects  | Unfavourable Effects                                                                 | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                    | Unfavourable Effects    |
| ADRs                  | Grade 3-4                                                                            | %                    | 72.2                 | -                    |                                                                                         | See ''clinical safety'' |
| Febrile neutropae nia | Grade 3-4                                                                            | %                    | 26.2                 | -                    |                                                                                         | section                 |
| Nausea                | Grade 3-4                                                                            | %                    | 5.6                  | -                    |                                                                                         |                         |
| Vomiting              | Grade 3-4                                                                            | %                    | 4.8                  | -                    |                                                                                         |                         |
| Abdominal pain        | Grade 3-4                                                                            | %                    | 3.2                  | -                    |                                                                                         |                         |
| Diarrhoea             | Grade 3-4                                                                            | %                    | 4.8                  | -                    |                                                                                         |                         |
| Pyrexia               | Grade 3-4                                                                            | %                    | 5.6                  | -                    |                                                                                         |                         |
| Headache              | Grade 3-4                                                                            | %                    | 4.8                  | -                    |                                                                                         |                         |
| Decreased appetite    | Grade 3-4                                                                            | %                    | 4.8                  | -                    |                                                                                         |                         |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

In study CA180372 the 3-year binomial EFS rate with dasatinib plus chemotherapy was 66.0% (90% CI:  57.7,  73.7).  As  an  indirect  comparison,  to  the  EFS  rate  was  49.2%  (90%  CI:  38.0,  60.4)  with chemotherapy alone in AIEOP-BFM 2000 and to 59.1% (90% CI: 51.8, 66.2) with continuous imatinib plus chemotherapy in the amended EsPhALL trial in all treated subjects.

Further,  the  safety  profile  of  dasatinib  is  acceptable,  manifestations  manageable  and  without  new concerns.  Pleural  effusions  were  unusual,  no  pericardial  effusions  were  reported,  and  likewise  very serious potential complications like cerebral haemorrhage, pulmonary oedema or pulmonary hypertension was not observed.

## 3.7.2. Balance of benefits and risks

Clinically  meaningful  results  have  been  observed  with  the  use  of  dasatinib  combination  with chemotherapy in the treatment of paediatric patients with newly diagnosed Ph+ ALL which outweighs the ADRs that are considered manageable, despite the combination with intensive chemotherapy.

## 3.7.3. Additional considerations on the benefit-risk balance

N/A.

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

The overall B/R of Sprycel is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends, the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include a paediatric indication for Philadelphia chromosome positive acute lymphoblastic leukaemia for Sprycel; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated.

The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes to the product information.

The RMP version 16.1 has also been submitted.

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) ) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

<div style=\"page-break-after: always\"></div>

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0042/2018 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Sprycel is not similar to Xaluprine, Blincyto, Iglusig and Besponsa within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of Indication to include a paediatric indication for Philadelphia chromosome positive acute lymphoblastic leukaemia for Sprycel; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated.

The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes to the product information.

The RMP version 16.1 has also been submitted.

## Summary

Please refer to Scientific Discussion ''Sprycel-H-C-709-II-59''

## Attachments

1. SmPC, Package Leaflet (changes highlighted) of Sprycel as adopted by the CHMP on 13 December 2018.

## Appendix

1. CHMP AR on similarity dated 13 December 2018.

<div style=\"page-break-after: always\"></div>

## REFERENCES

1. Steliarova E et al. Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991-2010 (Automated Childhood Cancer Information System): a population-based study. Lancet Oncol. 2018 Sep; 19(9):1159-1169.
2. Biondi A et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, openlabel, intergroup study. Lancet Oncol. 2012 Sep;13(9):936-45.
3. Heerema NA. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004 Apr;18(4):693-702.
4. Giles FJ et al. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2009 Oct;23(10):1698-707.
5. Chiaretti S and Foa R. Management of adult Ph-positive acute lymphoblastic leukemia. ASH Educ Book 2015. 2015 Dec; 406-413.
6. Schultz KR et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014 Jul;28(7):1467-71.
7. Bernbeck B.  Symptoms of childhood acute lymphoblastic leukemia: red flags to recognize leukemia in daily practice. Klin Padiatr. 2009 Nov-Dec;221(6):369-73.
8. Bacher et al. Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genetics and Cytogenetics. Volume 157, Issue 1, February 2005, Pages 53-61
9. Chang B et al. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ALL: a Children's Oncology Group (COG) study. Br J Haematol. 2012 May; 157(4): 507-510.
10. Cortes JE et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 Jul 10;34(20):233340.
11. Rousselot P et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016 Aug 11;128(6):774-82.
12. Ravandi F et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23;116(12):2070-7.

i Final Clinical Study Report for CA180015: A Phase 2 Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate. BristolMyers Squibb; 2007. Document Control Number 930025471.

ii Clinical Study Report for Study CA180035: A Randomized, Two-arm, Multicenter, Open-label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to Imatinib Mesylate. Bristol-Myers Squibb; 2008. Document Control Number 930029431.